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ABSTRACT 
Lymphocytes and myeloid cells (monocytes/macrophages) play important roles in 
multiple types of diseases characterized by unresolved inflammation. The relatively 
recent appreciation of obesity and type 2 diabetes (T2D) as chronic inflammatory 
diseases has stimulated interest in understanding the role immune cells play in metabolic 
imbalance. Myeloid cells regulate inflammation through cytokine production and the 
adipose tissue remodeling that accompanies over-nutrition, and thus are critical players in 
metabolic homeostasis and T2D. However, multiple studies indicate important pro-
inflammatory changes in B cells and T cells in mouse models of T2D, yet their specific 
contributions have yet to be fully elucidated in human T2D. The studies herein identify 
novel pro-inflammatory changes in the B cell compartment of T2D patients, showing that 
v 
B cells from diabetic patients contribute to the inflammatory milieu through TLR 
mediated IL-8 production, along with a reduction in IL-l 0 production. These studies 
further demonstrate that T cells from T2D patients contribute to the inflammatory milieu 
by secreting elevated levels of the potent pro-inflammatory cytokine IL-17, following 
requisite cell contact with monocytes. Previous studies had established that interactions 
between monocytes, T cells and B cells are essential for proper immune responses and 
changes in disease states can alter these interactions. The data presented here show an 
important role for cell-cell cross-talk between B cells, T cells and monocytes, in which 
monocyte-T cell interactions lead to moderate levels of IL-17 from both T2D patients and 
ND controls but the interaction between B cells and T cells increases IL-17 production 
only in T cells from T2D patients. Taken together, these studies indicate that, in addition 
to accepted pro-inflammatory roles of myeloid cells in T2D, pro-inflammatory skewing 
of both major lymphocyte subsets and cross-talk among them play important roles in 
T2D disease pathogenesis. These conclusions are integrated into a model consistent with 
the general emerging view that alterations in lymphocyte function in obesity and T2D are 
an integral part of a feed-forward pro-inflammatory loop involving additional cell types 
such as adipocytes, which respond to pro-inflammatory cytokines produced by immune 
cells. 
Vl 
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Chapter 1- INTRODUCTION 
Type 2 Diabetes 
T2D is a chronic metabolic disorder characterized by elevated levels of glucose in 
the blood, insulin resistance (IR) and islet dysfunction. The American Diabetes 
Association (ADA) states that over 25 million Americans and 170 million individuals 
worldwide have T2D along with an additional 79 million pre-diabetic (blood glucose 
levels that are higher than normal but not yet high enough to be diagnosed as diabetes) 
individuals in the United States. This large population with T2D makes it an extremely 
large health care concern and a burden on the economy with $174 billion spent in direct 
and indirect costs due to diabetes. Yet, treatments thus far for T2D are expensive and 
inefficient since they treat the symptoms rather than the cause. Studies defining the 
mechanisms that induce IR will lead to the development of more efficacious treatments 
aimed specifically at the cause ofT2D. 
T2D is caused by multiple factors, although individuals who are obese and have a 
sedentary lifestyle are at the highest risk for developing T2D and IR. T2D is tightly 
associated with obesity, though the exact mechanisms linking are still being studied. The 
causal link between obesity and IR are controversial. However obese patients with hyper-
caloric diets have elevated levels of free fatty acids (FF As) and endotoxin [ 1-3] which 
have been shown to activate the production of inflammatory cytokines [ 4, 5] and lead to 
IR through inhibition of the insulin signaling pathway. As IR develops, the body is 
unable to clear the blood of excess glucose because insulin is required to move glucose 
1 
from the blood into cells where it can be used. This leads to high concentrations of 
circulating glucose thereby contributing to the development of complications such as 
cardiovascular disease. However tight glucose control does not lead to better 
cardiovascular outcomes, indicating this co-morbidity could be induced by inflammation 
[6]. Finally, studies have shown that IR can promote hunger and depression, both 
leading to increased consumption, thus inducing a feed-forward mechanism of increasing 
obesity and IR. Discovering the pathway(s) linking inflammation and IR could lead to 
targeted treatments which help prevent and manage IR and other co-morbidities. 
T2D co-morbidities 
T2D is associated with a number of serious, sometimes life threatening co-
morbidities which include vascular, ocular , renal and neurological complications. The 
American Diabetes Association (ADA) statistics indicate that individuals with T2D have 
a two to four times increased likelihood of death due to cardiovascular complications 
such as stroke and/or myocardial infarction. Accumulation of plaque due to high fat diets 
and elevated low-density lipoprotein (LDL) levels leads to macrovascular complications 
in which large blood vessels such as coronary arteries and the aorta become restricted. 
Microvascular complications, in which small capillaries become restricted, lead to 
nephropathy and ocular complications, making T2D the leading cause of kidney disease 
and blindness in the United States. Nephropathy (disease of the kidney) is caused by 
consistent levels of high blood sugar which burden the kidneys and leads to micro- and 
macroalbuminuria (accumulation of protein in the urine) and finally kidney failure. There 
are several types of ocular complications that include retinopathy (both nonproliferative 
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and proliferative), glaucoma and cataracts. Nonproliferative retinopathy occurs when the 
capillaries in the back of the eye become blocked, become inflamed and form pouches. 
Nonproliferative retinopathy is treatable. However, if this blockage is left untreated, it 
can become proliferative retinopathy in which these damaged blood vessels close off 
causing scar tissue and eventual retinal detachment. Glaucoma occurs when the pressure 
in the eye builds up and people with diabetes are 40% more likely to suffer from 
glaucoma. Cataracts results from the lens of the eye clouding up causing vision 
impairment. Individuals with diabetes are 60% more likely to develop cataracts than 
non-diabetic individuals. Neurological problems occur in the form of peripheral 
neuropathy or autonomic neuropathy. In peripheral neuropathy, there is a loss of feeling 
in limbs such as the feet, which result in foot ulcers and other complications. 
Additionally, 60% of non-traumatic amputations in the United States due to peripheral 
neuropathy occur in adults with T2D. Autonomic neuropathy occurs due to changes in 
the autonomic nerves that control the bladder, and intestinal tract among other organs. 
These changes lead to diarrhea, constipation, paralysis of the bladder and heart 
complications (ADA). Multiple studies have indicated that inflammation can contribute 
to the development of these and other T2D-associated complications [7 -9]. I therefore 
hypothesize that T2D-Iinked complications could be attenuated or inhibited by reducing 
inflammation. Thus targeting the immune system is a viable treatment for T2D associated 
complications . 
3 
Insulin signaling pathway 
One of the main characteristics of T2D is dysregulation of the insulin signaling 
pathway. Insulin is produced by pancreatic beta cells in response to elevated levels of 
nutrients, specifically glucose, in the blood. Once insulin binds to the insulin receptor, 
the cytoplasmic tail of the insulin receptor gets autophosphorylated. This leads to the 
recruitment and phosphorylation, by the kinase domain on the insulin receptor, of insulin 
receptor substrate 112 (IRS1 /2) [10] (Fig. 1-1). Once IRSl /2 is bound to the insulin 
receptor through its pleckstrin homology (PH) and phosphotyrosine binding (PTB) 
domains and activated via phosphorylation, IRSl /2 then phosphorylates AKT, which 
activates glycogen synthase kinase 3 (GSK3) (Fig. 1-1). A major substrate ofGSK3 is 
glycogen synthase, an enzyme important for the final catalysis step in glycogen synthesis. 
Phosphorylation of glycogen synthase results in inhibition of glycogen synthesis. AKT 
also activates translocation of glucose transporter type 4 (GLUT4) to the plasma 
membrane. GLUT4 (or GLUT1 in lymphocytes) is responsible for shuttling glucose 
molecules into the cell, thus linking insulin binding to the insulin receptor to increased 
glucose uptake [10, 11]. Alterations in this signaling pathway have been studied in 
muscle and adipose tissue from IR, obese and T2D patients indicating that IR can be 
caused by defects in this signaling cascade [12-14]. Phosphorlyation ofiRSl Ser312 
instead oftyrosine Tyr608 and Tyr628 leads to insulin resistance by impairing IRSl binding 
to the activated insulin receptor [15, 16]. Importantly, inflammatory mediators can be 
responsible for inappropriate phosphorlyation, thereby closely linking inflammation to IR 
[17, 18]. 
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The importance of IRS 1 and IRS2 in insulin action has been demonstrated by 
multiple studies [19-22]. In an IRS-1-/- deficient mouse, there is a 50% decrease in 
glucose tolerance and insulin/insulin-like growth factor !-stimulated glucose uptake. The 
residual insulin action is due to IRS2 as a compensatory mechanism [19]. To decipher 
whether IRS-I and IRS-2 were expressed in a tissue specific manner, IRS-I and IRS-2 
single and double heterozygous knockouts were developed and skeletal muscle and liver 
were analyzed [22]. IRS-I+/- mice develop severe insulin resistance in the skeletal muscle 
and liver, however IRS-2+/-mice develop severe insulin resistance in the liver but only 
mild insulin resistance in the skeletal muscle [22]. Both models had compensatory ~cell 
hyperplasia [22]. These data indicate that IRS 1 is important for insulin action in the 
skeletal muscle and both IRS-1 and IRS-2 are important for insulin action in the liver. 
Both IRS-1 and IRS-2 are expressed in human adipocytes. Adipocytes from T2D 
subjects have decreased insulin-stimulated tyrosine phosphorlyation ofiRS-1; however, 
this is most likely due to the 70% reduction in IRS-1 expression [23]. IRS-2, however, is 
expressed at normal levels and thus becomes the main docking protein for insulin-
stimulated PI3K activation [23]. Additionally, there is a 70-80% decrease in GLUT4 
protein and rnRNA expression in T2D patients, which is additionally responsible for a 
dramatic reduction in glucose transport in response to insulin [23-25]. These changes 
occur early in the adipose tissue, long before systemic glucose intolerance develops [26]. 
Taken together, these data indicate the importance ofiRS1 and IRS2 in the insulin 
signaling pathway and also suggests that although insulin resistance is most often studied 
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in skeletal muscle, adipose tissue could be the initiating organ and/or the initial target 
organ for insulin resistance. 
T2D as a chronic inflammatory disease 
Chronic inflammation in T2D is thought to initiate as an inflammatory response to 
altered lipolysis and remodeling/necrosis of expanding adipose tissue compartments [27, 
28]. Altered lipolysis in response to over nutrition and rapidly expanding adipose tissue 
results in elevation of generally pro-inflammatory saturated fatty acids (such as FFA's) 
and endotoxin (also called lipopolysaccrides, LPS) [1 , 2, 29], which serve as ligands for 
cell surface receptors on immune cells [4, 5]. The increased concentration of LPS in the 
bloodstream occur due to a "leaky gut" (in response to obesity) , in which excessive levels 
of LPS are released into the bloodstream. These surface receptors activate the signaling 
cascades that culminate in inflammation [30]. The following sections outline the various 
mechanisms by which inflammation is induced and maintained in T2D by various cells, 
proteins and receptors and describes data from both humans and mouse models which 
have lead to the hypothesis that T2D is an inflammation driven disease. 
MECHANISMS OF INITIATING AND SUSTAINING INFLAMMATION 
Toll-like Receptors 
Toll-like Receptors are a family of pattern recognition receptors charged with 
binding microbial ligands and eliciting an immune response through activation of nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-xB), a transcription factor 
essential in the induction of cytokines (Figure 1-2). There are two TLR-associated 
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signaling pathways: MyD88-dependent and MyD88-independent, although both lead to 
activation of NF-xB in addition to interferon regulatory transcription factor 3 (IRF3). In 
the MyD88 dependent pathway, TLR activation leads to binding of the adaptor molecules 
MyD88 and Tirap (Mal) to the cytoplasmic tail of the TLR receptor [31]. These adaptor 
molecules then recruit the interleukin-1 receptor-associated kinase 4 (IRAK) proteins 
IRAK-1 and IRAK-4. The IRAK proteins activate TNF receptor associated factor 6 
(TRAF6) and Akt. TRAF6 activates llcB kinase, which is responsible for releasing the 
active subunit ofNF-xB (also called p65) to the nucleus [32]. Alternatively , in the 
MyD88-independent pathway, TLR activation leads to recruitment of the adaptor 
proteins TIR-domain-containing adapter-inducing interferon-P (TRIP) and TRIP-related 
adaptor molecule (TRAM). These proteins activate receptor interacting protein (RIP-1) 
which activates TRAF-6 eventually leading to the release of p65 [33] . However, TRIF 
and TRAM can also activate TANK-binding kinase 1 {TBKl) and IKKi which lead to the 
activation of IRF3 making this an alternative mechanism of inducing inflammatory 
cytokines [34]. Importantly, there are negative feedback loops that regulate TLR 
signaling . In the IRAK family , IRAK-M inhibits TRAF6 signaling by anchoring 
IRAKl/4 to the TLR/MyD88 complex [35], preventing activation ofTRAF-6 and Akt. 
Single Ig IL-l-related receptor (SIGIRR) binds to the Toll/IL-l receptors and prevents 
adaptor molecules from binding. SIGIRR deficiency leads to prolonged activation of 
NF-xB by Toll/IL-l stimulation [36, 37]. SIGIRR has also been shown to be important in 
regulating the T helper cell (Th) subset, Th17, in which SIGIRR deficiency leads to 
elevated numbers of Th17 cells and IL-17 [38]. Additionally, SIGIRR directly influences 
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Th17 differentiation but not Th1 differentiation indicating differential regulation ofTh-
subsets [38]. These regulators function to control the extent and duration ofTLR 
signaling to prevent uncontrolled activation which would lead to elevated cytokine 
production and chronic inflammation. 
TLRs play important roles in T2D, as shown both in humans and in animal 
models of T2D. Obese and T2D patients have an increase in endogenous ligands such as 
FFAs which bind TLR4 and activate adipose tissue macrophages (ATM) which leads to 
inflammatory cytokine production and local insulin resistance [39] . Mice with an inactive 
TLR4 gene were significantly less prone to diet-induced insulin resistance [40, 41]. Also, 
TLR4 deficient macrophages were protected against insulin resistance [42]. Likewise, 
inhibition of TLR2 function in mice exposed to a high-fat diet led to improved insulin 
sensitivity and decreased activation of pro-inflammatory pathways [43]. Mice lacking 
TLR2 were protected from increased abdominal adiposity after high fat diet and had 
demonstrated decreased inflammatory cytokine expression [44]. Furthermore , 
polymorphisms in TLRs and in members of TLR-downstream signalling pathways that 
encode hyper- or hypoactive responses predict the development of type 1 and type 2 
diabetes [45-47] . Overall , these studies support the idea that TLR2 and TLR4 activities 
generally promote T2D, regardless of the general rejection of TLR2 or TLR4 as direct 
receptors for FFAs in unpublished work. 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NFKB) 
NF -KB is a family of transcription factors that includes RelA (p65), NF -KB 1 (p50 
and p105), NF-KB2 (p52 and plOO), c-Rel, and RelB (reviewed in (48]). These five 
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transcription factors share anN-terminal DNA binding domain which bind KB sites on 
DNA to modulate gene expression (reviewed in[49]). RelA, c-Rel and RelB also have C-
terminal transactivating domains (T ADs), which allow them to activate expression of 
target genes [49]. RelA (p65) is the most well known NFKB protein involved in the 
canonic signaling pathway [50]. NF-KBl 's p50 subunit and NF-KB2's p52 subunit do 
not have T ADs and homodimerize to repress transcription. However, these subunits can 
alternatively act as transcriptional co-activators if they are associated with TAD-
containing subunits such as Bcl-3 , RelA, c-Rel or RelB [49]. A family of inhibitory 
proteins called hcB which is composed ofiKBa, IKB~, IKBs and Bcl-3 regulate the 
activation ofNFKB by sequestering the active subunits ofNFKB and prevent 
translocation into the nucleus [ 49]. These inhibitory proteins prevent inappropriate 
activation of the NFKB signaling pathway, in addition to being involved in the resolution 
of inflammation. NFKB is important for an abundant number of processes which include 
hematopoiesis, the development of the innate immune cells, B cells and T cells, lymphoid 
organogenesis and most relevant for this dissertation, inducing inflammation [51-54] . 
The family ofNFKB proteins is indispensible for the induction and resolution of 
inflammation [ 49, 55-60]. In unstimulated cells, RelA/p65 is sequestered by any of the 
family of inhibitory IKB proteins in the cytoplasm [61]. In the canonical pathway, 
activation of cytokine receptors or TLRs on the surface of immune cells results in 
activation of the IKB kinase (IKK) which phosphorlyates IKB, resulting in the 
dissociation of the RelA/p65 subunit (in addition to phosphorylation ofp65) allowing 
activated NF-kB to migrate into the nucleus and bind to its target DNA (Fig. 1-3). The 
9 
IKK complex is composed of three subunits, IKKa, IKK~ and IKKy, in which a and~ 
are the catalytically active subunits, while they subunit has a regulatory role [62]. One of 
the early transcriptional targets ofNF -KB proteins are the expression of adhesion 
molecules which allows extravasation of leukocytes to the site of infection [ 63] indicating 
the importance ofNF-KB in inducing the immune response. Other immediate targets are 
cytokine receptors such as tumor necrosis factor a receptor (TNFaR) which again 
activate NF-KB, propagating cytokine responses through a feed-forward loop [59]. 
Resolution of inflammation is critical to prevent pathology. The most obvious 
mechanism to resolve NFKB-induced inflammation would be to prevent NF-KB re-
activation. However, multiple studies indicate that NF-KB takes on a more active role in 
resolving inflammation. An NF-KB responsive gene, Bcl-3 (in a complex with p50) is an 
inhibitory protein induced late after LPS activation and is thought to be involved in LPS 
tolerance in macrophages [64]. Bcl-3 has also been shown to turn off pro-inflammatory 
genes via chromatin remodeling in addition to facilitating the expression of the critical 
anti-inflammatory cytokine IL-10 [65-68]. Suppressor of cytokines 1 (SOCS-1), a NFxB 
target gene, negatively regulates LPS signaling to NF-xB. This is demonstrated by 
SOCS 1-i- mice which have uncontrolled inflammation [69 , 70]. Taken together, these 
data indicate an elegantly orchestrated response by NFKB proteins to microbial pathogens 
in which waves of inflammation followed by resolution initiates and control the immune 
response. 
It is not surprising that NFKB has been shown to play an important role in the 
induction and maintenance of chronic inflammation found in T2D. A role for NFKB was 
10 
first hinted at when the use of salicylates improved glucose tolerance [71-7 4]. High dose 
salicylates reverse insulin resistance in murine diet-induced obesity models [75]. In a 
randomized clinical trial, patients who took high dose salicylates had reduced HbAlc, a 
clinical marker of blood glucose over a span of several months, along with decreases in 
circulating triglyceride and adiponectin concentrations [76] . Salicylates may target IKKB 
directly, inhibiting fat-induced insulin resistance in skeletal muscle [77]. Also, treatment 
with an IL-l BR antagonist improved insulin resistance and glucose tolerance in diabetic 
patients [78, 79], however these improvements were modest, indicating that perhaps 
targeting one pro-inflammatory cytokine may not have the most beneficial results. This 
conclusion is further supported by inconsistent results after administration of anti-TNF 
antibodies to inhibit inflammation in T2D patients [80, 81]. NFKB may regulate normal 
glucose uptake and insulin secretion thus blocking NFKB activation in B cells (in the 
pancreas) decreased glucose-stimulated insulin secretion [82]. These data indicate that 
inhibition ofNFKB in B cells while reducing overall glucose levels could help improve 
insulin resistance. Overall, these data indicate that NFKB plays a critical role in insulin 
resistance and T2D. 
c-Jun N-terminal kinase (JNK) 
JNK has been shown to play critical roles in the development of insulin resistance 
[83]. The c-Jun N-terminal kinase (JNK) family of kinases is part of the larger mitogen-
activated protein kinase (MAPK) family and is responsible for activating activator 
protein 1 (AP-1) (Fig. 1-4), a transcription factor that upregulates inflammatory 
mediators. Importantly , JNK can inhibit insulin signaling by serine phosphorylation of 
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IRS-1 [84]. This phosphorylation impairs IRS-1 binding to the insulin receptor in 
addition to degradation of IRS-1, consequently blocking insulin action downstream of 
receptor activation [85 , 86] (Fig. 1-4). JNK is activated by a multitude of mediators 
which are mostly stress stimuli [87-89] (Fig. 1-4). Pathogen sensor protein kinase R 
(PKR) has been shown to activate JNK in response to lipids, inflammatory stimuli and 
endoplastic reticulum stress [90-98] thus represents a mechanistic link between JNK and 
metabolic changes (Fig. 1-4). JNK proteins are directly activated by dual 
phosphoryalation by the MAPK kinases MKK4 and 7 [99-101] . There are three isoforms 
of mammalian JNK: JNK1 , JNK2 and JNK3. JNK1 and 2 are ubiquitously expressed, 
however JNK3 is restricted to the brain, pancreatic islet cells , testes and heart [102]. 
Due to the high degree of similarity between the isoforms (>70%), JNK proteins 
often compensate for each other , making genetic deletion models for each isoform 
complex to interpret [103]. However a large number of studies focused on murine JNK 
knock-out models have managed to show an important role for JNK1 and 2 in obesity 
and T2D [104]. Murine models of both genetic and diet-induced obesity (DIO) show an 
increase in JNK protein in liver, muscle and adipose tissue. JNK1_,_ but not JNK2_,_ mice 
are resistant to obesity [84]. JNK2_,_ mice, when combined with a heterozygous JNK 1 
mouse, JNK+'-, in a DIO model have milder hyperinsulinemia and hyperglycemia with an 
increase in insulin receptor signaling and are protected against diet-induced IR, T2D and 
fatty liver disease [84] . Additionally , JNK is activated in many tissues from obese human 
patients [105-107] and a genetic linkage in humans exists between JNK hyperactivity and 
T2D [108]. Although these studies indicate a central role for JNK in metabolic disease, it 
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is important to determine whether JNK-mediated abnormalities result from JNK function 
in one tissue or multi-organ systems. Expression of a dominant-negative JNK in the liver 
of obese diabetic mice improves IR, decreases blood glucose levels and suppresses 
hepatic glucose production [109]. Liver-specific knockdown of JNK-1 using RNAi in 
obese mice had similar results [110, 111] . JNK-1 deletion in skeletal muscle of obese 
mice decreased fasting glucose and insulin concentrations and protected against obesity-
induced IR [112]. Importantly, in in vitro studies, the induction of IR in adipocytes 
through the addition of inflammatory cytokines or free fatty acids required JNK 
activation, and suppression of JNK restores insulin-stimulated glucose uptake and insulin 
signaling pathways [113 , 114]. Additionally , JNK1 deletion specifically in adipocytes 
(JNK1 -'fat) decreased hyperinsulinemia and improved insulin sensitivity during insulin 
tolerance tests relative to wild-type obese mice [115]. Interestingly , this adipocyte-
specific deletion of JNK1 also improved hepatic insulin sensitivity indicating that 
changes in the insulin sensitivity of adipose tissue could have repercussions in the liver 
[115]. Based on these data, small molecule inhibitors of JNK have been tested and show 
improved glucose control and enhanced glucose-stimulated insulin secretion in leptin-
deficient receptor mice [116]. Furthermore, an ATP-competitive JNK inhibitor, called 
Compound A developed by Pfizer, decreases body weight, blood glucose and triglyceride 
concentrations in addition to increasing insulin sensitivity to levels comparable to lean 
controls in obese mice [117] . Taken together , these data indisputably link inflammation 
and inflammatory signaling pathways to insulin resistance and metabolic disease through 
the JNK proteins. 
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IMPORTANT PLAYERS IN T2D INFLAMMATION 
Monocytes 
Many cell types produce inflammatory cytokines [118-120] , but multiple lines of 
evidence show hematopoietic cells are major determinants of the inflammation that links 
obesity with insulin resistance and T2D. Cytokine-producing hematopoietic cells are 
necessary and sufficient for obese mice to become insulin resistant, at least under some 
conditions [121] . Additional studies have specifically implicated myeloid cell cytokines 
in insulin resi stance in mice [122], which is further supported by demonstrations that 
monocytes from T2D patients secrete elevated levels of key pro-inflammatory cytokines 
such as IL-1(3 and TNF-a [123]. Peripheral blood monocytes from T2D patients are also 
constitutively activated [124], most likely due (at least in part) to the elevated levels of 
TLR ligands circulating in these patients [3 , 124-127]. Monocytes from T2D patients 
have been shown to hyper-produce multiple pro-inflammatory cytokines in response to 
TLR ligand, most commonly lipopolysaccride (LPS), the ligand for TLR4 [123, 128-
131]. According to conventional logic, hyper-responsiveness to TLR ligands in the TLR 
ligand-rich milieu ofT2D is unexpected . Instead, continuous TLR engagement by 
endogenous TLR4 ligands would be expected to result in an ameliorated response to a 
second ligand dose via a well-understood phenomenon termed TLR/endotoxin tolerance 
[132, 133]. Regardless of the expected results , overwhelming evidence in mice 
demonstrated that TLR4 function and downstream cytokine production is required for the 
development of insulin resistance [40, 41] . 
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Despite the molecular inconsistencies in describing exactly how myeloid lineage 
cells contribute to insulin resistance and T2D, the fact remains that macrophages 
aggressively infiltrate the expanding adipose tissue in response to over nutrition in 
models of insulin resistance [27 , 28]. Furthermore the percentages and numbers of 
monocytes are elevated in adipose tissue of obesity patients [134-136]. Timing of 
macrophage infiltration/cytokine production relative to lymphocyte infiltration/cytokine 
production in the expanding adipose tissue is controversial , probably due to slight 
variations in protocols used for the various analyses[1 , 137-141]. Regardless , both 
scenarios emphasize the likely importance of monocyte/lymphocyte cross talk through 
cytokine production alone or perhaps in combination with cell-cell interactions in 
organisms responding to high fat diet (HFD). In vitro studies have also identified the 
likely presence of a paracrine pro-inflammatory loop between monocyte/macrophage and 
adipocytes, the cell type most traditionally associated with metabolic balance. This loop 
involves elevated release of inflammatory cytokines from monocytes that activate 
adipocytes, plus elevated levels of saturated fatty acids from obese adipose tissue that 
further activate macrophages [142]. 
In addition to elevated cytokine responses by circulating monocytes [123, 143], 
tissue macrophages in obese and T2D patients take on a classically activated or "M1" 
macrophage phenotype, and become a major source of pro-inflammatory cytokines [144]. 
The increase of M1 macrophages in adipose tissue during diet-induced expansion and 
concomitant increased adipocyte diameter is followed by a remodeling event, 
characterized by further immune cell infiltration/expansion, an overall decrease in 
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adipocyte size, and shift in macrophage phenotype to the "M2" (alternatively activated) 
subset [27]. Careful time course analyses show expression of both pro-inflammatory 
tumor necrosis factor a, interleukin-6, monocyte chemotactic protein 1 (TNF-a, IL-6, 
MCP-1) and anti-inflammatory interleukin-10 (IL-10) cytokines peak coincident with the 
maximum expression of activated macrophage associated genes such as F4/80. 
Interestingly, these peaks occur slightly after adipocytes reach maximum size and 
expression of the pan-macrophage gene COlle is highest (12 weeks post-HFD) [27]. 
These data suggest that macrophage phenotype changes from M1 to M2 following 
macrophage infiltration into the expanding adipose tissue. This change presumably aids 
in remodeling and adipocyte downsizing. Although initial observations suggested that 
alternatively activated M2 macrophages, which promote tissue remodeling and control 
inflammation via IL-10 production, resolve adipose inflammation following diet-
mediated expansion, more comprehensive analyses suggest that both M1 and M2 
macrophages influence adipose physiology throughout the time course of the disease 
[145]. Taken together, these findings strongly support the conclusion that cytokine 
balance, instead of a simple Ml!M2 paradigm, determines the adipose response to over 
nutrition. The "cytokine balance hypothesis" raises the possibility that that other potent 
sources of cytokines, such as T cells and B cells, significantly contribute to disease 
pathogenesis in obesity and T2D. 
B cells 
In contrast to the strong association between altered myeloid function and T2D, 
antibody-dependent or -independent roles forB cells in T2D have been addressed in very 
16 
few studies. Studies inDIO mice demonstrated that B cells infiltrate the adipose tissue in 
an early response to DIO, followed by T cells, then macrophages [138], although this 
order is controversial [137]. RAG-null mice (lacking both B and T lymphocytes) have an 
elevated number of macrophages in the adipose tissue late inDIO compared to the 
numbers in lymphocyte-sufficient controls, indicating cellular infiltration into adipose 
tissue is a highly regulated process perhaps orchestrated by initial B cell infiltration 
[138]. Furthermore, RAG-null mice responded to DIO by increased weight gain, 
accumulation of more epididymal fat (a leading measure of altered lipid metabolism), and 
larger diameter adipocytes (a second measure of changes in lipid metabolism) compared 
to RAG-sufficient rnice[146]. As discussed above , follow-up analyses in these reports 
showed T cells play non-redundant roles in insulin resistance [141, 146, 147] . In a recent 
study, B cells promote DIG-induced insulin resistance and glucose tolerance through 
activation of macrophages and T cells and production of autoimmune IgG antibodies 
[148] . B cell depletion through administration of the CD20 antibody attenuates disease, 
however transfer of pathogenic IgG autoantibodies from DIO mice induce insulin 
resistance and glucose intolerance [148]. These data indicate an important pro-
inflammatory role forB cells in promoting obesity-induced insulin resistance . Recently, a 
new subset of regulatory B cells (Bregs) has been reported [149-154]. These cells are 
characterized by their suppressive capabilities through IL-10. The function of B cells and 
regulatory B cells in the above mentioned studies mice were not reported. 
Human B cells express multiple TLRs and can produce both pro- and anti-
inflammatory cytokines in response to TLR ligands [155-158]. The most commonly 
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studied B cell TLR is TLR9, which mediates B cell response to CpG. B cells from 
healthy humans , in contrast to mice, generally express little to no surface TLR2 and 
TLR4 [155 , 156, 159, 160]. B cell TLR activation results in , among other biological 
outcomes , production of cytokines that exhibit generally pro-inflammatory biological 
functions [157, 161-164]. 
B cells are demonstrated sources of cytokines both in healthy individuals and 
those with chronic inflammatory disease, with the anti-inflammatory cytokine IL-10 
identified as the B cell cytokine most commonly implicated in unresolved inflammation. 
For example, B cells from multiple sclerosis (MS) patients secrete lower levels of IL-10 
than B cells from healthy donors, and secretion increases in patients treated palliatively 
with mitoxantrone [164]. IL-10-secreting B cells from healthy donors , but not Lupus 
patients, also block Th1 differentiation [165]. B cell IL-10 is also critical for recovery 
from arthritis and a mouse version of MS (Experimental Autoimmune Encephalitis) 
[166]. Finally, genetic studies have linked elevated IL-10 levels to protection from 
metabolic syndrome and T2D in humans [167], and thus indicate IL-10 can protect 
against a wide array of chronic inflammatory diseases . These data suggest that B cell IL-
10 production decreases clinical symptoms [164]. IL-10 producing human B cells arise 
upon stimulation through surface Ig alone or in combination with CD40 [157] , or upon 
TLR-mediated stimulation[l68]. Studies in mice have identified IL-10 producing B cells 
as a separate B cell subpopulation , designated B10 cells , or as a more inclusive subset 
designated regulatory B cells/Bregs [151, 153 , 154, 169-171]. Evidence for a human 
equivalent of Bregs was first uncovered in a population of transitional B cells that might 
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protect against inflammatory disease in humans[172] . Additional studies have confirmed 
the existence of anti-inflammatory human B cell populations, although the markers 
associated with this subset remain controversial [150, 165]. 
T cells 
A role forT cells in T2D was perhaps predictable, given that T cells are 
implicated in the pathogenesis of multiple inflammatory diseases, and specific T cell 
subsets play demonstrated roles in such diseases [173-177]. For example, CD4+ cells are 
a major T cell subset implicated in the pathogenesis of multiple sclerosis (MS), 
rheumatoid arthritis (RA) and psoriasis, which are characterized by elevated numbers of 
pro-inflammatory cytokine-positive CD4+ T cells in blood and diseased tissues [178]. 
Many recent studies have specifically implicated IL-17-producing CD4+ T cells, Th17 
cells, in pathogenic inflammation [179 , 180]. IL-17 activates inflammation through the 
widely expressed IL-17 receptor. Activation of the IL-17R triggers NF-x.B, thus cytokine 
production by monocytes, fibroblast, stromal, epithelial and endothelial cells [181-183]. 
IL-17 also induces mobilization, recruitment and activation of granulocytes via induction 
of G-CSF [184]. Importantly, IL-17 activates JNK, one of the kinases responsible for 
inappropriate phosphorylation of IRS-1leading to insulin resistance [185, 186] indicating 
a potential role for IL-17 -induced insulin resistance. In addition to IL-17 production, 
Th17 cells are phenotypically and functionally defined by activation of the transcription 
factor RAR-related orphan receptor C (RORC, RORyt in mouse) and secretion of IL-21 
[187-189]. Genetic deletion of the RORC equivalent in mice, RORyt, decreases the 
number of Thl7 cells and these mice are less susceptible to autoimmune conditions such 
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as experimental autoimmune encephalomyelitis demonstrating RORyt's important role in 
Th17 differentiation [1S9]. Overall , these diseases indicate an important role forT cells 
in the induction and exacerbation of multiple chronic inflammatory diseases, at least in 
part through their ability to trigger NF-KB target genes. 
Several recent studies utilizing a mouse model of DIO demonstrate important 
roles for multipleT cell subsets in adipose-associated inflammation . Subcutaneous and 
visceral adipose tissue (SAT and VAT, respectively) inDIO mice have increased 
numbers of CD4+ and CDS+ T cells [141 , 146]. CD4+ and CDS+ T cells are also elevated 
in obese human omental and abdominal adipose tissue, which indicates parallel changes 
in T cell infiltration and inflammation in human adipose tissue[190] . Although these 
reports suggest a role forT cells in adipose inflammation, there is controversy among 
studies as to which T cell subset (CD4+, CDS+) play dominant roles, or whether T cells in 
general necessarily have an important role in inducing inflammation in obesity and T2D. 
Studies focused on pro-inflammatory functions of CDS+ T cells in DIO show these cells 
infiltrate adipose tissue and produce chemotactic cytokines such as MCP-1 and MCP-3. 
Such chemokines induce macrophage activation and recruitment into the adipose ti ssue 
[141]. Thus CDS T cells function, in part , by directing myeloid cell trafficking . 
Furthermore, genetic depletion of CDS+ cells can decrease inflammation and improve 
insulin resistance to further demonstrate the importance of CDS+ T cells in adipose 
associated inflammation[141] . Overall, these studies support the concept that T cells 
promote T2D through pro-inflammatory activities , some of which involve other immune 
system members. 
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Multiple in depth studies on pro-inflammatory CD4+ T cells showed that these 
cells likely bolster CD8+ T cell-mediated inflammation in obesity and insulin resistance . 
CD4+ T cells from DIO mice produced elevated levels of IFN-y and IL-17 (although 
CD4+IL-17+ cells were only significantly elevated in subcutaneous adipose tissue) [146] . 
A companion study also showed the T2D-linked cytokine IL-6 increased the number of 
IL-17 producing cells in spleen of obese mice , supporting the possibility that Th17s 
contribute to T2D-associated inflammation and insulin resistance[l91] . Taken together, 
pro-inflammatory T cell subsets play an important role in promoting the chronic systemic 
inflammation found in T2D patients. 
Several studies expanded the demonstration that T cell subset imbalance promotes 
inflammation thus insulin resistance in DIO mice . As outlined above, pro-inflammatory 
Th1 and Th17 cells increase in blood and adipose tissue of obese/insulin resistant mice 
and humans. Importantly, elevated pro-inflammatory T cell subsets are reinforced by the 
natural depletion of CD4+Foxp3+ regulatory T cells (Tregs) in adipose tissue from insulin 
resistant mice[141, 147]. Importantly, ex vivo or in vivo expanded Tregs protect against 
inflammation and insulin resistance [147, 192], at least in mice. These data indicate 
Tregs overall inhibit T2D and promote metabolic health. Further evidence supporting 
this conclusion is that Tregs can reverse the Th1-mediated pathology [146], again 
indicating the importance ofT cell compartment balance in the regulation of adipose 
tissue homeostasis. Overall, multiple studies identify T cell subset imbalances that either 
promote or associate, respectively, with insulin resistance. Our studies outlined in Aim 2 
confirm similar changes in patients with T2D. 
21 
Adipocytes 
Cytokines secreted by multiple immune and non-immune cell types are dominant 
regulators of the pathological inflammation that characterizes and promotes T2D. 
Cytokines originating from the adipose compartment, designated adipokines , play both 
pro- and anti-inflammatory roles in obesity and T2D. The two adipokines linked most 
strongly to insulin resistance and T2D are adiponectin and leptin [193]. Adiponectin is 
generally anti-inflammatory, as exemplified by its ability to decrease macrophage growth 
and function, and NF-KB activation [194, 195] . Leptin has pro-inflammatory activities , 
including the promotion of pro-inflammatory T cell subsets [196]. Overall, adipocytes 
cells are potent sources of strongly diabetogenic cytokines that can induce a feed-forward 
loop in inflammation with immune cells. 
The link between inflammation, fatty acid metabolism and IR 
One of the central questions in the immunometabolism field is to identifY 
mechanisms by which adipocyte and systemic inflammation induces insulin resistance in 
organs such as the muscle and liver. Skeletal muscle is the largest tissue by mass 
regulated by insulin and is responsible for >80% of insulin-stimulated glucose disposal, 
and thus has been the focus of studies in the development of IR [ 197]. It is generally 
accepted that T2D patients have a serious breakdown in lipid dynamics, which is 
reflected by elevated levels of circulating FF As and triglycerides (TG), in addition to 
increased deposition of fat in various tissues, such as the muscle bed [198, 199]. There is 
accumulating evidence indicating that the increased accumulation of fat in muscle and 
other organs plays an important role in the development of IR and potentially in the death 
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of the P-cell in T2D [200]. Multiple labs have indicated that the TG content of muscle has 
a negative relationship to whole-body insulin sensitivity [201]. To demonstrate effects of 
TG within the myocyte, intramyocellular lipid (IMCL) vs. extramyocellular lipid 
(EMCL) were measured using 1H magnetic resonance spectroscopy. This technique takes 
advantage of the fact that there is a small difference in signal between these two types of 
TG, allowing separate quantification ofthe two pools. Interestingly, IMCL was found to 
more tightly correlate with IR than any of the other measurements such as BMI, waist-to-
hip ratio, or total body fat [202]. These data indicate that changes in fatty acid 
metabolism in muscle tissue, specifically inside the myocyte, leads to IR. 
Several studies have shown that inflammatory mediators can affect fatty acid 
metabolism, thereby inducing IR. These inflammatory mediators are produced by 
adipocytes and immune cells in response to increases in endogenous ligands due to 
increasing obesity. TNF-a, adiponectin and leptin have been demonstrated to play 
important roles in changing fatty acid metabolism, leading to IR. TNF -a had no effect on 
FA oxidation but increased FA incorporation into diacylglycerol (DAG) by 45% [203 , 
204] . DAG is an important signaling molecule that activates protein kinase C (PKC), 
leading to the activation of many signaling pathways and has been implicated in the 
pathogenesis of skeletal muscle IR. Adipokines could act as a link between accumulated 
fat mass and altered insulin sensitivity. Adiponectin and leptin, two important adipokines, 
increase fatty acid oxidation and decrease muscle lipid content thereby improving insulin 
sensitivity. However, the ability of leptin and adiponectin to stimulate FA oxidation in 
muscle tissue is impaired in obesity [ 197]. Leptin and adiponectin resistance may be the 
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first step in the accumulation of intramuscular lipids such as DAG, initiating the 
development ofiR [203, 204]. Additionally, inflammatory changes in adipose tissue have 
been associated with obesity-related liver alterations. For example, in high-fat-diet fed 
mice, macrophage infiltration into fat preceded hepatic lipid accumulation [27]. The 
degree of macrophage infiltration into omental fat in humans corresponds to histological 
changes in liver biopsies [205]. TNF -a-induced production of IL-l~ by adipocytes 
induces IR in primary rat hepatocytes, indicating that pro-inflammatory changes in 
hepatic-tissue-associated adipocytes can lead to hepatic IR [206]. Taken together, these 
data indicate that inflammatory mediators can affect fatty acid metabolism thereby 
linking adipose tissue inflammation, systemic inflammation and IR in multiple organ 
systems. 
Aims of this Study 
Recent findings have unequivocally identified type 2 diabetes (T2D) as yet 
another example of a chronic inflammatory disease with changes in immune cell function 
[207 -211]. Most studies have focused on the role of monocytes, demonstrating that 
monocytes from T2D patients constitutively and inducibly secrete elevated levels of IL-6, 
IL-8, TNF-a and IL-l~ [143 , 210-213] . Based on these studies, there have been several 
clinical trials aimed at reducing these inflammatory cytokines thereby reducing IR [78-
81]. Thus far, these trials have had limited success in decreasing inflammation and IR in 
T2D patients despite spectacular results with similar treatments in mouse models ofT2D. 
These data indicate a more complex mechanism involved in inducing chronic 
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inflammation and IR in T2D patients. The potential role of other important immune cells, 
such as lymphocytes, has not been fully elucidated. In this dissertation, B and T cell 
function are examined in addition to the interaction between B cells, T cells and 
monocytes that leads to sustained inflammation in T2D patients. 
To identify roles for lymphocytes in inducing inflammation in T2D patients we 
examined cytokine production in T cells and B cells. First, B cell cytokines have been 
shown to be important mediators of disease in other chronic inflammatory diseases [164, 
214]. To determine whether B cell cytokines could exacerbate inflammation in T2D 
patients, we investigated cytokine production through activation ofTLRs. We also 
determined whether stimulation with different TLR ligands alone or in combination to 
different TLRs lead to changes in cytokine production, testing the possibility that the 
canonic NFKB pathway induced by TLR stimulation has unappreciated layers of 
complexity based on ligand binding and disease state. Second, preliminary studies 
indicated T cells exacerbated inflammation through elevated secretion of IL-l 7. To 
determine the potential mechanisms involved in elevated production ofiL-17, we sought 
to identify whether the IL-17 gene was constitutively active, and if other immune cells 
were involved in activating T cells through soluble factors or cell-cell contact in T2D 
patients. Lastly, we examined whether the interaction between B cells, T cells and 
monocytes played a role in exacerbating inflammation in T2D patients. This work sets 
the baseline for further investigations into the specific mechanisms involved in inducing 
inflammation via these immune cells in T2D patients, leading to the development of new 
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therapeutics or the use of tested autoimmune drugs in decreasing inflammation in T2D 
patients to improve IR. 
26 
In suRa 
Figure 1-1 
Insulin signaling pathway 
Insulin receptor substrate (IRS)-1 is a key protein in the insulin-signaling pathway. 
Binding of insulin to the insulin receptor results in activation of IRS-1. IRS-I then alters 
the activity of a number of downstream signaling pathways to mediate the diverse effects 
of insulin. A detailed description of this pathway can be found in the section "Insulin 
signaling pathway". 
The image is free to use from www. heartandmetabolism.org 
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Figure 1-2 
TLR signaling pathway 
Activation ofTLR4 through ligand binding results in activation of two signaling 
pathways which lead NFKB and IRF3. The MyD88-dependent pathway activates PI3K 
and the IKK's which leads to the release of the NFKB's active subunit p65. P65 then 
translocates into the nucleus to act as a transcription factor. TRIF/TRAM activates IRF3 
which also acts as a transcription factor. In combination, the TLR4 signaling pathway 
activates the inflammatory cascade. Dashed grey lines represent unknown associations. 
Full details describing this pathway can be found in the text in the "Toll-like receptor" 
section. 
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This image is freely available from Wikipedia 
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In this figure, the NF-KB heterodimer between Rel and p50 proteins is used as an 
example. While in an inactivated state, NF-KB is located in the cytosol complexed with 
the inhibitory protein IKBa. Through the intermediacy of integral membrane receptors, a 
variety of extracellular signals can activate the enzyme IKB kinase (IKK). IKK, in turn, 
phosphorylates the IKBa protein, which results in ubiquitination, dissociation of IKBa 
from NF-KB, and eventual degradation ofiKBa by the proteosome. The activated NF-KB 
is then translocated into the nucleus where it binds to specific sequences of DNA called 
response elements (RE). The DNA/NF -KB complex then recruits other proteins such as 
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coactivators and RNA polymerase, which transcribe downstream DNA into mRNA, 
which, in turn, is translated into protein, which results in a change of cell function. 
This image is freely available from Wikipedia. 
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Inflammatory response 
Inflammatory disruption of metabolic functions. Obese or high-fat diet conditions lead to 
the induction of inflammatory signaling pathways in metabolic cells through several 
paths. Nutrients or other metabolites may result in the activation of cytokine or Toll-like 
receptor (TLR) pathways and have access to cellular targets directly or via chaperoning 
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molecules. Three prominent kinases downstream of these receptors are JNK, IKK, and 
PKR, which play important roles in relaying stress signals throughout the cell and 
engaging metabolic responses. All three of these kinases can inhibit insulin signaling via 
serine phosphorylation ofiRS-1. This phosphorylation blocks insulin action downstream 
of receptor activation. In addition, PKR can negatively regulate the translation initiation 
factor eiF2a, leading to inhibition of general translation, and influence ER function. 
These three kinases can induce an inflammatory response through activation of the 
transcription factors AP-1, NF-KB, and IRF, which upregulate inflammatory mediator 
gene expression. The increase in inflammatory cytokines can then lead to exacerbated 
receptor activation as the cytokine signals combine with excess nutrients and establish a 
positive feedback loop of inflammation. Adapted from [215]. 
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CHAPTER 2- MATERIALS AND METHODS 
Cells 
Human samples were obtained after informed consent under a protocol approved 
by the Boston University Institutional Review Board and conducted in accordance with 
the Declaration of Helsinki. We analysed cells from a cross-sectional group of T2D 
patients recruited from the Center for Endocrinology , Diabetes and Nutrition at Boston 
Medical Center. The cohort excluded individuals with common infections s2 weeks prior 
to donation or those with non-T2D related inflammatory or auto-immune disease. T2D 
patients were defined as: (1) under the care of a Center for Diabetes provider; (2) on one 
or more diabetes medications; and (3) having a diagnosis of diabetes on the clinical 
"problem" list. Approximately 50% of the T2D patients would be considered average risk 
and several as high risk for cardiovascular disease , as previously defined by CRP [216]. 
Aim 1 
Peripheral blood was collected into heparinised tubes by venous puncture and B 
cells were purified with CD19 excluding magnetic beads (Pan B cell kit , Miltenyi). The 
majority of contaminating cells in the >96% pure B cell preparations were T cells; 
monocyte contamination was undetectable. Table 1-1 outlines the T2D patients (n=ll; 
nine with type 2 diabetes , two with type 1 diabetes but lacking autoimmune antibodies) 
who provided blood B cells for cytokine analyses. B cells were also provided by ND 
periodontal disease (PD) patients who had diagnoses of localised aggressive periodontitis 
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[217] but no other known disease. These patients (n=14) were recruited from the Clinical 
Research Center at Boston University Medical Center (Table 1-2). The patients were 
characterized by periodontal infection with multiple organisms including P. gingiva/is 
and Actinobacillus actinomycetemcomitans. In most cases, chronic infection leads to 
severe, aggressive, and early-onset bone loss around first molars and incisor teeth only. 
Clinical and radiographic criteria of PD included age of onset around the circumpubertal 
period ( <13 years old) and alveolar bone loss localized around the first permanent molars 
and incisors [217]. In addition, the subject' s periodontal diagnosis was confirmed further 
by neutrophil functional analysis [218]. Healthy donors had no indication of metabolic or 
PD excepting mild gingivitis (n=19; Table 1-2). None of the subjects smoked. 
Aim2 
Peripheral blood was collected into heparinized tubes by venous puncture and 
PBMCs or CD3+ T cells were purified by histopaque 1077 and negative selection with 
CD3 cell-excluding magnetic beads (PanT cell kit , Miltenyi) as applicable. Only T cell 
preparations that were >97% pure as re-analyzed by flow cytometry for CD3 expression 
were used in all analyses requiring purified T cells. For "fresh ex vivo" chromatin 
immunoprecipitation (ChiP) assays, CD3+ T cells were analyzed after a 1 hr rest on ice 
following negative isolation . CD14 positive selection was used to deplete monocytes 
(CD14-) from PBMCs for add-back experiments. Alternatively, T cells or monocytes 
were purified by negative selection and were co-cultured at a 1:1 ratio (designated M+ T) 
for 40 hours in the presence or absence of stimuli. 
Aim3 
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Peripheral blood was collected into heparinized tubes by venous puncture and 
PBMCs, monocytes (human monocyte kit, Miltenyi), B cells (Pan B cell kit, Miltenyi) or 
CD4+ T cells (CD4 negative selection kit, Miltenyi) were purified by histopaque 1077 
(GE healthcare) and negatively selected with CD14, CD19 or CD4 cell-excluding 
magnetic beads as applicable. CD19 positive selection was used to deplete B cells 
(CD19-) from PBMCs for depletion experiments. Negatively selected monocytes, B cells 
and CD4+ T cells were co-cultured at physiological concentrations (B cells and 
monocytes at 10% ofT cells) for 40 hours in the presence or absence of stimuli. Table 2-
1 outlines the ND donors (n=22) and T2D patients (n=23) who provided blood cells for 
cytokine analyses. 
Flow cytometry 
Aim 1 
For surface staining, 100 !-!1 whole blood (coded to avoid bias) was labelled with 
conjugated antibodies purchased from BD Pharmingen (San Diego, CA, USA: anti-CD3, 
-CD14 and -CD19 or eBioscience (San Diego, CA, USA: anti-TLR4 and isotype 
controls). Erythrocytes were lysed with 2 ml 1xFACS Lysing Solution for 30 min. Cells 
were washed with 0.2% (wt/vol.) bovine serum albumin/phosphate buffered saline 
(BSA/PBS) and fixed with 2% (wt/vol.) paraformaldehyde, then analysed on a 
FACSCaliber (BD Biosciences, San Jose, CA, USA) with WinMDI software (Joseph 
Trotter, The Scripps Institute, Palo Alto, CA, USA). Intracellular staining was completed 
on mononuclear fractions incubated in medium or with anti-Ig!-! for 24 h. Brefeldin A 
(eBioscience) was added at 21 h. Cells were stained with anti-CD14 or anti-CD19 for 
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20 min at 4°C , and then washed with 0.2% (wt/vol.) BSA/PBS, and treated with Fixation 
buffer then IxPermeabilisation buffer (eBioscience). Cells were then stained with anti-
TNF-a, anti-IL-IO (eBioscience) or anti-IL-8 (BD Pharmingen), and washed with 
I xPermeabilisation buffer. Resuspended cells were analysed on a F ACScan (BD 
Biosciences) with CellQuest (BD Biosciences) and FloJo (Tree Star, Ashland, OR, USA) 
software. 
Aim2 
I 00 fll of whole blood was incubated with :fluorescently labeled antibodies for 
30 min at 4°C. Red blood cells were lysed with 2 ml of IX FACS™ Lysing Solution (BD 
Pharmingen) for 30 min RT. Stained cells were washed with 0.2% BSA/PBS and 
resuspended in PBS for analysis of CD3/CCR4/CCR6. The following antibodies were 
purchased from eBioscience: FITC-labeled anti-CD3, PE-labeled anti-CCR4, PE-Cy5-
labeled anti-CCR6, FITC-labeled anti-IL-I7A, PE-labeled IFNy and the human Foxp3 
staining kit: PE-labeled Foxp3 , APC-labeled CD25 and FITC-labeled CD4. Alternatively, 
PBMCs were incubated with plate bound a-CD3 (2f,lg/ml of a-CD3 in PBS incubated in 
plate for Ihr at 37°C) and soluble a-CD28 (2f,lg/ml) or PHA (3f,lg/ml) for 40hrs with 
3ug/ml of Brefeldin A ( eBioscience) added during the last 5 hours of culture. Cells were 
stained for intracellular cytokine expression with PE-Cy5-labeled anti-CD3 then treated 
with IX permeabilization buffer (eBioscience) and stained with FITC-labeled anti-IL-
I7 A or PE-labeled IFN-y. Freshly isolated PBMCs were used for Foxp3 staining 
following the eBioscience protocol. Cells were analyzed on a F ACSCalibur or an LSRII 
(BD Biosciences) run by FACS Diva and FlowJo software (Tree Star). 
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Biochemistry 
Aim I 
B cells were negatively isolated with magnetic beads (Miltenyi, Auburn, CA, 
USA) and rested (1 h 3rC) before stimulation. Cultures were 250,000 cells/250 ~J.l in U-
bottom wells. For constitutive cytokine production, B cells were incubated in complete 
medium (RPMI, 10% [vol./vol.] heat-inactivated FCS) alone. Alternatively, TLR ligands, 
or anti-Ig~J./anti-CD40 were each added to a concentration of 1 ~J.g/ml. TLR ligands 
(Invivogen; San Diego, CA, USA) were: Pam3CSK4 (Pam3; TLR2ligand), Rhodobacter 
sphaeroides lipopolysaccharide (LPS) (rLPS; TLR4 ligand [31 ]), CpG 
oligodeoxynucleotide (ODN) 2006 (TLR9ligand) and ultrapure E. coli LPS 0111 :B4 
(TLR4 ligand). Cells were stimulated for 24 h prior to cytokine analysis with an 
Invitrogen (Carlsbad, CA, USA) kit that measured IL-l j3, IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, IFN-y, TNF-a and granulocyte/macrophage colony stimulating factor (GM-CSF) on a 
Lurninex 200 machine (Luminex, Austin, TX, USA) using the Human inflammatory 
cytokine 10-plex kit. Chromatin accessibility by real-time PCR (CHART-PCR) was 
completed as published [219]. 
Aim2 
Cells were cultured in complete medium (RPMI, 10% [vol./vol.] heat-inactivated 
FCS with penicillin/streptomycin) with or without a-CD3 (2!J.g/ml of a-CD3 in PBS 
incubated in plate for lhr at 37°C) and soluble a-CD28 (2J.Lglrnl) and/or LPS (lOOng/ml) 
for 40 hours. Cytokines were quantified in 40 hr supernatants by ELISA or cells were 
analyzed by chromatin immunoprecipation (ChiP) either fresh ex vivo, or following a 40 
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hr. stimulation. ChiPs were performed using 500,000 human or 107 murine cells per 
antibody. Fold enrichment was calculated by 2(Ctinput-CtChiP) after quantitative 
amplification of equivalent picogram amounts of DNA [220]. The appropriate amount of 
antibody was determined empirically, and the same microgram amount of a.-histidine tag 
antibody was added in the control samples. ChiP-competent antibodies were as follows: 
a.-histidine tag antibody (SC-803; Santa Cruz Biotechnology) as a nonspecific 
isotype/species-matched control and a.-acetylated histone H3 (06-599; Upstate). 
Precipitated DNA was quantitatively amplified with primers specific to IL-17A: 5'-
GTGGTTGACCCGGAGTTACfG-3 'and 5' -CCTTCGGGAAATGGAATAAAAA-3' or 
RORC: 5'-CCCAGCACACAGTAAGTGATTAATAAA-3' and 5'-
TGGAGCCTTGAGGAGAAACAG-3'. For IL-17 secretion analyses, supernatants were 
alternatively collected from cultures 4 days following stimulation. 
For monocyte mRNA analyses, negatively isolated monocytes were rested for one 
hour at 37°C followed with LPS (lOOng/ml) stimulation for 0.5hr, lhr, 2hrs , 3hrs, 4hrs, 
5hrs and 6hrs. Cells were lysed with Buffer RLT (Qiagen) containing 10% beta-
mercaptoethanol. RNA isolation was performed with the RNAeasy kit (Qiagen). RNA 
was DNAase treated for 20mins at 37°C and the enzyme was inactivated for lOmins at 
65°C. Reverse transcription was performed using 0.5 U AMV RT (Promega) for lhr at 
42°C. "No RT" controls were universally blank. eDNA was quantitatively amplified with 
primers specific to IL-l~ [221] or TNFa: 5 '-GGCCT ACAGCTTTGATCCCTG-3' and 
5'-AAAGGCTCCCfGGTCTCCAG- 3'. Cytokine levels in cell culture supernatants 
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were measured by ELISA or multiplex assays (Invitrogen) and analyzed with the 
Softmax program or Bioplex Manager 5, respectively. 
Aim3 
Cells were cultured in complete medium (RPMI, 10% [vol./vol.] heat-inactivated 
FCS with penicillin/streptomycin) with or without a-CD3 (1f.Lg/ml) and a-CD28 
(1f.Lg/ml) and/or LPS (lOOng/ml) for 40 hours. IL-17 was quantified in 40 hour 
supernatants by ELISA (R&D Systems catalog# DY317) and analyzed with the Softmax 
program. 
Statistics 
The Mann-Whitney U test or an unpaired t-test was used to compare values 
within cohorts as indicated in the figure legends. A 2-way ANOV A was used to identify 
differences in between cohorts (ND vs. T2D) as indicated. Paired non-parametric 
(Wilcoxon) t tests established significance for cytokine production by variously 
stimulated B cells from the same individual. A Pearson test was used to identify 
parametric correlations for all applicable panels. A linear regression was used to identify 
relationship indicated in Figure 2-7D. p<0.05 was defined as a significant difference. 
Analyses were performed on Prism (GraphPad Software, La Jolla, CA, USA). Sample 
numbers varied because of the variable number of cells isolated per donor . 
Notes: 
Two of the subjects in Aim 1 in the "diabetes" cohort were type 1 diabetics but 
were not outliers in any of the analyses and had no autoimmune antibodies. Removal of 
these patients would result in a decrease in the power of the analysis. Due to this they 
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were included in the study . Thus , in Aim 1 patients will be referred to as "diabetics" 
rather than "T2D". In Aims 2 and 3 the diabetic cohort will be referred to as "T2D", 
which does not include any type 1 diabetic patients . 
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CHAPTER 3-RESULTS 
Aim 1: Toll-like receptors regulate B cell cytokine production in patients with 
diabetes. 
Human B cells express multiple TLRs and can produce both pro- and anti-
inflammatory cytokines in response to TLR ligands [155-158]. B cells from healthy 
humans, in contrast to mice, generally express little to no surface TLR2 and TLR4 [155, 
156, 159, 160]. However, our work demonstrated that B cells from chronic inflammatory 
disease patients , specifically periodontal disease (PD), have elevated responses to TLR2 
and TLR4ligands compared with B cells from healthy donor ([159]. These studies also 
showed that cross-talk between TLRs differentially regulate cytokine production by B 
cells from patients compared with healthy donors (Appendix 2, also published in [168]) . 
Overall, this work highlighted the complexity and elegant specificity of the B cell 
response to TLR ligands, and suggested that B cell TLR expression and downstream 
cytokine production influences the overall milieu in chronic inflammation . Our studies 
introduced B cell TLRs and TLR-downstream cytokine production as potential players in 
chronic non-autoimmune inflammatory disease for the first time. Based on high incidence 
of PD in diabetes patients, these studies raised the possibility that B cells from many 
diabetes patients may also play roles in systemic inflammation. 
Differences between TLR expression and function in B cells from chronic 
inflammatory disease patients [168, 222] led us to question how B cell TLRs function in 
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diabetes patients. We demonstrate that TLR ligands activate B cell cytokine production, 
most significantly IL-8, in diabetes mellitus (DM) vs . non-diabetic (ND) donors. Pro-
inflammatory cytokine production is likely to be physiologically bolstered by the 
complete inability of B cells from DM patients to upregulate IL-10 secretion in response 
to TLR ligands. Surprisingly, the B cell response to combinations of TLR ligands 
uncovered disease-associated changes in TLR function. These results indicate that altered 
TLR function rather than surface expression levels regulate the B cell contribution to 
diabetes. The unexpected anti-inflammatory function of TLR4 coupled with signatures 
more characteristic of pro-inflammatory cells indicates that fundamental alterations in B 
cell responses play complex, overall pro-inflammatory roles in systemic inflammation in 
diabetes. 
B cells from DM patients constitutively secrete IL-8 
B cells are important sources of multiple cytokines in vivo [164, 166]. We 
reasoned that if B cell cytokines play a role in systemic inflammation in DM, fresh ex 
vivo B cells from DM vs. ND donors should differentially produce cytokines. We 
analysed constitutive cytokine production by highly purified populations of B cells, 
devoid of monocytes (Fig. 2-1A). Additional measures, previously described [168], 
ensured even small numbers of theoretically contaminating monocytes contributed <10% 
of total measured cytokines in these assays. B cells from DM and ND donors 
constitutively secreted similar levels of GM-CSF and IL-6 (Fig. 2-1B). In contrast, B 
cells from DM vs. ND donors constitutively secreted significantly lower levels of TNF-a 
and the anti-inflammatory cytokine IL-10 (Fig. 2-1B), but significantly higher levels of 
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the pro-inflammatory cytokine (a neutrophil chemokine) IL-8 (Fig. 2-lC). Intracellular 
staining data confirmed that cytokines originated from the CD19+ B cell population (Fig. 
2-lD). Importantly, comparison of intracellular cytokine staining forB cells vs. 
monocytes from the same individuals show that B cells from DM patients are uniquely 
defective for IL-10 production (Fig. 2-lD,E) . For all cytokine analyses, results from type 
1 (n=2) and type 2 DM patients (n=9) were indistinguishable (data not shown). These 
data support the conclusion that B cells from OM patients make a significantly different 
contribution to the circulating balance of cytokines than B cells from ND donors. The 
mixed anti-inflammatory (lower TNF-a production) and pro-inflammatory (decreased 
IL-l 0 and increased IL-8 production) signature suggests that B cells may play an 
unappreciated role in the chronic inflammation of DM. 
A modestly elevated percentage of B cells from DM patients express surface TLR4 
Monocytes produce IL-8 in response to ligands that engage TLR2 or TLR4 [160]. These 
findings raise the possibility that constitutive B cell IL-8 production (Fig. 2-lC) may 
stem from chronic TLR engagement in vivo. However, multiple studies have shown 
human B cells respond poorly to TLR2 and TLR4ligands, probably because of low 
surface expression of their receptors [156, 159, 223]. We therefore speculated B cells 
from DM patients constitutively secrete high levels of IL-8 owing to elevated expression 
of surface TLRs that allow increased engagement by endogenous ligands. We first 
measured surface levels of TLR4 on B cells from DM and ND donors in whole blood as 
shown in Fig. 2a. The median percentage ofTLR4-positive B cells from the DM cohort 
(Fig. 2-2B, 27.1%) was significantly higher ("60%, p=0.024) than the median percentage 
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of TLR4-positive B cells from healthy individuals (16.5% ). The mean fluorescence 
intensity (MFI), an indication of the number of cell smface TLR4 molecules, was similar 
between the two cohorts (not shown). This modest increase in the percentage of surface 
TLR4-positive B cells in DM patients is consistent with the demonstration that the TLR4 
promoter is packaged into an equivalently accessible chromatin structure in B cells from 
DM and ND donors (Fig. 2-2C). Notably, preliminary detailed flow cytometric analyses 
showed TLR4 was globally upregulated on all circulating B cell subsets (data not shown). 
Furthermore, we detected no overall differences in the distribution of B cell 
subpopulations in ND vs. DM donors for a standard group of human B cell surface 
markers (data not shown). Percentages of TLR4-positive B cells did not correlate with 
age, BMI, PD or statin use in preliminary analysis of confounding factors (not shown). 
Importantly, the percentage of TLR4-expressing blood monocytes (CD 14+ cells) or 
neutrophils (CD141owCD631owMac-1high) was similar between DM and ND donors (Fig. 2-
2D), suggesting that modestly increased percentages of TLR4-positive B cells in (Fig. 2-
2B) was cell-type limited and of potential biological significance. Note that the monocyte 
data contrast with reports showing increased TLR4 expression on purified monocytes 
from newly diagnosed type 2 DM patients [124], raising the possibility that either DM 
drugs taken by our DM cohort, or activation of monocytes during processing in the cited 
work may influence monocyte TLR4levels. Regardless, B cells from DM and ND donors 
expressed indistinguishable smface levels of RP105, an alternative LPS receptor, as 
measured by mean fluorescence intensity (MFI) (Fig. 2-2E) or percentage of positive 
cells (>95% for both cohorts, not shown). Furthermore, our published analyses showed 
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no difference in the percentage ofTLR2-positive B cells from OM and ND donors [160]. 
These modest/insignificant changes in surface TLR expression on B cells from DM 
patients suggest that if constitutive IL-8 production is TLR-dependent, TLR function, 
rather than TLR expression must differ between DM vs . ND B cells . 
TLR2 and TLR4 ligands regulate B cell cytokine production 
To identify OM-associated differences in B cell TLR function, we stimulated 
purified B cells from DM and ND donors with model TLR ligands and measured 
cytokine production. Pam3ffLR2 activation of B cells from DM and ND donors showed 
that DM B cells produced significantly increased levels of IL-8 (Fig . 2-3A) . The TLR-
activated IL-8 levels produced by B cells were in the same range as levels of IL-8 
production reported for monocytes [224]. B cells from DM patients, but not healthy 
donors, also produced IL-8 in response to anti-lgfl stimulation (Fig. 2-3B) , indicating DM 
B cells may be abnormally poised to produce IL-8. Although TLR2ligand significantly 
increased production of multiple cytokines by DM B cells (Table 1-3), increased cytokine 
production was indistinguishable in comparisons between B cells from DM and ND 
donors (Fig. 2-3C,D), and increased IL-10 production (to "'10 pg/ml) was quantitatively 
meagre. These results are consistent with published data showing NOB cells respond 
modestly to TLR2 stimulation [223] . In addition, B cells from DM vs. ND donors 
responded to the TLR4ligand rLPS by producing elevated levels of IL-8 , but similar 
levels of other cytokines tested (Fig. 2-3A,C,D). Under all conditions, B cells from DM 
and ND donors produced undetectable levels of interleukin-2, interleukin-4, interleukin-5 
and interferon-y (IL-2, -4, -5 and IFN-y) (not shown) , consistent with the interpretation 
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that T cells, the major contaminant of B cell preparations (<2%) insignificantly 
contributed to TLR-induced cytokine production. Overall, these data support the idea that 
elevated constitutive IL-8 production shown for DM B cells in Fig. 2-lC could result 
from in vivo hyper-response to TLR2 and/or TLR4 ligand, in the absence of highly 
elevated surface TLR expression (Fig. 2-2B and Noronha et al. [20]). 
To further test the possibility that IL-8 is uniquely poised for TLR-mediated 
activation in DM B cells, we expanded our analysis of TLR-responsive cytokines by first 
measuring cytokine production in B cells responding to the prototypic TLR4ligand E. 
coli LPS. Although B cells from DM donors produce significant amounts of IL-8 in 
response to E. coli LPS (>2 ng/ml on average [Fig. 2-3A]), B cells from both DM and 
ND donors responded similarly to E. coli LPS (Fig. 2-3E) as indicated by quantification 
of GM-CSF, IL-l~ and TNF-a production. Note that high variability in values from ND 
donor B cells prevented direct comparison with IL-8 production by NO B cells (not 
shown). The overall response of all B cells to E. coli LPS was relatively modest (i.e. 
<200 pg/ml cytokine, Fig. 3e), consistent with the general dogma that human B cells fail 
to respond vigorously to this TLR4ligand. This lack of response is probably because of, 
at least in part, the lack of the LPS deli very molecule CD 14 on the B cell surface (data 
not shown). Importantly, E. coli LPS failed to activate even modest production of IL-10 
by B cells from DM donors, instead producing levels that were lower than levels 
produced by ND B cells (Fig. 2-3E). We conclude that DM-associated differences in B 
cell TLR function specifically increase IL-8 production (Fig. 2-3A), but are not 
'generally' pro-inflammatory as measured by diabetogenic cytokines such as TNF-a and 
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IL-l~ . Furthermore, the data suggest that B cells from DM patients are deficient in anti-
inflammatory IL-10 production. 
TLR engagement can activate B cell IL-10 production, which is critical for 
inflammatory disease resolution [225]. To more rigorously test the possibility that B cells 
from DM patients fail to produce IL-10 in response to TLR engagement, we measured 
IL-10 production by DM and ND B cells responding to a more comprehensive panel of 
TLR ligands. In contrast to B cells from NO donors, B cells from DM patients fail to 
activate even modest IL-10 production (>20 pg/ml) in response to TLR2 (Pam3) or TLR4 
(rLPS) ligand (Fig. 2-4A). The latter finding is consistent with decreased IL-10 response 
in DM vs. NOB cells stimulated by E. coli LPS (Fig. 2-3E). More surprisingly, B cells 
from DM patients fail to produce IL-10 in response to CpG, a TLR9ligand known to 
activate ND B cells (Fig. 2-4a). As a control, we confirmed that CpG equivalently 
activates B cells from DM and ND donors to produce GM-CSF, TNF-a and IL-6, and 
that CpG-triggered pathways that activate cytokine production are fundamentally intact in 
B cells from OM patients (Fig. 2-4B and Table 1-3). These data support one of two 
possible interpretations: TLR engagement fails to activate IL-10 production, or TLR 
engagement actively represses IL-10 production by B cells from DM donors. Our 
preliminary data showing IL-l 0 is not produced by B cells from OM patients responding 
to anti-Igf,l plus CD40 (n=6; not shown) support the possibility of TLR-independent 
defects in IL-10 activation in these cells. 
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TNF-a is uniquely regulated by TLR4 engagement in B cells from DM patients 
Many endogenous and pathogen-associated pro-inflammatory ligands activate 
innate immune system cells through combinations of TLR2 and TLR4 ligands [226]. 
These findings raise the possibility that differences in TLR4 function play an important 
role in responses to more complex ligands in B cells from DM patients. To model B cell 
interactions with complex ligands and to further identify alterations in TLR function in B 
cells from DM patients, we co-stimulated cells with Pam3 and rLPS to simultaneously 
activate TLR2 and TLR4. We then compared cytokine production in B cells stimulated 
with Pam3 alone vs the two-ligand combination. For some cytokines, rLPS (TLR4 
ligand) significantly decreased Pam3 (TLR2)-mediated cytokine production by B cells 
from both DM and ND donors (GM-CSF; IL-6, Fig. 2-SC,G). However, rLPS 
significantly decreased TLR2-mediated TNF-a production in B cells from DM patients, 
but failed to consistently alter TNF-a production by B cells from ND donors (Fig. 2-
50 ,H). Importantly, B cells from DM patients fail to secrete IL-l 0 even in the presence 
of dual stimuli, further supporting the conclusion that IL-10 production is uncoupled 
from TLR-downstream pathways only in B cells from DM patients (Fig. 2-SB,F). The 
quantitative decrease in TNF-a production by B cells from DM patients caused by TLR4 
engagement is modest (""'30% decrease). Nonetheless, these findings support the 
conclusion that TLR4 function is fundamentally altered in B cells from DM patients . 
Furthermore, the data reveal the specificity by which altered TLR function regulates B 
cells. 
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The TLR ligand response of B cells from DM patients is disease-influenced 
B cells from multiple chronic inflammatory diseases, including Periodontal 
Disease (PD), secrete cytokines in response to TLR engagement. Because many DM 
patients have confounding PD, we asked whether responses of B cells from DM and ND 
PD patients are similar. Although TLR-induced production of some cytokines by B cells 
from DM vs. PD patients was statistically indistinguishable (Fig. 2-6A,C; GM-CSF and 
IL-6, respectively) , only B cells from PD patients produced IL-10 in response to all 
stimuli tested (Fig. 2-6B) . Furthermore, IL-8 responses to TLR4ligand were 
quantitatively lower in B cells from DM compared with PD patients (Fig. 2-6D). Finally, 
B cells from PD vs. DM patients produce significantly more TNF-a in response to TLR4 
and TLR9ligand (Fig. 2-6E). The TNF-a results are consistent with the demonstration 
that TLR4ligand decreases TLR2-stimulated TNF-a production by B cells from DM 
(Fig. 2-5) but not PD donors. Furthermore, the overall increase in pro-inflammatory 
responses of B cells from PD patients supports the probability that the differences in the 
age of the cohorts (PD and ND median age is indistinguishable but DM patients are 
significantly older; Tables 1-1 and 1-2) cannot explain pro-inflammatory changes in DM 
B cells. Finally, differences in the subcategory of PD in our defined PD cohort vs : our 
periodontally undefined DM cohort may underlie differences in B cell cytokine 
production . We conclude that disease pathology influences the B cell response to TLR 
ligands. These data further show that lack of B cell IL-10 production is specific to DM. 
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Section summary for Aim 1 
Our data indicate that B cells in DM patients contribute to the inflammatory 
milieu through TLR mediated IL-8 production, along with a loss in IL-10 production. 
Importantly, these data also demonstrate an elegant specificity of TLR-mediated B cell 
activation in disease. Taken together, an increase in the potent pro-inflammatory cytokine 
IL-8, along with a loss in the anti -inflammatory cytokine, IL-10 in B cells from DM 
patients indicates an important role for these cells in inducing or sustaining the 
inflammatory state of DM. 
Aim 2: Elevated production ofiL-17 by a skewed T cell compartment promotes 
inflammation in T2D. 
T cells have been implicated in the pathogenesis of multiple inflammatory 
diseases, and many autoimmune and inflammatory disorders are driven by specific T cell 
subsets [173-177]. Overall, links between IL-17 /IFNy downstream functions and chronic 
inflammatory conditions indicate an important role for these T cells in the induction and 
exacerbation of multiple diseases. Several studies specifically demonstrate a role forT 
cell subset imbalance in mouse models ofT2D inflammation . Regulatory T cells (Tregs) 
are naturally depleted in adipose tissue in an insulin-resistant model of obesity compared 
to adipose tissue from lean mice. These data clearly indicating the importance ofT cell 
compartment balance in the regulation of adipose tissue homeostasis. However, similar 
studies have not been reported in T2D patients despite the compelling demonstrations 
that T cell subset imbalance promotes insulin resistance in animal models . 
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T2D patients have elevated serum levels of IL-6, IL-1~ and TGF~, three 
cytokines known to induce Th17 differentiation [187, 227-230]. These data, in 
combination with the mouse studies outlined above, raise the possibility that elevated 
Th 17 -associated cytokines in T2D patients promote Th 17 skewing and/or IL-17 
secretion, while potentially inhibiting Treg differentiation. We sought to identify whether 
there are changes in the T cell compartment which could promote chronic inflammation 
in T2D patients. Studies herein identify an increased percentage of circulating memory 
Th17 cells in T2D vs. non-diabetic (ND) donors, and stimulation of PBMCs with T cell 
mitogens results in elevated IL-17 secretion. Additionally , monocytes are required for 
maintenance of the pro-inflammatory T cell phenotype in T2D samples. In contrast, T2D 
patients have decreased percentages of circulating Tregs compared to ND donors, thus 
recapitulating findings in T2D mouse models. We conclude that T cells in T2D patients 
are skewed towards a pro-inflammatory phenotype that requires monocytes for 
maintenance and likely promotes chronic inflammation in T2D through elevated IL-17 
production. 
Th17 cells are elevated in T2D patients. 
T2D patients have elevated serum levels of cytokines implicated in human Th17 
differentiation [187, 228-230]. To test the possibility that these cytokines promote 
inflammation in T2D patients through increased Th17 differentiation, we took advantage 
of the demonstration that C-C chemokine receptor type 4 and 6 (CCR4/CCR6) double 
positive staining identifies human memory Th17 cells [231]. We quantified the 
percentage of CD3+ CCR4+ CCR6+ T cells in whole blood ofT2D and ND donors as 
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shown in Fig. 3-1A. T cells were identified first by gating of the lymphocyte population 
based on forward and side scatter (not shown) followed by identification of the CD3+ 
population (not shown). On average, an increased percentage ofT cells in T2D patients 
co-express CCR4 and CCR6, compared to percentages measured in ND donors 
(13 .03 %+/-3.4% or 7.19%+/-2.5%, respectively; p<0.01 ; Figs. 3-1A, right , and 3-1B). To 
independently verify these findings, we purified T cells from T2D or ND donors (Fig. 3-
1C) and measured molecular signatures ofiL-17 gene activation in fresh ex vivo purified 
T cells. Fig. 3-lD shows that only T cells from T2D patients package the IL-17 promoter 
into active chromatin structures as evidenced by significant association of acetylated 
histone H3 measured by ChiP. 
Obesity and T2D are tightly linked; therefore, either condition could explain the 
elevated percentage of CCR4+CCR6+ T cells in our generally obese T2D cohort. To test 
whether obesity plays a major role in determining levels of circulating Th17 cells, we 
calculated the relationship between BMI (body mass index), a standard measure of 
obesity, and percentage of CD3+CCR4+CCR6+ T cells for each donor. We found a 
positive correlation between BMI and percentage of CD3+CCR4+CCR6+ T cells only in 
the T2D cohort (Fig. 3-lE, right). This analysis indicates that obesity likely plays a minor 
role in determining levels of circulating Th17 cells. Overall, we conclude that the chronic 
inflammatory milieu of T2D patients associates with elevated percentages of circulating 
Th17 cells. 
53 
PBMCsfrom T2D patients secrete elevated levels of IL-17. 
Based on the elevated percentages of CCR4+/6+ T cells and the activate IL-17 
gene structure shown in Fig . 3-1 , we predicted that T cells from T2D patients would 
secrete increased levels of the pro-inflammatory cytokine IL-17. We first tested the 
possibility that T cells in the context of PBMCs from T2D patients produce elevated 
levels ofiL-17 constitutively and/or in response to stimuli. Constitutive IL-17 production 
by PBMCs from T2D donors was modestly , but statistically insignificantly , elevated 
compared to PBMCs from ND donors (Fig. 3-2A "media"). However, PHA stimulation 
resulted in significantly elevated IL-17 production by PBMCs from T2D patients 
compared to ND donor PBMCs (3.6-fold increase, p=0.0079) or to unstimulated T2D 
PBMCs (15.5-fold increase, p=0.0002). IL-17 production by stimulated PBMCs from 
T2D vs. ND donors remained significantly elevated after 4 days in culture (data not 
shown). aCD3+aCD28 stimulated PBMCs from T2D patients also secreted elevated 
levels of IL-17 compared to stimulated PBMCs from ND donors (2.5 fold increase, 
p=0.04) or to unstimulated T2D PBMCs (8.8 fold increase , p=0.0008). Furthermore, the 
levels of IL-17 production in PHA stimulated PBMCs is higher than in aCD3+aCD28 
stimulated PBMCs (1.75 fold) in the T2D patients , but this increase did not achieve 
statistical significance. Finally, LPS stimulation increased IL-17 secretion only in 
PBMCs from T2D patients (p=0.01 compared to media); however, the increase was 
quantitatively modest. Overall , PBMCs from T2D patients secrete elevated levels of IL-
17 in response toT cell stimuli compared to PBMCs from ND donors . 
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Based on the tight link between obesity and T2D patients, we investigated 
whether this elevation in IL-17 production in T2D patients could be due to obesity rather 
than T2D. We tested this possibility by comparing IL-17 secretion in PBMCs from lean 
ND's (BMI<30) and obese ND's (BMI>30). Both of these cohorts secrete approximately 
equivalent levels of IL-17 when stimulated with aCD3+aCD28 (Fig. 3-2B). These data 
indicate that the increase in IL-17 secretion in the T2D cohort is specific to T2D and is 
not attributable to obesity. 
Th17 cells are characterized by activation of multiple genes including the 
inflammatory cytokine IL-17 and the Th17 master regulator RORC [232-235] . To 
independently verify elevated IL-17 production in Fig. 3-2A, we compared activation 
signatures on key Th17 genes in PBMCs from T2D and ND donors. Only PBMCs from 
T2D patients constitutively package the IL-17 (Fig. 3-2C) and RORC (Fig. 3-2D) 
promoters into active structures as evidenced by increased association of acetylated 
histone H3. These findings support the likelihood that T cells from T2D patients are 
constitutively activated and are therefore poised for IL-17 production, as further 
evidenced by analysis of fresh ex vivo T cells (Fig 3-1D). In contrast, PBMCs from ND 
donors have an activated chromatin signature at the IL-17 and RORC genes only if they 
are stimulated with aCD3+aCD28 (Figs. 3-2C and D, white bars). These data indicate 
activation ofiL-17 signature genes requires aT cell receptor-specific signal in T cells 
from ND donors. Despite quantitatively similar association of acetylated H3 with the IL-
17 promoter in aCD3+aCD28 stimulated ND and T2D cells , IL-17 protein production 
remains significantly lower in the ND donor samples (Fig. 3-2A). This comparison 
55 
suggests multi pie layers of regulation for IL-17 production in ND donors is lost in T2D 
patients. We conclude that T cells from T2D patients are poised to express IL-17, 
consistent with skewing ofT cells to the pro-inflammatory Th17 subset. 
Molecular signatures ofTit17 cells and elevated IL-17 production are specifically 
attributable to T cells. 
New evidence demonstrates that non-T cells can also secrete IL-17, albeit at much 
lower concentrations than Th17 cells [236]. These data highlight the importance of 
specifically showing that T cells are the source of elevated IL-17 in T2D. Intracellular 
staining confirmed significant IL-17 protein was limited to the T cell population, with a 
statistically significant elevation in samples from T2D donors stimulated with PHA or 
aCD3+aCD28 (Figs. 3-3A&B). Note that only T cells from T2D patients significantly 
elevated IL-17 production when stimulated with PHA and CD3+28 (Fig. 3-3B). 
Evaluation of MFI for IL-17 in CD3+ T cells indicated that the estimated number of IL-17 
molecules per cell does not increase with stimulation, although each cell constitutively 
hyper-produced IL-17 (Fig. 3-3C). The percentage of IL-17+ T cells did not correlate with 
age or BMI in analyses of all samples used for these measures (Fig. 3-3D), although the 
relationship between the percentage of IL-17+ T cells and age trended towards 
significance in aCD3 plus aCD28-stimulated samples (top right panel; p=0.07). 
Regardless, the lack of strong correlation indicates that differences in age or BMI 
between ND and T2D donors (see below) do not play dominant roles in determining the 
percentage of circulating IL-17+ T cells. 
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To verify that the molecular signatures of poised and activated Th17 cells implied 
in Figs. 3-2B&C are T cell-specific, we cultured PBMCs from T2D patients and ND 
donors for 40 hours and then isolated purified T cells (denoted "P2T") and evaluated 
Th 17 signature genes by ChiP. T cells from T2D patients have elevated association of 
acetylated histone H3 to both the IL-17 (Fig. 3-3E) and the RORC (Fig. 3-3F) promoters, 
although the former failed to reach significance in unstimulated samples (Fig. 3-3E, left). 
As expected, association signals in the P2Ts are quantitatively greater compared to the 
PBMCs, probably due to dilution of the T cell signal in the PBMC cultures (Figs. 3-
4A&B). Additionally, comparison of molecular signatures in fresh ex vivo T cells and 
P2T T cells confirms that the in vivo Th17 signatures are stable in culture when T cells 
are maintained in the context of PBMCs (Fig. 3-4C, compare fresh ex vivo to P2T values, 
no statistically significant changes, p>0.05). These data also indicate that P2T T cells 
recapitulate fresh ex-vivo T cell attributes. 
T cells require monocyte co-culture to maintain skewed Th17 phenotype. 
To more rigorously verify that IL-17 production in the PBMCs largely originated 
from T cells, we purified T cells from ND and T2D donors, stimulated them with a-CD3 
plus a-CD28 and measured IL-17 secretion. Unexpectedly, purified T cells from T2D 
and ND donors secreted similar amounts of IL-17 (Fig. 3-SA). Furthermore , and in 
contrast to PBMCs or P2T samples, molecular signatures of IL-17 and RORC promoter 
activation were similar in purified T cells from T2D and ND donors (Figs. 3-SB&C). 
These data unveil a requirement for the inflammatory milieu or, more likely, non-T cells 
in the elevated production of 1L-17 in T2D. 
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Previous studies demonstrated that monocytes are important forT cell skewing in 
T lD [237] and a similar role for monocytes in Th17 function in T2D patients is 
suggested by multiple studies [238, 239]. Monocytes from T2D patients constitutively 
and inducibly produce elevated IL-l~ and IL-6, as compared to monocytes from ND 
donors [143, 213, 221]. These pro-inflammatory cytokines are known to induce IL-17 
production by human central memory T cells [187, 230]. We confirmed that monocytes 
from our T2D cohort transcribed elevated levels of IL-l~ and TNFa mRNA, indicating 
both pro-inflammatory and pro-Th17 functions of these cells (Fig. 3-SD, p<O.OOl 
between ND and T2D cohorts). Taken together, these studies suggest that monocytes 
indirectly promote elevated IL-17 production by T cells in T2D patients. To test this 
possibility, we depleted CD14+ monocytes from PBMCs (CD14-), then stimulated the 
cultures with aCD3 plus aCD28 and measured IL-17 secretion. As we predicted, 
monocyte-depleted PBMCs from T2D donors constitutively secreted IL-17 at levels that 
approximated amounts secreted by PBMCs from ND donors, (Fig. 3-SE, CD14-). 
Preliminary intracellular flow cytometry confirmed IL-17 expression was limited to the 
CD3+CD4+ population of the CD14+ monocyte-depleted PBMCs (not shown). IL-17 
production by PBMCs from T2D, but not ND donors was decreased by monocyte 
depletion (p=0.0081, compare PBMC CD3+28 to CD14- CD3+28), indicating changes in 
monocyte function underlie elevated Th17 function in T2D. 
To independently confirm CD14+ monocytes played important roles in elevated T 
cell IL-17 production in T2D patients, we added back the positively selected CD14+ 
monocytes into the CD14 depleted PBMCs (CD14-+M) and measured IL-17 production. 
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Re-introduction of autologous CD14+ monocytes rescued elevated IL-17 production by T 
cells from T2D donors (Fig. 3-SE, p=0.0066). To most rigorously confirm a specific role 
for monocytes in inducing elevated IL-17 production by T cells in T2D patients, we 
negatively isolated T cells and monocytes from T2D donors and co-cultured purified 
autologous cells in the presence or absence of aCD3 plus aCD28 stimulation. Co-culture 
of monocytes and T cells (M+ T) rescued elevated IL-17 production by T cells from T2D 
donors, with levels indistinguishable from levels produced by intact PBMC cultures (Fig. 
3-SE). Monocytes cultured alone had nearly undetectable levels of IL-17 (not shown). 
We conclude that monocytes play a critical role in elevated IL-17 production by T cells 
from T2D patients. 
Neither IFNy or IL-4 is elevated in PBMCs and T cells from T2D patients. 
Based on the relationship between IL-17/Th17 cells and IFNy/Thl cells shown in 
published work [240], we predicted that IFNy production would also be elevated in T 
cells from T2D patients. Surprisingly , PBMCs from T2D patients stimulated with 
aCD3+aCD28 secrete similar levels of IFNy (Fig. 3-6A) compared to ND donors. The 
levels of the generally anti-inflammatory cytokine IL-4 (Fig . 3-6B) were also comparable 
in PBMCs between the ND and T2D cohort. These data are consistent with Th-specific 
cytokines preventing the production of other Th subset cytokines [241]. Intracellular 
staining confirmed that IFNy production is T cell-specific and MFI was statistically 
indistinguishable in ND vs. T2D T cells (Fig. 3-6C). Importantly, IL-17+IFNy+ T cells 
were absent (data not shown); thus, different T cell populations produce IL-17 and IFNy. 
Finally , comparison of IL-2 secretion by unstimulated vs. aCD3+aCD28 stimulated 
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PBMCs confirmed relatively equal levels of overall T cell activation between T2D 
patients and ND donors (Fig. 3-8). We conclude that the pathogenic T cell cytokine IL-17 
likely prevents elevated secretion of IFNy and promotes chronic inflammation in T2D 
patients. 
The percentage of anti-inflammatory Tregs is decreased in T2D patients. 
Multiple groups have indicated that Tregs and Th17 cells have a reciprocal 
developmental relationship demonstrated by an expansion of Th17 cells coupled with 
decreased Tregs, the latter being strongly implicated in protection from T2D 
inflammation and insulin resistance [147 , 242]. Therefore, we hypothesized that the 
elevation of Th 17 cells in T2D patients associates with decreases in the Treg 
compartment. To test this possibility, we measured the percentage of CD4+CD25+Foxp3+ 
cells in fresh ex vivo PBMCs from ND and T2D patients (Fig. 3-7A). We found a 
statistically significant reduction in the percentage of circulating Tregs in T2D patients 
compared to ND donors (4.321 %+/-0.37% or 7 .33%+/-0.5% respectively, Fig. 3-7B) 
despite the fact that we detected no difference in IL-2 (per Fig. 3-8), a cytokine that 
supports Treg differentiation [243-245] . This result contrasts with analysis of type 1 DM 
(TID) samples , which have similar percentages of CD4+CD25+Foxp3+ T cells compared 
to samples from NO donors [246-248]. Our data therefore show significant differences in 
Treg presence between TID and T2D patients for the first time. Furthermore , decreased 
percentages of Tregs in T2D PBMCs remained stable over time in culture and did not 
require the continued presence of B cells or monocytes for stability (CD19- or CD14-, 
respectively , Fig . 3-7C). Importantly, and in contrast to loss of elevated IL-17/Th17 
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function in purified T cells from T2D patients (Figs 3-SA-C), purified CD4+ T cells from 
ND donors maintained an elevated percentage of Foxp3+ Tregs in culture (Fig . 3-7C, 
compare CD4 white and black bars) . 
The balance between the pro-inflammatory Th17 and anti-inflammatory Treg 
compartment is essential to maintain homeostasis. To evaluate the physiological impact 
of an elevated Th1 /Th17 axis and decreased Treg percentages in T2D patients, we 
compared percentages ofTh17 cells (CD3+CCR4+CCR6+) to percentages ofTregs 
(CD4+CD25+Foxp3+) in T2D and ND donors. This comparison showed a highly 
significant difference in percentage of pro-inflammatory Th17s vs. protective Tregs in 
T2D but not NO donors (Fig. 3-7D). This dramatic shift in the CD4+ T cell compartment 
highlights the skewed pro-inflammatory T cell phenotype in T2D patients. 
Previous reports have indicated a negative correlation between BMI and Tregs 
[146, 147]. Consistent with these reports , we found a negative correlation between BMI 
and Tregs (CD4+CD25+Foxp3+) in the T2D cohort (Fig. 3-7E). This finding perhaps 
indicates that with increasing obesity in T2D patients , protective Tregs decrease, further 
skewing these patients toward a pro-inflammatory phenotype. 
/L-17 protein secretion positively correlates with T2D severity. 
Because our study was cross-sectional and blinded , it was important to more 
rigorously determine if our data depicted alterations in T cell subset distribution and 
function that were solely attributed to T2D. Our T2D and ND cohorts statistically 
differed in both BMI and age (Table 2-1 and Fig. 3-8A top panels). To determine 
whether differences in age or BMI explained elevated Th17 cells in the T2D cohort, we 
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determined the relationships between either percentages of Th17 cells (based on CCR4/6) 
or IL-17 secretion and clinical parameters. This analysis showed a positive relationship 
between percentage of memory Th17 cells and age (Fig. 3-8B). However, we found no 
relationship between age and IL-17, IFNy or IL-4 secretion (Fig. 3-9, top row) in analysis 
of all donors tested. These data could indicate that although there is an increase in pro-
inflammatory Th17 cells, other regulatory elements that prevent pro-inflammatory 
cytokine secretion in aging individuals are lost in T2D patients, further supporting a 
unique chronic inflammatory state in T2D patients. Furthermore, we found no 
relationship between IL-17, IFNy, or IL-4 secretion with BMI, race or sex (Fig. 3-9, 
Rows 2-4). Taken together , we conclude differences in BMI or age of our overall patient 
cohorts are unlikely to significantly contribute to differences T cell function identified in 
our assays. 
Hemoglobin Ale (HbAlc) is the most common marker used in the clinic to 
measure DM severity . We found a positive relationship trending towards significance 
between HBAlc and BMI in our T2D cohort (Fig. 3-10, p=0.0664) and consistent with 
previous reports [249, 250]. Due to the positive correlation between memory Th 17 cells 
and BMI in the T2D cohort (Fig . 3-IE), we predicted IL-17 production may associate 
with T2D severity. To test this prediction, we determined the relationship between 
o/oHbAlc from T2D patients and IL-17 production. We found a positive correlation 
between o/oHbAlc and IL-17 protein secretion in the T2D cohort (Fig. 3-8C). Lack of 
%HbAlc information in most ND donors prevented this analysis in the control cohort. 
We conclude that it is unlikely that T2D-independent differences between the ND and 
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T2D cohorts explain pro-inflammatory T cell imbalances in our study. Importantly , a 
positive correlation between %HbA1c and IL-17 secretion highlights a potential role for 
Th17 cells in T2D previously suggested by analysis in model organisms [191]. 
Section summary for Aim 2 
PBMCs from T2D patients secreted elevated levels of IL-17, a potent pro-
inflammatory cytokine, which required cell-cell contact between T cells and monocytes. 
T cells were the sole source of IL-17. These data indicate that T cells in T2D patients 
contribute to the inflammatory milieu through the production ofiL-17. Furthermore, 
these data also begin to show the complex interactions between immune cells that lead to 
dysregulation and uncontrolled inflammation in T2D patients . 
Aim 3: Immune cell crosstalk influences IL-17 production by T cells 
Monocytes and macrophages are considered important mediators of the 
inflammatory response via their role as antigen presenting cells (APCs). T cells require 
contact with co-stimulatory molecules on APCs for proper activation, however it is yet 
unknown if different co-stimulatory molecules induce specific T cell cytokine 
production. Interactions between monocytes and T cells have been shown to be important 
in activating antigen specific memory T cells in immune responses or in activation ofT 
cells in cancer therapy . Monocytes are also major sources of soluble cytokines, which can 
induce T cell activation and cytokine production [123]. Taken together, these paradigms 
of immunology highlight monocytes-T cell interaction is a vital step in the propagation of 
the immune response. 
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Multiple studies specifically indicate an important role for monocytes in the 
induction of the T cell cytokine, IL-17. Monocytes from type 1 diabetic (TlD) patients 
spontaneously secrete the cytokines IL-6 and IL-l~, which are known to be important for 
Th17 cell induction (Eva V Acosta-Rodriguez). Not surprisingly , there was an increase in 
the number of circulating IL-17-secreting cells in TlD patients (Bradshaw). Hyper-
activated monocytes from TID patients therefore likely modulate T cell responses 
through cytokine production. However, another study demonstrated, using cells isolated 
from the blood of healthy donors, that maximal induction ofiL-17 required T cell contact 
with TLR activated monocytes [251]. Therefore, TID-specific changes in either the T 
cell threshold for IL-17 production or the levels of monocytic cytokines involved in Th17 
skewing, may explain elevated Th17 function in TlD. The requirement for monocyte-T 
cell contact forT cell IL-17 production was independently confirmed [238]. 
Interestingly, this group found equivalent production of IL-17 when using monocytes 
derived from peripheral blood of healthy or rheumatoid arthritis (RA) patients [238]. 
However, they found T cells produced elevated levels of IL-17 when they were in contact 
with monocytes derived from the synovial fluid of inflamed joints from RA patients 
[238]. These data indicate that disease associated changes in cells, such as the monocytes 
residing in the synovial fluid of RA patients , result in alterations in their interactions with 
T cells. These data speak to the importance of the complex disease-specific changes 
occurring in the interactions between immune cells in different disease states. 
B cells play an important role as APCs in the activation ofT cells. Several 
studies hint that B cell APC activity has unique properties forT cell activation [252, 
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253]. Studies implicating B cells as strong players in autoimmunity and other 
inflammatory diseases (reviewed in [214]) along with their important interaction with T 
cells lead to the hypothesis that B-T interactions can maintain and exacerbate 
inflammation and autoimmunity . In systemic lupus erythematosus (SLE), B cell induced 
inhibition ofT cells via a CD40-CD40 ligand interaction is lost, suggesting that the T cell 
role in disease is an extension of B cell intrinsic changes [254]. However, disease-
specific alterations in B and T cell function could result in unique phenotypes that are 
physiologically variable from disease to disease. Although B cell induced inhibition ofT 
cells have been studied, further work on the opposing phenomenon of B cell activation of 
T cells is required. The goal of this aim was to investigate the mechanisms of elevated 
IL-17 production in T cells from T2D patients and to elucidate whether T cell interactions 
with monocytes and B cells influence IL-17 production. 
Classically, B cells are charged with antibody production as their main 
contribution to the immune response. However, recent work has established B cells as 
important mediators of inflammation in autoimmunity and other inflammatory diseases 
through multiple mechanisms (reviewed in [214]). B cells function through indirect 
(antibody/cytokine) and direct (T cell interaction) mechanisms in establishing and 
maintaining an inflammatory milieu. Interactions between T cells and B cells induce 
changes in both cell types , leading to propagation or in some cases, inhibition of the 
immune response [255]. B cell-induced inhibition ofT cells is most commonly mediated 
through B cell IL-10 production [151, 255, 256] . IL-10 knock-out mice develop 
spontaneous colitis , indicating an important role for IL-10 in maintaining a homeostasis 
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in the gut [257]. B cell IL-l 0 has been shown to be important in T cell mediated diseases 
such as MS [164] and SLE [165]. Conversely, B cells have been shown to be important 
for CD4 Th subset differentiation, although this has only been demonstrated for Thl and 
Th2 cells [258]. B cell production of Thl or Th2 cytokines (such as IFNy or IL-4), in the 
context of antigen and the presence of effector Th cells leads to skewing ofT cells toward 
those specific subsets, leading to an amplification of the inflammatory response (259]. 
This crosstalk indicates an important relationship between B cells and T cells that is 
essential for a proper immune response. However, dysregulation of this positive 
feedback loop could lead to uncontrolled inflammation and autoimmunity. 
Studies herein demonstrate that although monocyte-T cell contact is required for 
IL-17 production, B cell-T cell contact is essential for the T2D-specific elevation of IL-
17. These data indicate that although monocytes have been considered the major player 
involved in T2D-associated inflammation, their role is downplayed with respect to the 
induction of Thl7 cells, in which monocytes appear to serve simply as a rheostats for 
disease- associated B cell function. Taken together, these data indicate complex disease-
influenced changes in multiple immune cells and immune cell cross-talk, which lead to 
elevated levels of a potent pro-inflammatory cytokine, IL-l 7 to exacerbate chronic 
inflammation in T2D patients. 
Elevated IL-17 production by T cells from T2D patients is maintained in monocyte, 
T cell and B cell cocultures. 
Based on data from Aim 2, which shows that PBMCs from T2D patients secrete 
elevated levels of IL-17, we wanted to independently confirm that the IL-l 7 defining cell 
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types included monocytes and B cells. We negatively isolated each cell of interest, 
monocytes, T cells and B cells, then cultured them together in physiological proportions 
(monocytes and B cells were cultured with T cells at a ratio of 1 :20). IL-17 production by 
MTB cultures (monocytes, T cells and B cells) recapitulated IL-17 production in the 
PBMC cultures, in which T cells from T2D patients produce elevated levels ofiL-17 
(p<0.0258) in comparison to ND donors (Fig. 4-1). Stimulation with a-CD3, a-CD28 and 
LPS elevates IL-17 production slightly in the ND cohort (p<0.0137, Fig 4-1 white bars), 
compared to stimulation ofT cells alone (CD3+28). This result is consistent with the 
interpretation that LPS-induced cytokines further activate Thl7 production above levels 
achieved by cytokines secreted as a direct or indirect result of TCR engagement. In 
contrast, LPS-induced changes (likely monocyte and/or B cell cytokines) are unable to 
further activate Thl7 function above levels achieved by direct T cell stimulation. 
Surprisingly, stimulation with a-CD3, a-CD28 and LPS does not affect IL-17 production 
by T cells from T2D patients (Fig. 4-1, black bars). These data could indicate that T cells 
from T2D patients have reached a maximum threshold in terms of IL-l 7 production, and 
thus LPS-induced cytokines do not have an effect. Stimulation with LPS alone 
recapitulates the media control (data not shown). Taken together, negatively isolated 
monocytes, T cells and B cells co-cultured together demonstrate the same pattern of 
elevated IL-17 production in the T2D cohort as seen in the PBMC cultures. These data 
confirm that monocyte, T cell and B cell interactions induce elevated IL-l 7 production in 
samples from T2D patients as compared to samples from ND donors. 
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Monocyte-T cell contact is required for IL-17 production. 
Our data in Aim 2 indicated monocytes are required for elevated IL-l 7 secretion 
from T2D T cells. Other groups have indicated that IL-l~' a cytokine produced mainly by · 
monocytes, is an important cytokine for Thl7 differentiation [230]. These data propose 
that elevated IL-1~ in T2D patients skew T cells to the Thl7 subset. We confirmed 
monocytes from T2D donors hyper-transcribe IL-l~ in response to LPS (Fig. 4-5D). To 
investigate whether monocytes from T2D patients produce elevated levels of IL-l~ 
protein that explain increased Thl7 function /IL-17 secretion, we measured IL-l~ protein 
levels in PBMC cultures stimulated with a-CD3, a-CD28 and/or LPS. We found no 
difference in IL-l~ protein production between the ND and T2D cohort (Fig 4-2A) 
stimulated through the TCR in the presence or absence of LPS. This is contrary to our 
mRNA data (Fig. 3-5D demonstrating that monocytes from T2D patients hyper-
transcribe IL-l~· These data indicate that mRNA levels do not mirror protein levels 
accurately, however this is not surprising since IL-l~ has complex post-transcriptional 
regulation. Overall, despite the differences between the cohorts in IL-l~ mRNA, there is 
no difference in protein levels indicating IL-l~ is not responsible for the elevated IL-l 7 
production in the PBMCs from the T2D cohort. 
A second possible explanation for elevated Thl7 function is cell-cell contact. To 
determine whether T cell/monocyte contact or at least close physical approximation is 
required for elevated Thl7 function, we cultured isolated monocytes and T cells together 
or separated by a transwell, which prevents cell-cell contact/close physical proximity but 
allows soluble factors to diffuse freely. Monocyte-T cell contact, or alternatively, close 
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proximity is required for IL-17 production in both the ND and T2D cohorts in the 
CD3+28 stimulated cultures. This requirement, however, is more dramatic in the ND 
cohort with a 6 fold decrease IL-17 production (Fig. 4-2B, white bars) compared to a 2.8 
fold decrease in the T2D cohort (Fig. 4-2B, black bars) when cell-cell contact is lost. 
These data indicate that T cells from both ND and T2D patients require monocyte contact 
for IL-17 production when there is no direct monocyte stimulation (CD3+28 alone). 
Although we saw only a minor effect ofLPS-induced cytokines in the MTB 
cultures (and only in the ND cohort) (Fig 4-1), we tested the possibility that LPS-induced 
cytokines could play a role in IL-l 7 production when monocyte-T cell contact is lost. The 
decreased dependence on monocyte-T cell contact in the T2D cohort with CD3+28+LPS 
stimulation is quite dramatic, with only a 1.4 fold loss in IL-17 production in 
CD3+28+LPS cultures (Fig. 4-2B, black bars) when compared toT cells from ND donors 
with a 2.8 fold loss (Fig. 4-2B, white bars) in IL-17 production without monocyte 
contact. Both cohorts boosted IL-17 production in response to LPS-induced cytokines 
(ND cohort had a 1.5 fold increase in IL-17 vs. 2.3 fold increase), although this boost is 
more dramatic in the T2D cohort (Fig. 4-2B, CD3+28 vs. CD3+28+LPS within cohorts) . 
Perhaps, LPS induced cytokines from monocytes are sufficient to induce IL-l 7 
production from T cells; however these soluble factors are not as potent as direct 
monocyte/T cell interaction. However, these soluble factors may have a more potent IL-
17 inducing effect on T cells from T2D patients. These data indicate that T cells from 
T2D patients are primed for IL-17 production since LPS-induced monocyte cytokines are 
sufficient to tum on IL-17 production in T cells from T2D patients, but not in ND donors. 
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Interestingly, the addition of LPS in the MTB cultures does not result in elevated IL-17 in 
the T2D cohort (Fig. 4-1 ), indicating that cell-cell contact could induce a maximum 
threshold in T cells for IL-17 production. Taken together, these data indicate that 
monocyte-T cell contact is important for elevated IL-17 production, but this is not T2D 
specific and thus is not likely the interaction that results in elevated IL-17 production by 
T cells in T2D patients. 
B cells induce the disease-specific elevation of IL-17 production by T cells in T2D 
patients. 
Our data indicates that although monocytes are important for IL-17 production in 
Th17 cells from T2D patients, the requirement for monocyte-T cell interaction is not 
disease-specific. To identify the disease specific interaction that results in elevated IL-17 
secretion in T2D vs. ND patients, we focused on the possibility that B cells interact with 
T cells to elicit elevated IL-17 production. Our previous data (Aim 1) indicated that B 
cells from T2D patients secrete very high levels of IL-8 along with extremely low levels 
of the anti-inflammatory cytokine IL-10, indicating that B cells in T2D patients have pro-
inflammatory functions. Additionally, multiple studies have indicated that the B cells can 
induce T cell activation through cell-contact mechanisms [255]. Based on these data we 
hypothesized that B cells from T2D patients could play a disease-associated role in 
inducing elevated IL-17 production. To test this possibility we cultured monocytes, T 
cells and B cells (MTB) together orB cells and T cells together (BT) and measured IL-17 
production. Loss of monocytes completely abrogated IL-17 production in the ND cohort 
indicating that B cells cannot replace the role ofmonocytes in the ND samples (p<0.03 , 
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Fig. 4-3A, white bars). However, T cells from T2D patients maintain measurable levels 
of IL-17 in the presence of B cells despite the absence of monocytes (Fig. 4-3A, black 
bars). Importantly, the BT cultures require activation with TCR+LPS in order to elicit IL-
17 production from T cells (Fig. 4-3A, BT CD3+28+LPS black bars). Although, it is not 
definitive whether LPS is influencing T cells orB cells, it is likely that LPS-induced B 
cell cytokines play a role in this interaction. T cells from ND donors also secrete IL-l 7 in 
response to LPS-activated B cells however the levels were near the limit ofiL-17 
detection (Fig. 4-3A, BT CD3+CD28+LPS white bars). We speculate that LPS activation 
could replace an interaction occurring between B cells and monocytes which activate B 
cells thereby allowing B cell activation ofiL-17 from T cells. These data indicate that B 
cells from T2D patients, when stimulated with a TLR4 ligand have the ability to induce 
IL-17 production from T cells in T2D patients, in the absence of aid from monocytes. 
Importantly, T cells from T2D patients produce almost 3.5 times more IL-17 when 
cultured in the presence ofB cells and LPS compared toT cell monocultures (Fig. 4-3B). 
These data indicate that although T cells from T2D patients are primed to secrete IL-l 7 
(Fig. 3-2C, D), they also require APC interaction with both monocytes and B cells. Taken 
together, these data indicate that monocytes respond as a rheostat, but B cells are 
essential for the disease specific differences in IL-17 production between ND and T2D 
patients. 
B cell-T cell contact is essential for elevated IL-17 production in T2D patients. 
Our data indicated an important role for B cells in inducing disease specific 
differences in IL-17 production. Multiple studies indicate important cell contact 
71 
mechanisms impacting T cell activation [255]. Based on these data, we hypothesized that 
cell-cell contact (or close physical proximity) would also be important for the B cell-
mediated Thl7 function. Monocytes were included in these experiments to increase the 
signal to noise ratio based on our previous data indicating that monocytes act as a 
rheostat forB cell induced T cell activation. To test this possibility, we cultured 
monocytes, B cells and T cells together or monocytes and T cells with B cells separated 
by a transwell, to identify whether contact between B cells and T cells was important for 
T cell IL-l 7 production. Separation of B cells did not alter IL-l 7 production in the ND 
cohort (Fig. 4-4A, white bars) but had a dramatic impact in the T2D cohort (Fig. 4-4A, 
black bars). Loss of B cell-T cell contact resulted in decreased production of IL-17 in T 
cells from T2D patients, down to ND levels (p<0.0266, 3.3 fold decrease with CD3+28 
stimulation and p<0.0431 , 2.8 fold decrease with CD3+28+LPS stimulation, Fig.3-4A, 
black bars). These data demonstrate the dramatic impact ofB cell-T cell contact in T2D 
patients. 
To independently confirm the importance ofB cell contact in elevated IL-17 
production by T cells from T2D patients, we cultured B cell depleted PBMCs (CD 19-) 
and compared IL-17 production to MTB and MT /B cultures. We found that CD 19-
cultures produced similar levels ofiL-17 when compared to the MT/B cultures, 
indicating that complete loss ofB cells recapitulates loss ofB cell contact in the MT/B 
cultures (Fig. 4-4B, black bars). Not surprisingly, we saw no elevation ofiL-17 between 
CD3+28 and CD3+28+LPS stimulated cultures (as seen in the BT cultures) in either the 
MT IB or the CD 19- cultures, confirming that monocytes simply act as a rheostat for IL-
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17 production and B cell-T cell interaction is the detrimental relationship in T2D patients. 
Taken together, these data indicate that B cells play a pathogenic role in T2D patients by 
exacerbating IL-17 production through cell-cell contact mechanisms. 
Loss of IL-10-induced inhibitory function in cells from T2D patients. 
Multiple studies have shown an important role for IL-l 0 in regulation of IL-17 
responses [260, 261] . Our data indicates loss ofB cell IL-10 in T2D patients (as shown 
in Aim 1). To determine whether this loss in B cell IL-10 is mirrored by changes in the 
overall levels of IL-l 0, we cultured monocytes, T cells and B cells (MTB) with CD3 and 
CD28 and/or LPS and measured IL-10. Surprisingly, there was no difference in IL-10 
production between ND and T2D patients (Fig. 4-SA). These data indicate that although 
B cells produce very low levels of IL-l 0, overall IL-l 0 levels are equivalent between ND 
and T2D patients (this data is further discussed in the Discussion section). This led us to 
question whether IL-l 0 produced by cells from T2D patients can activate the IL-l 0 
signaling pathway. To test this, we measured mRNA transcript of an IL-10-responsive 
gene, SOCS3. SOCS3 inhibits inflammatory cytokines by inhibiting the activity of the 
Janus kinase 2 (JAK2), which is one ofthe kinases involved in the cytokine-induced 
signaling pathway, the JAK-STAT pathway. Preliminarily, SOCS3 mRNA is 
dramatically decreased in MBT cultures from T2D patients, potentially indicating a loss 
in IL-l 0 function via an inability to induce SOCS3 (Fig. 4-SB). IL-l 0 function is 
dictated by its ability to bind the IL-l 0 receptor (IL-l OR) and induce the activation of 
inhibitory genes, such as SOCS3. To test whether the IL-l OR is functional in monocytes 
and T cells from T2D patients, we added recombinant IL-l 0 (riL-l 0) at the beginning of 
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the 40 hour cultures to B-cell depleted PBMC's (CD19-) stimulated with CD3+28 and/or 
LPS cultures. The addition of riL-l 0 decreased IL-17 production equivalently in both ND 
and T2D cohorts, indicating functional IL-l ORs in both cohorts (Fig. 4-SC). These data 
contradict the hypothesis that the IL-l 0-induced responsible gene SOCS3 has a role to 
play in IL-17 regulation. However, although these data indicate that riL-l 0 can bind the 
IL-l OR and induce IL-l 0 mediated changes in IL-17 production, the function of IL-l 0 
produced by cells from T2D patients is still unknown. These data potentially show that 
although there is no difference in IL-l 0 production or IL-l OR function between the ND 
and T2D cohorts, perhaps there is a defect in the functionality of the IL-l 0 produced by 
cells in T2D patients. However, IL-17 may not be regulated by SOCS3, which would 
indicate that changes in SOCS3 expression are independent of elevated IL-l 7 production. 
However, these data allude to the possibility of intrinsic T2D-associated changes in T cell 
or monocyte responses to IL-l 0, indicated by loss of SOCS3 upregulation. Further 
studies specifically investigating IL-l 0 functionality in cells from T2D patients, along 
with changes in SOCS3 levels in T cells are required to determine whether IL-l 0 plays a 
role in IL-17 regulation. 
Section summary for Part 3/Aim 3 
Our data demonstrate an important role for cell-cell interactions between B cells, 
monocytes and T cells , in which monocyte-T cell interactions lead to moderate levels of 
IL-17 but the interaction between B cells and T cells is pathogenic in T2D patients with a 
dramatic increase in IL-17 production. Cell-cell contact or close physical proximity is 
required for these interactions although LPS-induced cytokines do seem to play a minor 
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or compensatory role in the absence of the more robust contact-mediated signals. B cell-T 
cell contact elevates IL-17 production by T cells in T2D patients, in the presence of 
monocytes, however LPS-stimulated B cells from T2D patients can still induce IL-17 
production from T cells without monocyte aid. Additionally, preliminary data indicates a 
defect in the IL-10-signaling pathway leading decreased SOCS3 activation in monocytes, 
T cells and/or B cells from T2D patients. Taken together, these data indicate that B cells, 
rather than monocytes, are the important pathogenic cell type in IL-17 production in T2D 
patients in addition to alluding to important changes in T cell responses to IL-10. 
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Figure 2-1 
Purified B cells from T2D patients constitutively secrete elevated levels of IL-8 and 
decreased levels ofiL-10. (A) Representative re-analysis ofB cell purity (upper left 
quadrant) by flow cytometry. Note monocytes were undetectable (bottom right quadrant). 
(B) Cytokine production by B cells from ND (white bars) or T2D (black bars) donors 
incubated in medium for 24 h. GM-CSF, TNF-a and IL-10 are quantified on the lefty-
axis; IL-6 is quantified on righty-axis. (C) IL-8 production by B cells from ND (white 
bar) or T2D (black bar) donors incubated in medium for 24 h. Shown is mean and SEM 
ofthe number of samples indicated by the value immediately below each bar. Not all 
supernatant fractions from all samples were assayed for every cytokine. Significance was 
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determined by Mann-Whitney U test and p values that are significant in comparisons 
between T2D and ND values are shown (b *p=0.0152, tp=0.0017; c *p=0.0081). (D,E) 
Intracellular cytokine staining in peripheral blood mononuclear cells from ND (white 
bars) or T2D (black bars) donors. (D) B cells were identified by surface CD 19 
expression. (E) Monocytes were identified by surface CD14 expression (absent on B 
cells). Shown is mean (after subtraction ofisotype control) and SD ofthe percentage of 
cytokine-positive cells from three donors. All significant differences, calculated by t test, 
are indicated (d *p=0.0398, tp=0.0309; e *p=0.0768). B cell intracellular TNF-a and 
monocyte intracellular IL-8 were highly variable (p>0.07) and hence not definitive. (D,E) 
Donors had a diagnosis of type 2 T2D and included one black female and two hispanic 
males, mean age 56 years. ND donors included two white females and one white male, 
mean age 4 7 years. 
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Figure 2-2 
A modestly elevated percentage of B cells from T2D patients express surface TLR4. (A) 
A representative flow cytometric analysis of TLR4 expression on the surface of B cells. 
Isotype control on sample from a representative T2D patient is shown in the left panel. 
Results from TLR4 staining of a representative ND donor and the same T2D patient are 
shown in the middle or right panels, respectively. B cells were identified based on CD19 
surface expression (y-axis ). Percentage numbers indicate the proportion of B cells that 
were also TLR4-positive. (B) Composite data showing percentage ofTLR4-positive B 
cells in ND donors and T2D patients as indicated. Each point shows analysis of a single 
sample; horizontal lines shows median percentage TLR4-positive B cells for each cohort. 
The difference (median= 16.45% or 27.1% forB cells from ND or T2D donors, 
respectively) was significant (p<O.OS). n=56 each for ND and T2D samples. (C) 
Accessibility of the TLR4 promoter to 2 U micrococcal nuclease in ND monocytes orB 
cells, or T2D B cells as labelled. Human Jurkat T cells are a negative control. (D) 
Percentage TLR4-positive monocytes (left) or neutrophils (right) in peripheral blood of 
ND or T2D donors as indicated. n=29 for ND monocytes; n=24 for T2D monocytes; 
n=3I for ND neutrophils; n=26 for T2D neutrophils. Horizontal lines show medians. 
Differences were insignificant. (E) RP105 surface expression levels as measured by MFI 
on B cells from ND donors or T2D patients. Bar shows mean (±SD) often samples from 
each cohort. Difference was insignificant (p>O.l). >95% ofB cells in each cohort 
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expressed surface RP105 (not shown). Statistical significance was determined by Mann-
Whitney U test for all comparisons, except panel d, which was analysed by ANOV A. 
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IL-8 is significantly increased in B cells from T2D patients vs. ND donors responding to 
TLR2ligand (Pam3). Purified B cells from T2D (black bars) or ND (white bars) donors 
were incubated for 24 h in medium alone or with TLR4 ligand (rLPS or E. coli LPS) or 
TLR2 ligand (Pam3) as indicated. Samples were analysed for production ofiL-8 (A,B), 
TNF-a (C), GM-CSF (D), or cytokines indicated below the x-axis (E) in B cell 
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responding to E. coli LPS. Number of samples is indicated by the value immediately 
below each bar. (A, C, D) Cytokines measured by multiplex protein analyses. (B) 
Percentage of CD 19+ B cells that were positive for intracellular IL-8, as compared towith 
isotype control upon stimulation with anti-lg!J.. Anti-lg!J. induced low but somewhat 
variable levels ofiL-10 and TNF-a in B cell parallel analyses (not shown). Bars show 
mean and SEM. Medium controls for panel a are shown in Fig. 2-3c. p values calculated 
by Mann-Whitney U test are shown above bars for samples that were significantly 
different (p<0.05; a *p=0.0123; tp=0.0381; b *p=0.0124; e *p=0.0635). All other 
comparisons were statistically insignificant (p>0.05). Comparison between medium and 
TLR-stimulated cytokine production indicated significant up-regulation for many 
cytokines in B cells responding to TLR ligand; these values are shown for T2D and ND 
B cell samples in Table 3. 
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Figure 2-4 
TLR ligands fail to activate IL-l 0 production by B cells from T2D patients B cells from 
ND individual (white bars) or T2D patient (black bars) donors were incubated for 24 h. 
with stimuli as indicated. (A) IL-l 0 production. (B) Positive control showing B cells 
from T2D patients are capable of producing cytokines in response to the TLR9 ligand 
CpG ODN 2006. Shown is mean and SEM of the number of samples indicated 
immediately below each bar. p values calculated by Mann-Whitney U test are shown 
above bars for samples that were significantly (p<0.05) different between ND and T2D 
cohorts (a *p=0.0023; tp=0.0040; tp=0.0012). 
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Figure 2-5 
TLR4 engagement decreases TLR2-mediated TNF-a production by B cells from T2D but 
not ND donors. Cytokine production by B cells from T2D patients (A-D) or ND donors 
(E-H) stimulated with the TLR2 ligand Pam3 alone or in combination with the TLR4 
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ligand rLPS. A line connects values from each donor sample. Significance was 
determined by a non-parametric paired two-tailed ttest. ap=0.0195; b NS; cp=0.0010; d 
p=0.0039; e p=0.0592; f p=0.0098; gp=0.0391 ; h NS. Results are from ten T2D or 11 
ND donor samples. 
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production by B cells from T2D (white bars) or PD (black bars) patients stimulated by 
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the single TLR ligand indicated on the x-axis. (A) GM-CSF; (B) IL-10; (C) IL-6; (D) IL-
8; (E) TNF -a. Bars show mean and SEM. Significant differences between values for the 
two patients cohorts were determined by non-parametric two-tailed t tests and are 
indicated by p values listed above some graphs (b *p=0.0076, tp=0.040, tp=0.014; d 
*p=0.034; e *p=0.019, tp=0.040. All other differences between B cells from the two 
cohorts stimulated with the same ligand were statistically insignificant (p>0.05). 
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Table 1-1 Description of diabetes mellitus patients used for cytokine analysis (n=11 
total) 
Characteristic Value 
Age, years (median and range) 55 (38-72) 
HbA1c, % (median and range) 8.2 (6.0-14.9) 
Duration of diabetes mellitus , years (median 10 (5-32) 
and range) 
BMI, kg/m2 (median and range) 32.4(17.0-43.1) 
CRPa, mg/1 (median and range) 9 ( 1-164) 
Insulin usage, n=8 (percentage oftotal) 72.7b 
Type 2 diabetes, n=9 (percentage of total) 82 
Type 1 diabetes, n=2 (percentage of total) 18 
Males, n=6 (percentage oftotal) 54.5 
Race 
White, n=6 (percentage oftotal) 54.5 
African-American, n=5 (percentage oftotal) 45.5 
3Single CRP values available for eight of 11 patients; median is within normal range 
blnsulin usage by one type 2 diabetes patient is unknown 
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Table 1-2 Description of PD and ND individuals 
PD ND 
Characteristic 
Age, years (median and range) 32 (20-38) 31 (22-52) 
N 14 19a 
Males, n (%) 7 (50) 9 (47) 
Race, n (%) 
White 2 (14.3) 6 (31.6) 
African-American 11 (78.6) 8 (42.1) 
Asian 1 (7.1) 0 (0) 
Hispanic 1 (7.1) 1 (5.2) 
Unknown 0 (0) 4 (31.6) 
aAge and sex of two ND individuals is unknown 
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Table 1-3 Cytokine production by TLR-stimulated B cells 
Cytokine Stimulus 
Medium Pam3 rLPS CpG 
GM-CSF 
TID mean 69.3 99.7 77.8 84.4 
p value 0.0051 * 0.0207* 0.002* 
n• 11 11 8 11 
ND mean 43 .6 108.1 71.4 120.8 
p value 0.0050* 0.0781 0.0625 
n• 14 14 9 7 
IL-10 
TID mean 4.0 10.4 5.1 14.0 
p value 0.0300* 0.2000 0.0754 
n" 7 7 4 7 
NDmean 24.2 71.0 34.4 110.5 
p value 0.0025* 0.1563 0.0313* 
n• 12 12 8 7 
IL-6 
TID mean 68.9 541.5 153.2 580 
p value 0.0010* 0.0078* 0.0049* 
n" 11 11 8 11 
NDmean 325.5 1622.5 989.7 715 .5 
p value 0.0020* 0.0078* 0.0313* 
n" 14 12 9 7 
TNF-a. 
T2D mean 16.5 86.5 28.5 116.8 
p value 0.0078* 0.2500 0.0781 
n• 8 10 7 10 
NDmean 40.2 87.4 65.6 193.0 
p value 0.0025* 0.0781 0.0625 
n• 14 14 9 7 
All values represent pg/ml. For IL-10, values from T2D B cells approached assay 
sensitivity. aNumber of donors in mean value *p<0.05 in TLR-stimulated with medium 
control forB cells from the same cohort (diabetes mellitus or ND) by paired t test. 
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Figure 2-7 
Comparison of cytokine production by B cells from T2D (left of each panel) or ND (right 
in each panel) donors stimulated with (A) the TLR4 ligand rLPS; (B) The TLR2 ligand 
Pam3CSK4 (Pam3); (C) the TLR9 ligand CpG ODN2006. Each line connects cytokine 
analysis from media (left) and TLR (right)-stimulated B cells from the same donor. 
Statistical significance determined by paired two-tailed t tests are indicated by p values in 
the upper left of each graph. N=10 for T2D or 11 for ND donor samples, respectively. 
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Figure 3-1 
T2D patients have elevated percentages of circulating Thl7 cells. (A) One representative 
+ + + 
flow plot of 10 ND and 11 T2D whole blood samples stained for CD3 CCR4 CCR6 
cells. Blood donors for these studies are described in Table II . T cells were identified 
based on forward and side scatter and CD3 staining (not shown) and plotted to show 
CCR4 (x-axis) and CCR6 (y-axis) staining. Note that slight elevation ofCCR6 
expression in lower left quadrant was inconsistent. Percent double-positive cells are 
indicated in the top right quadrant. (B) Summary of flow cytometric analyses of 
percentage CCR4/ CCR6 double-positive T cells in whole blood. Each dot represents one 
individual. n = 10 for ND or 11 for T2D samples. (C) Representative flow plot ofT cell 
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purity for fresh ex vivo T cells used in purified T cell analyses. T cells in this sample are 
98.8% pure based on CD3 expression (top left quadrant). CD69 is shown on the x-axis, 
and CD3 is displayed on y-axis, the former to indicate low T cell activation levels. (D) 
ChiP measuring constitutive association of acetylated histone H3 with the IL-17 
promoter in fresh ex vivo T cells from ND (white bar) or T2D (black bar) donors. Bars 
show average signal (6 SEM) compared with control immunoprecipitations with anti-
GST A b. p values calculated by Mann-Whitney U test highlight the significant difference 
between ND and T2D samples. n = 4 to 5 independent determinations(E) Relationship 
+ + + 
between BMI(x-axis) and percentage ofCD3 CCR4 CCR6 cells (y-axis) in ND (left 
panel)or T2D (right panel) cohorts. Correlation was calculated by a Pearson's test. 
Pearson's r value is shown below the significant (,0.05) p value. 
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Figure 3-2 
Elevated production ofiL-17 by PBMCs from T2D patients. (A) PBMCs from ND (white 
bars), T2D (black bars) donors, (B) lean ND (white bars) or obese ND (grey bars) were 
incubated for 40 h in media alone or with PHA, anti-CD3 plus anti-CD28, or LPS as 
indicated. Samples were analyzed for IL-17 by ELISA. Bars show average and SEM. p 
values were calculated by the Mann-Whitney U test and are shown above bars that are 
significantly different between ND and T2D donors (p ,0.05). Significant differences (not 
shown) within the ND cohort include: media versus PHA, p = 0.0 116; and media versus 
CD3+28, p = 0.0019. Significant differences (not shown) within the T2D cohort include: 
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media versus PHA, p = 0.0002; media versus CD3+28, p = 0.0008; and media versus 
LPS, p = 0.0 1. All other comparisons were statistically insignificant (p . 0.05). n = 8-11 
for ND donors and n = 7-13 for T2D patients described in Table III. ChiP measuring 
association of acetylated histone H3 to the IL-17 (C) or RORC (D) promoter in PBMCs 
from ND (white bars) and T2D (black bars) donors. Cells were unstimulated or 
stimulated as indicated for 40 h. Bars show average signal compared with control 
immunoprecipitations with GST Ab 6 SEM. n =3- 6. The p values that were significant 
(p, 0.05) or approached significance (p, 0.08) as measured by Mann-Whitney U test are 
indicated on graphs. 
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Molecular signatures of Th1 7 cells and elevated IL-1 7 production are T cell specific. (A) 
+ 
One representative of eight samples stained for intracellular IL-17 in CD3 T cells in 
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... 
PBMCs from ND (upper panels; n = 4) or T2D (lower panels; n = 4) donors. PBMCs 
were stimulated as indicated for 40 h. Brefeldin, PMA, and ionomycin were added 5 h 
+ 
before harvest. (B) Summary of intracellular cytokine staining for IL-17 in CD3 T cells 
from ND (white bars) and T2D (black bars) donors as shown in A (percent positive, top 
panels)or (C) (MFI). p values that were significant (p , 0.05) as measured by Mann-
Whitney U test are shown on graph. n = 4 for each bar. Due to differences in isotype 
control antibody staining between media and PHA or CD3+28stimulated samples, 
isotype staining in leftmost columns was used as a gating control for media-treated 
samples and PHNCD3+28 isotype (middle columns) was used for PHA or CD3+28-
stimulated samples (rightmost columns). In B, all comparisons between media 
(unstimulated) and stimulated values were statistically significant (p, 0.05) for the T2D 
cohort (media versus PHA, p = 0.0286; media versus CD3+28, p = 0.028). (D) 
Intracellular IL-17 levels fail to correlate with age (top panels) or BMI (bottom panels) in 
all ND (s) and T2D (d) donors. p. 0.05 for all analyses as calculated by the Pearson test. 
Quantitation of active IL-17 (E) or RORC (F) promoters as measured by ChiP for DNA 
associated with hyperacetylated histone H3. P2T denotes PBMCs cultured in the presence 
or absence of indicated stimulus for 40 h, after which T cells were purified by negative 
selection (.98% pure) and analyzed. The non-T fraction had extremely low signals (fold 
GST control Ab ,1: not shown). Data represent P2Ts from ND (white bars) and T2D 
(black bars) donors. Bars show average and SEM. n = 3-6. The p values above bars were 
calculated by Mann-Whitney U test. 
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Molecular signatures ofT cell activation are maintained in cultured PBMCs from ND and 
T2D patients. Comparisons of ChiP analyses showing association of acetylated histone 
H3 with the IL-17 (A) or RORC (B) promoters in stimulated or unstimulated PBMCs and 
P2Ts (see text) as indicated. Signals in the non-T cells from the P2T assays were below 
the level of detection (not shown). (C) Comparisons of ChiP analyses of association of 
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acetylated histone H3 to the IL-17 or RORC promoters of fresh ex vivo T cells and 
unstimulated or stimulated P2Ts from ND (white bars) and T2D (black bars) donors as 
indicated. Bars show average and SEM. n = 3-6 for each donor cohort. All comparisons 
were insignificantly different (p. 0.05) by Mann Whitney U test, indicating no changes in 
molecular signatures post-culture for 40 h. 
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Figure 3-5 
T cells require monocyte coculture to maintain Th17 phenotype. (A) Purified T cells 
(.97% pure) were incubated with the indicated stimuli for 40 h, then secreted IL-17 
protein was measured by ELISA. n = 11 to 12 for each donor cohort. ChiP measuring 
association of acetylated histone H3 to the IL-17 (B) or RORC (C) promoter in purified T 
cells from ND (white bars) or T2D (black bars) donors. Cells were unstimulated or 
stimulated as indicated for 40 h. n = 4 for each donor cohort. (D) Purified monocytes 
from ND (white bars) or T2D (black bars) donors were stimulated with Escherichia coli 
LPS for indicated time and analyzed by RT-PCR for expression ofiL-1b (top panel) or 
TNF-a (bottom panel) mRNA. The p value indicating a significant difference between 
ND and T2D cohorts (p , 0.0001) was calculated by two-way ANOV A. n = 9 for ND 
donors; n = 8 for T2D patients. (E) PBMCs, purified T cells, or CD14-depleted PBMCs 
from ND (white bars) or T2D (black bars) donors were incubated for 40 h in the presence 
or absence ofanti-CD3 + anti-CD28 as indicated. Alternatively, CD14-depleted PBMCs 
+ 2 
+ CD14 monocytes (CD14 +M) or purified T cells and monocytes (M+T) from T2D 
donors were co-cultured for 40 h with or without anti-CD3 plus anti-CD28. Supernatants 
were analyzed for IL-17. Bars show average and SEM. p values were calculated by 
Mann-Whitney U test and are shown above bars that are significantly different (p , 0.05). 
All other comparisons were insignificantly different (p. 0.05). 
104 
A 
10000 
8000 
e_6000 
~4000 
2000 
IFNy 
media CD3+28 
Figure 3-6 
B IL-4 c 
u:: 
:IE 
ICIFNy:MFI 
100 0 NO 
80 - T2D 
60 
40 
20 
0 
Me-dia PHA CD3+28 
Neither Thl nor Th2 cytokines are elevated in T cells from T2D patients. (A) and (B), 
PBMCs from ND (white bars) or T2D (black bars) donors were incubated for 40 h in the 
presence or absence of anti-CD3 plus anti-CD28. Samples were analyzed for IFNy (A) or 
IL-4 (B). Bars show average and SEM. p values were calculated by Mann-Whitney U 
test and all comparisons were insignificantly different (p<0.05). n = 12-20 for each 
donor cohort described in Table 2-3. (C) MFI for IFNy levels in T cells from ND 
(white bars) or T2D (black bars) donors. No comparisons between ND and T2D cohorts 
were statistically significant for MFI. n = 4 for each donor cohort. 
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45 
representative of eight ND samples or eleven T2D samples stained for 
+ + + 
CD4 CD25 Foxp3 cells in fresh ex vivo PBMCs as indicated. Isotype control is from the 
+ + + 
T2D sample shown rightmost. (B) Summary of percentage ofCD4 CD25 Foxp3 T cells 
in ND (white bars) or T2D (black bars) donors. The p value shown above bars was 
calculated by a Mann- Whitney U test. (C) Summary of percentage of 
+ + + 
CD4 CD25 Foxp3 T cells in fresh ex vivo PBMCs or from the following samples after 
2 
40 h (unstimulated) in culture: PBMCs, B cell-depleted PBMCs (CD19 ), monocyte-
2 + 
depleted PBMCs (CD14 ), or CD4 (negatively selected) T cells as indicated. ForB and 
+ + 
C, bars show average and SEM and n = 5-11. Analysis ofCD4 Foxp3 T cells gave 
+ + + 
similar results (not shown). (D) Comparison of percentage of CD3 CCR4 CCR6 T cells 
+ + + (Th17s) and CD4 CD25 Foxp3 (Tregs) in ND (gray dots) and T2D (black squares) 
PBMCs. Each point represents one donor. The p value shown was calculated by a Mann-
Whitney U test. (E) Linear regression between BMI (x-axis) and percentage of 
+ + + 
CD4 CD25 Foxp3 T cells (y-axis) in T2D patients. The p value is indicated on the 
2 
graph, and the r value is shown below the p value. 
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IL-17 secretion correlates with T2D disease severity. (A) Comparison of all ND and T2D 
donors described in Table I based on BMI (left panel) or age (right panel). Significant 
differences between ND and T2D cohorts were calculated by the Mann Whitney U test. 
+ + + (B) Relationship between age (x-axis) and percentage ofCD3 CCR4 CCR6 cells (y-
axis). (C) Relationship between hemoglobin Ale, a marker of diabetes severity (HBA1c; 
x-axis) and secreted IL-17 protein (y-axis). The p values indicated in Band C were 
2 
calculated using Pearson's correlation; r values are shown below p values. 
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Table 2-1: Description of all blood donors 
ND Median (range) T2D Median (range) 
Age (years) 46.5 (27-61) 54 (31-66) 
Ale(%) 5.6 (5.1-6.1)* 7.7 (4.8-14.9) 
BMI (kg/m2) 28.15 (20.3-46) 31 (17-65) 
Glucose 88 (77-101)* 147 (63 -474) 
N (31 total) N (44 total) 
Females 16 22 
Males 12 22 
Unknown sex 2 0 
Race 
-Caucasian 19 12 
-African American 6 19 
-Native American 0 1 
-Hispanic 2 9 
-Asian 1 0 
Unknown Race 3 3 
ND= Non-Diabetic, T2D= Type 2 Diabetes; Alc=Hemoglobin Ale; BMI=Body 
mass index; NA= Not Available; *On1y have information from 9 donors 
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Table 2-2: Description of blood donors for CCR4/CCR6 analysis 
Age (years) 
Ale(%) 
BMI (kg/m2) 
Glucose 
Females 
Males 
Unknown sex 
Race 
-Caucasian 
-African American 
-Native American 
-Hispanic 
-Asian 
Unknown Race 
ND Median (range) 1 
40 (27-61) 
NIA 
21 (21-35) 
NIA 
N (10 total) 
5 
4 
1 
5 
2 
0 
1 
1 
1 
T2D Median (range) 
51.5 (39-65) 
7.75 (6-10.5) 
30.4 (17-40) 
153 (98-432) 
N (11 total) 
5 
6 
0 
5 
5 
0 
1 
0 
0 
ND= Non-Diabetic, T2D= Type 2 Diabetes; A1c=Hemoglobin Ale; BMI=Body mass 
index; NA= Not Available, 1Age, Sex, Race and BMI unknown for one ND donor. 
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Table 2-3: Description of blood donors for IL-17, IFNy and IL-4 secretion 
Age (years) 
Ale(%) 
BMI (kg/m2) 
Glucose 
Females 
Males 
Unknown sex 
Race 
-Caucasian 
-African American 
-Native American 
-Hispanic 
-Asian 
Unknown Race 
ND Median (range) 
47 (30-57) 
N/A 
25.5 (21-29) 
N/A 
N (16 total) 
10 
6 
0 
12 
0 
1 
1 
1 
T2D Median (range) 
51.5 (31-66) 
7.7 (7-14.9) 
33 (23-65) 
153 (79-285) 
N (18 total) 
12 
6 
0 
5 
8 
1 
4 
0 
0 
ND= Non-Diabetic, T2D= Type 2 Diabetes; A1c=Hemoglobin Ale; BMI=Body mass 
index; NA= Not Available, 
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-120 
PBMCs from ND and T2D patients secrete similar levels ofiL-2 in response to 
stimulation. PBMCs from ND (white bars) or T2D (black bars) donors were unstimulated 
or stimulated with a-CD3 and a-CD28 for 40 hrs, then analyzed for IL-2 production as a 
measure of activation. Difference between stimulated cells from ND and T2D donors was 
insignificant (p>0.05). N=12 for each donor cohort. 
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Figure 3-10 
Relationship between age and T cell IL-17, IFNy or IL-4 secretion (Row 1 ). Relationship 
+ + + 
between BMI and %CD3 CCR4 CCR6 cells, IL-17, IFNy or IL-4 secretion (Row 2). 
+ + + 
Row 3 compares African American and white donor samples for %CD3 CCR4 CCR6 
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cells, IL-17, IFN y or IL-4 secretion. Row 4 compares results from male and female 
+ + + 
donors for %CD3 CCR4 CCR6 cells, or T cell production of IL-17, IFNy and IL-4. 
Lack of relationships in Row 1 and 2 was determined by Pearson's correlation. For 
analyses in rows 3 and 4, results shown include both ND and T2D donor samples and 
differences were calculated by Mann Whitney U test. There are no statistically significant 
compansons. 
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Correlations between BMI and HbAlc for T2D donors. P value (0.06) was calculated 
2 
using Pearson's correlation, r value is shown below p value. 
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Figure 4-1 
I 0.0137 I 
MTB 
Cl ND 
- T2D 
Elevated IL-l 7 production by T cells from T2D patients is maintained in monocyte/T cell 
IB cell cocultures. Negatively isolated monocytes, T cells orB cells (MTB) from ND 
(white bars) or T2Ds (black bars) were co-cultured and incubated for 40hours in media 
alone, with a-CD3+a-CD28 or with a-CD3+a-CD28 + LPS as indicated. Supernatants 
were analyzed for IL-17 by ELISA. Bars show average and SEM. P values were 
calculated by a 2-way ANOV A between cohorts or the Mann Whitney U test within each 
cohort and are shown above bars that are statistically significant (p<0.05). All other 
comparisons were statistically insignificant (p>0.05). N=l0-11. 
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Monocyte-T cell contact is required for IL-17 production, but is not disease-specific. 
(A) PBMCs from ND (white bars) or T2D (black bars) donors were incubated for 40hrs 
with or without a-CD3, a-CD28 and/or LPS as indicated. Samples were analyzed for IL-
1~ by multiplex protein assays. (B) Negatively isolated monocytes and T cells (MT) or 
monocytes separated by a transwell from T cells (M/T) from ND (white bars) or T2Ds 
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(black bars) were co-cultured and incubated for 40hours in media alone, with a-CD3+a-
CD28 or with a-CD3+a-CD28 and LPS as indicated. Samples were analyzed for IL-17 
by ELISA. Bars show average and SEM. P values were calculated by the Mann Whitney 
U test and are shown above bars that are statistically significant (p<0.05). All other 
comparisons were statistically insignificant (p>0.05) . N=14-20 for the PBMC cultures , 
N=13-15 for the MT cultures and N=6-8 for the MIT cultures for each patient cohort. 
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B cells induce the disease-specific elevation ofiL-17 production in T2D patients. 
(A) Negatively isolated monocytes, T cells orB cells (MTB) orB cells and T cells {BT) 
or (B) CD4+ T cells from ND (white bars) or T2Ds (black bars) were co-cultured and 
incubated for 40hours in media alone, with a-CD3 and a-CD28 as indicated . Samples 
were analyzed for IL-17 by ELISA. Bars show average and SEM. P values were 
calculated by the Mann Whitney U test and are shown above bars that are statistically 
significant (p<0.05). All other comparisons were statistically insignificant (p>0.05). 
N=l0-11 for the MTB cultures, N=7-9 for the BT cultures and N=7-8 for the CD4 T 
cultures for each patient cohort. 
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B cell-T cell contact is essential for elevated IL-17 production by T cells from T2D 
patients. 
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(A) Negatively isolated monocytes, T cells orB cells (MTB) or monocytes and T cells 
with B cells separated by a transwell (MT/B) or (B) B cell depleted PBMCs (CD19-) 
from ND (white bars) or T2Ds (black bars) were co-cultured and incubated for 40hours in 
media alone, with a-CD3 and a-CD28 or with a-CD3 and a-CD28 and LPS as indicated. 
Samples were analyzed for IL-17 by ELISA. Bars show average and SEM. P values were 
calculated by the Mann Whitney U test and are shown above bars that are statistically 
significant (p<0.05). All other comparisons were statistically insignificant (p>0.05). 
N=l0-11 for the MTB cultures, N=7-8 for the MT/B cultures and N=8 for the CD19-
cultures for each patient cohort. 
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Loss of IL-10-induced inhibitory function in cells from T2D patients. 
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CD3+28+LPS 
(A,B) Negatively isolated monocytes , T cells and B cells (MTB) or (C) B cell depleted 
PBMCs (CD19-) from ND (white bars) orT2Ds (black bars) were co-cultured and 
incubated for 40hours in media alone, with a-CD3 and a-CD28 or with a -CD3 and a -
CD28 and LPS as indicated . (C) Recombinant IL-10 (lOOOpg/ml) was added to cultures 
(+IL-10) at time 0. Samples were analyzed for (A) IL-10 by multiplex assay or (C) IL-17 
by ELISA. (B) Samples were analzyed by RT-PCR for expression of SOCS3. Bars show 
average and SEM. P values were calculated by the Mann Whitney U test and are shown 
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above bars that are statistically significant (p<0.05). All other comparisons were 
statistically insignificant (p>0.05). N=6-7 for the IL-10 MTB cultures, N=6-8 for the 
CD19- cultures , N=l for SOCS3 RT-PCR for each cohort. 
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Table 3-1: Description of all blood donors 
ND Median Range T2D Median Range 
Age** N=22 42.5 22-67 N=23 56 24-79 
HbAlc** 5.6 4.3-5.8 7.5 5.9-10.6 
Glucose** 88 62-109 136 63-292 
BMI 33 28-52 33.00 25-57 
TG 100.5 53-258 122 38-369 
HDL** 50 32-82 39 19-99 
LDL** 101.5 58-207 94 44-146 
SBP 123 102-161 127.0 103-150 
DBP** 79 67-101 75 54-95 
Sex 
Male 3 13 
Female 19 10 
Race 
White 9 6 
Black 8 10 
Hispanic 5 6 
Asian 0 1 
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ND= Non-Diabetic, T2D= Type 2 Diabetes; Alc=Hemoglobin Ale; BMI=Body mass 
index; TG= Triglyceride; SBP= Systolic blood pressure; DBP= diastolic blood pressure; 
* * indicates a statistically significant difference between the ND and T2D cohort 
(P<0.05). 
Chapter 4-DISCUSSION 
B cells from T2D patients have a pro-inflammatory phenotype 
Taken together thus far, our data indicate that altered TLR function in B cells 
from T2D patients affects cytokine production, and highlights the elegant specificity of 
TLR-mediated outcomes of B cell activation in disease. Importantly , surface TLR 
expression may not be the best predictor of B cell cytokine production in T2D. The final 
outcomes of TLR-activated cytokine production by T2D B cells are, on balance, pro-
inflammatory: increased IL-8 and decreased IL-10, which may override quantitatively 
small decreases in TNF-a. Although the precise ratio of pro- to anti-inflammatory 
cytokines required to promote chronic inflammation is unknown, our data clearly indicate 
that the B cell contribution to the overall ratio is significantly altered in T2D and may, for 
at least IL-8 and IL-10, rival the importance of monocytes as cytokine producers. The 
complex contribution of B cells and B cell TLRs to T2D inflammation is reminiscent of 
the mixed contribution ofT cells to inflammation in diet-induced obesity , in which CDS 
T cells promote pathology, but regulatory T cells block pathology [141, 146, 147]. 
Elevated IL-8 production by B cell from T2D patients was unexpected, but may 
link B cells to T2D based on several studies implicating IL-8 in T2D. IL-8 levels are 
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elevated in serum and in the adipose-associated stromal vascular fractions of T2D 
patients, but the cellular source of IL-8 was not identified by these studies [262, 263]. B 
cell IL-8 may also play a role in IL-8-associated complications of T2D , such as vascular 
disease [264]. This possibility is further supported by data showing palliative treatments 
that decrease IL-8 levels in vivo appear to have benefits for insulin resistance and 
cardiovascular risk factors [265]. Taken together, these studies suggest that elevated IL-8 
production by B cells from T2D patients may have important implications in T2D disease 
pathogenesis. The concomitant decrease in B cell IL-10 production undoubtedly skews 
the pro- to anti-inflammatory cytokine ratio even further to promote an inflammatory 
milieu . Although B cells produce lower levels of TNF-a either constitutively or in 
response to TLR4ligand (following TLR2 stimulation), the absolute changes in TNF-a 
production are modest in both assays. Therefore we predict these results hold value as 
indicators of altered TLR function in T2D B cells, but may not identify critical 
quantitative changes in this T2D-linked cytokine [266]. The simplistic dogma that TLR-
mediated nuclear factor kappa B translocation activates cytokines must be significantly 
refined to facilitate the design of new T2D treatments that exploit knowledge of the 
highly specific mechanisms that control TLR-activated cytokine production . 
A potential role for LPS/TLR4 in B cell activation in the absence of monocytes 
Our data, in combination with data from multiple other groups [267], indicate an 
important role for TLRs in inflammatory diseases. LPS is the prototypic TLR4ligand 
known to activate monocytes and B cells, leading to inflammatory cytokine production. 
Our data indicate that LPS activated B cells from T2D patients can induce reasonable 
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levels ofT cell IL-17 production without monocyte aid (Fig. 4-3A, compare BT CD3+28 
vs. BT CD3+28+LPS, black bars), however the addition ofLPS in the MTB cultures only 
raises IL-17 production in the ND donors, albeit at extremely modest levels (Fig. 4-1, 
141 pg/ml difference). Potentially, T cells from ND donors can secrete IL-17 in response 
to both cell-cell contact and LPS-induced cytokines; however T cells from T2D patients 
have reached a maximum threshold in terms of IL-17 production due to cell-cell contact. 
Additionally, In the MTB cultures, T cell specific activation (CD3+28) is sufficient for 
elevated IL-17 production in T2D patients (as opposed to the BT cultures), indicating a 
potential interaction between B cells and monocytes which is replaced by LPS activation 
of B cells in the BT cultures but only in the T2D cohort. These data could show that LPS 
is a redundant activator of B cells in the presence of monocytes, explaining the lack of 
IL-17 elevation with the addition of LPS in the MTB cultures in the T2D patients. 
Intriguingly, TLR4 surface expression can be upregulated by activated CD4+ T cells 
[268] , bringing up the possibility of direct T cell activation by LPS, which in the context 
of pathogenic B cell interaction boosts IL-17 production without the aid of monocytes in 
the T2D cohort. Unfortunately, a direct comparison between BT CD3+28+LPS and CD4+ 
CD3+28+LPS will require additional patient samples. Further studies investigating LPS 
induced CD4+ T cell activation and IL-17 production are required to dissect the exact role 
of LPS in IL-17 induction. 
The use of TLR ligands as adjuvants in T2D diabetes 
Clinical treatments that attempt to decrease inflammation in T2D patients have 
had variable results [79-81], perhaps caused in part by a lack of appreciation of non-
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conventional functions of B cells and B cell TLRs defined herein. Apart from the role B 
cells likely play in T2D, B cells certainly play significant roles in vaccine responses. 
Therefore, the current push to exploit TLR ligands in vaccine adjuvants, some of which 
will inevitably be used in the growing population of T2D patients, makes understanding 
the responses of these patient B cells and changes in B cell TLR function more broadly 
important. Both treatment and vaccine strategies must take into account the net effect of 
TLR action, including unexpected sources of TLR activity, to most effectively harness 
the promise of immune system modulation in chronic inflammatory disease patients. 
The role ofT cells in adipose tissue inflammation 
Several groups have recently identified important roles forT cells in adipose 
tissue inflammation and insulin resistance in a mouse model of T2D. Predictably, 
inflammatory IL-17+ and IFNy+ cells are elevated in at least some adipose depots of 
obese/insulin resistant mice [146, 147, 191]. Additionally, previous work shows that 
IFNy down regulates the insulin response in adipocytes [269], thus identifying a .. 
mechanism that links pro-inflammatory T cell function to a more traditional diabetogenic 
cell type. Complementary studies showed Tregs play impmtant roles in inhibiting insulin 
resistance , and loss of Tregs promoted inflammation [147]. Our data critically extend the 
conclusions of these animal studies into humans, and demonstrate that a focus on T cells 
represents a clinically important area of T2D research. Although our new studies did not 
specifically define a role for Th1 and Th17 cells in adipose tissue inflammation, the data 
provide evidence for a role of IL-17- and IFNy-producing T cells in systemic T2D 
inflammation, which likely parallels adipose associated events. 
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A pro-inflammatory feed-forward loop in T2D patients 
Data from multiple studies indicate a potential pro-inflammatory feed-forward 
loop between adipocytes and T cells in obesity and T2D. Over nutrition and obesity 
induce adipose tissue to secrete pro-inflammatory factors such as IL-6, a cytokine that 
induces Th17 differentiation [230, 263 , 270]. Increased secretion of IL-6, along with IL-
1B and TGFB [187, 227-230] can lead to systemic inflammation and a pro-Th17 skewing 
milieu , which in tum results in elevated levels of IL-17. Conversely , adipocytes are 
potential targets of pro-inflammatory T cell cytokines. Adipocytes express significant 
levels of the IL-17 receptors IL-17RA and IL-17RC [271], and respond to IL-17 by 
secreting IL-6, which may reinforce the IL-6 produced under hyper-caloric conditions 
[271] . Additionally, IL-17A upregulates cyclooxygenase-2 (COX-2) gene expression and 
prostaglandin E2 (PGE2) levels in differentiated adipocytes which is inhibited by the 
addition of blocking antibodies to IL-17 (Jennifer Shin 2009). Additional work on the 
specific role ofTh17 cells in exacerbating chronic inflammation (perhaps via adipocytes) 
would further our understanding of the complex interplay between two seemingly 
unrelated cell types in T2D. Overall, these data indicate a pro-inflammatory feed-forward 
loop between adipose tissue and T cells potentially inducing a "snow ball effect" 
consequently transitioning an obese insulin-sensitive individual to an obese insulin-
resistant T2D patient. 
Expression and potential role of CCR4 and CCR6 
Two chemokine receptors , CCR4 and CCR6, identify IL-17 producing memory 
Th17 cells [231]. Later reports found CCR4 and CCR6 on the surface ofTregs as well, 
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although these were primarily in the tonsil [272], which, by its nature, is chronically 
inflamed when excised from patients. Based on the reciprocal relationship between Th17 
cells and Tregs, it is possible that CCR4 and CCR6 could be yet another set of features 
that these functionally opposed cell types share, at least under some conditions. 
Importantly, elevated secretion of IL-17 in T2D patients independently confirmed 
conclusions from the initial CCR4/CCR6 studies, regardless of whether these chemokine 
receptors uniquely identified Th17 cells in T2D patients . An alternative explanation for 
the elevated percentages of CCR4+CCR6+ cells, along with elevated secretion of IL-17, is 
that in the inflammatory milieu found in T2D patients, Foxp3+ cells could be induced to 
produce IL-17. Foxp3/IL-17 A double positive T cells identified by published studies on 
ND T cells [273-275] demonstrate that generally anti-inflammatory Tregs may have pro-
inflammatory activities under some conditions. CCR4/6 expression on Tregs and Thl7 
cells may explain the seeming contradictory findings that the percentage of CCR4+CCR6+ 
T cells , but not IL-17 secretion, positively correlates with age (Fig. 8B and Fig. 4-10). 
Likewise, IL-17 secretion but not %CCR4/6 T cells correlated with T2D severity as 
measured by HBA1c (Fig. 4-8C and Fig. 4-10). Future studies will identify the 
mechanistic underpinnings of these related , but biologically discernible cell populations. 
Chemokine receptors such as CCR4 and CCR6 are critical for recruitment of 
appropriate immune cells to sites of inflammation. Preliminary mRNA analysis indicates 
expression of CCL20, the ligand for CCR4, in human adipose-associated stromal 
vascular fractions (S. Fried and D. Gong , unpublished data). Interestingly , because Tregs 
and Th17 cells share trafficking receptors, both cell types could be recruited to adipose 
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tissue. These findings raise the possibility that Tregs recruited to a pro-Th17 milieu in the 
adipose tissue through CCR4 and CCR6 are subsequently skewed towards the Th17 
phenotype. The plasticity between Tregs and Th17 cells indicate a potential for 
phenotypic changes based on signals from the environment, which in a non-disease state 
would be beneficial for a balanced immune response, but highly detrimental when 
homeostasis is lost. 
A pro-inflammatory triad 
Our data show an important interaction between three immune cells: monocytes, 
B cells and T cells which exacerbate inflammation in T2D patients. The interaction 
between monocytes and T cells maintains IL-l 7 production in both ND and T2D patients, 
indicating a non-T2D specific mechanism ofT cell activation. Additionally, this 
interaction requires cell-cell contact implicating a role for co-stimulatory molecules that 
induce IL-l 7 production. The interaction between B cells and T cells is T2D-specific in 
which B cell-T cell contact results in disease-specific elevated IL-17 production in T2D 
patients compared to ND donors. These data demonstrate changes in B cell surface 
receptors perhaps due to hyper-activation via elevated FFA's, LPS or inflammatory 
cytokines found in the circulation of T2D patients. Additionally, preliminary data 
postulates intrinsic changes in T cell IL-l 0 responsiveness in T2D patients demonstrated 
by loss of SOCS3 mRNA and elevated IL-17 secretion. Taken together, our data show for 
the first time complex disease and non-disease specific interactions between three 
immune cells that induce changes in T cell activation, along with potential disease-
associated intrinsic changes in these immune cells, thereby promoting chronic 
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inflammation in T2D. However, the mechanisms behind these interactions have yet to be 
elucidated. The next three sections will discuss the monocyte-T cell and B cell-T cell 
interactions and the potential mechanisms involved in these relationships. 
The monocyte-T cell interaction: cell-cell contact or soluble factors? 
Multiple groups have found an important interaction between monocytes and T 
cells required for T cell IL-17 production [23 7, 23 8, 251]. However, there seems to be 
differences in whether this interaction is through monocyte cytokine activation or through 
cell-cell contact mechanisms. These differences depend on the source of the cells being 
used: healthy donor peripheral blood [251], TlD patient peripheral blood [237], RA 
patient peripheral blood or RA synovial fluid [238]. These data indicate differential 
changes in either monocyte co-stimulatory molecules or the T cell activation threshold 
based on differences in diseases. Importantly, these experiments focus on IL-17 
production from the T cell memory pool and are unlike differentiation experiments in 
which naive T cells are skewed using various cytokines. TlD and T2D share certain 
disease characteristics but have very different mechanisms of induction. T 1 D is an 
autoimmune disease with a large T cell component and dramatic intrinsic changes in the 
T cell pool (reviewed in [276]. T cells from TlD patients can elevate IL-17 production 
just with monocyte cytokines, rather than requiring cell-cell contact as described in all the 
other studies [23 7]. This group also compared T cells from T2D patients, confmning our 
data that T cells from T2D patients do not elevate IL-17 secretion when stimulated with 
monocyte cytokines alone [237]. These data could indicate a decreased activation 
threshold for IL-l 7 production as one of the intrinsic changes in the autoimmune T cell 
132 
pool in TID patients. However, a direct comparison of these studies should be made with 
caution due to differences in protocols. In the TID study, monocytes and T cells were 
co-cultured for 5 days followed by 7 days of additional T cell stimulation with IL-2 
[237]. In the RA [238] and healthy blood studies [251], monocytes and T cells were co-
cultured for 3 days making these studies more comparable to our 40 hour cultures. Taken 
together, there exist differences in monocyte cytokine or cell contact requirement forT 
cell IL-17 production based on disease; however it must be said that these differences 
could reflect variations in protocols. 
Potential co-stimulatory molecules involved in the monocyte-T cell interaction 
Many studies have shown that co-stimulatory molecules are essential for proper T 
cell activation (reviewed in [277]. Our data demonstrate that T cells from both ND and 
T2D patients require monocyte contact for T cell IL-l 7 production indicating a role for 
co-stimulatory molecules in IL-17 induction. CD40, CD86, CD54 (ICAM1) and HLA-
DR are co-stimulatory molecules which potentially have important roles in IL-17 
induction as they are shown to be elevated on monocytes residing in the synovial fluid of 
RA patients [23 8]. CD40 blockade leads to a dramatic decrease in IL-17, and not IFNy 
production in a mouse model, indicating that APC interaction with monocytes is more 
important for Th 17 cells [278]. This group also demonstrated that a transient blockade of 
MHC class II also decreased IL-17 production indicating the importance of the APC-T 
cell interaction early on in T cell activation [278]. Interestingly, CD54 (also called 
ICAM-1) binds to CD 11 b [279] which is found on monocytes and is a co-stimulatory 
molecule for T cells making this an interesting target for further work investigating the 
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mechanisms of IL-l 7 production after monocyte-T cell interactions. Inducible co-
stimulator (ICOS) is an activation marker found on T cells that has also been shown to be 
important for IL-17 production [280], however its ligand ICOS-L is found on both B cells 
and monocytes, indicating no specificity for the monocyte-T cell interaction. Taken 
together, these data indicate that interactions between co-stimulatory molecules are a 
potential mechanism ofiL-17 induction that requires further exploration. Importantly, 
monocyte-T cell interactions seem to be more important for IL-l 7 production in 
comparison to Thl and Th2 cytokines, implying a specific strategy for IL-17 suppression 
or amplification for autoimmune or cancer therapies, respectively. 
The mysterious B cell-T cell interaction 
The most prominently described B cell-T cell interaction is B cell inhibition ofT 
cells through IL-10-dependent mechanisms. However, a group recently described B cell 
inhibition ofT cells through an indirect mechanism [254]. CD40 ligation on B cells 
through cell-cell contact with activated T cells initiates B cell regulatory properties which 
lead to the induction ofTregs [254], demonstrating an indirect B cell-induced mechanism 
of effector T cell inhibition. Our data indicates a unique, T2D-specific B cell contact-
dependent mechanism ofT cell activation, in which B cell-T cell contact leads to T cell 
activation rather than inhibition. These data lead to the intriguing possibility that the loss 
in the Treg compartment in T2D patients (as described in Aim 2) is a reflection of the 
loss in B cell regulatory properties. Preliminary data investigating surface molecules 
involved in the B cell-T cell interaction indicates no difference between ND or T2D 
patients in B cell surface levels of CD80, CD86 or CD40L (data not shown). These data 
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could indicate no role for these co-stimulatory molecules in elevated IL-l 7 production. 
However, it is possible that temporal changes in levels of these receptors on a particular 
B cell subset could be responsible for differences in IL-17 production. Our experiments 
only tested surface levels of these molecules at 40 hours. There is a possibility that early 
upregulation of these B cell surface molecules in T2D patients induces activation of IL-
17 production, which is missed by our 40 hour time-point. Interestingly, we see B cell 
induced elevated IL-17 production with aT cell specific stimuli, a-CD3 and aCD-28 
indicating that T cell activation has an indirect effect on B cells, perhaps through T cell 
cytokines. It is yet unknown whether it is changes in T cell cytokines or the B cell 
response toT cell cytokines (i.e. upregulation of a co-stimulatory molecule(s)) which 
results in T cell elevation of IL-17. Further studies investigating changes due to disease 
states in co-stimulatory molecules on B cells or changes in B cell responses to T cell 
cytokines would uncover disease-influenced changes in immune cell interactions, 
promoting drug development to influence or inhibit these changes and have wide-spread 
repercussions that extend beyond T2D. 
The use of B cell targeted treatments in T2D 
Our data suggest that monocytes act simply as a rheostat in IL-17 production, but 
B cells are responsible for the T2D specific elevation of IL-17 and perhaps, the decrease 
in the Treg population indicating B cells are the important inflammatory cell in T2D. 
T2D treatments targeted at improving IR by reducing inflammation have had mixed 
results [80, 281 ], perhaps because they were targeted at monocyte cytokines such as IL-
l p, which we have found to be no different between ND and T2D patients (Fig. 4-2A), 
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despite widely published differences in T2D-associated IL-1~ rnRNA production [123, 
213, 282, 283]. We predict that B cell targeted drugs have the potential to be developed 
as fundamentally novel treatments for T2D. Notably, B cell targeted treatments have 
been successful in autoimmune diseases, making these approved treatments viable for use 
in T2D from a regulatory perspective. These types of treatments use drugs that have 
already been tested for safety, making them an attractive and quick addition to the T2D 
clinician's toolbox. Importantly, our data demonstrate that disease influenced changes in 
immune cells have a ripple effect and so it is important to consider the interactions 
between these immune cells in order to understand the pathogenic changes in the disease 
state. Understanding the mechanistic underpinnings of these interactions in various 
disease states would add to our knowledge of how changes in the inflammatory milieu 
lead to changes in immune cell interaction and function and perhaps allow us to 
manipulate these interactions for disease prevention or cancer therapies in which 
inflammation can be helpful. 
The use ofT cell targeted treatments in T2D 
Our data in T2D patients indicate that one potential approach towards T -cell 
specific treatments to reduce inflammation would be to re-set the balance between the 
pro-inflammatory and anti-inflammatory T cell subsets, Th 17 and Treg cells respectively, 
perhaps by identifying factors that drive BMI-mediated elevations in CCR4+CCR6+ T 
cells that are present in T2D donors but absent ND donors (Fig. 4-lE). Alternatively, 
identifying mechanisms that explain BMI-dependent decreases in Tregs from T2D 
samples (Fig. 7E) may offer therapeutic options. An intimate understanding of the 
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molecular mechanisms behind the reciprocal Th17/Treg relationship is essential to be 
able to safely manipulate T cell subset balance to re-establish homeostasis in a disease 
environment. Targeting the imbalance in T cells as a treatment for T2D patients could be 
used as an Achilles heel to reduce inflammation leading to improved glucose tolerance 
and reduced insulin resistance. 
A comprehensive model for the role of immune system cells in T2D. 
Data from multiple studies, in combination with our data indicate an important 
relationship between immune cells in both ND and T2D patients. Furthermore, data from 
other groups demonstrate a potential pro-inflammatory feed-forward loop between 
adipocytes and immune system cells in obesity and T2D. One potential working model 
describing these interactions is shown in Fig. 5-1. In non-diabetic (ND) individuals, 
cytokines produced by monocytes, T cells and B cells affect adipose tissue and vice versa 
in a non-pathogenic homeostasis (Fig. 5-lA, black arrows below bracket). T cells and T 
cell cytokines are potentially further regulated indirectly by B cells through B cell 
induction of Treg expansion, as indicated by the red hatch. With increasing obesity, 
circulating free fatty acids (FFAs) and endotoxin increase (Fig 4-1B gold stars)[125]. 
These FF As can activate monocytes and B cells through an undefmed mechanism, 
inducing inflammatory cytokine production [126] (Fig. 5-1B, black arrows from gold 
stars). Increasing obesity also induces necrosis of adipocytes leading to recruitment of 
monocytes into the adipose tissue (in addition to B cells and T cells), where they become 
resident macrophages and secrete inflammatory cytokines (Fig 5-1B, dotted arrow below 
bracket) [138, 284]. Cross-talk between monocytes and T cells induce IL-17 secretion 
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(Fig. 5-1 , double-headed arrow between monocytes and T cells, although this interaction 
is not T2D specific. Activated B cells induce elevated levels of IL-17 by T cells from 
T2D patients, implicating B cell contact as a pathogenic stimulus in T2D (Fig. 5-1B, 
double-headed arrow between B cells and T cells). B cells from T2D patients produce 
elevated IL-8 and very low levels ofiL-1 0 (Fig. 5-1 B, indicated below B cells) indicating 
the pro-inflammatory status of these cells. It is yet unclear whether these changes in B 
cells from T2D patients play a role in the pathogenic interaction with T cells either 
through changes in surface co-stimulatory molecules or potentially, the loss in their 
ability to induce Treg expansion (Fig. 5-1B, black X over Treg). Importantly, the 
interaction between monocytes and B cells is still a mystery (Fig. 5-1 , black arrow with 
question mark between monocytes and B cells); though our data indicate that monocytes 
could potentially serve as an additional B cell activator prior to B cell-T cell interaction. 
Whether these T cells have a low activation threshold due to the pro-inflammatory milieu 
found in T2D patients, and/or hyper-activated B cells induce elevated IL-17 production 
from these T cells is still uncertain. Additional work on the specific roles of immune 
cells and their interactions along with their potential interactions with adipocytes to 
exacerbate chronic inflammation are essential towards furthering our understanding of 
the complex interplay between these two seemingly unrelated systems in T2D. 
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(A) Monocytes and T cells interact through cell-cell contact mechanisms (black double 
headed arrow between monocytes and T cells) to induce appropriate levels ofT cell IL-
17 _The interaction between monocytes and B cells is still unclear (black double headed 
arrow with question mark between monocytes and B cells). B cells can indirectly inhibit 
T cells by inducing Treg expansion , although the exact mechanism is still unknown 
(dotted line from B cells to Tregs with question mark). B cell IL-10 can also inhibit T 
cells (red hatch). Immune cell induced cytokines interact with adipocytes (black down 
arrow below bracket). Adipose tissue also produce mediators (black up arrow below 
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bracket), which can affect immune cells. In general , there is a homeostasis between 
adipose tissue and the immune system. (B) Increased free fatty acids or endotoxin (gold 
stars) due to increasing obesity activate monocytes and B cells via TLR4 (black arrows 
from gold stars) . Activated monocytes produce elevated levels of inflammatory 
cytokines . B cells produce increased IL-8 and very low levels of the anti-inflammatory 
cytokine IL-10. Monocytes and T cells interact to produce ND-equivalent levels of IL-17 
(black double-headed arrows between monocytes and T cells). However, pro-
inflammatory B cells induce T cells , through cell-cell contact mechanisms (black double-
headed arrows between B cells and T cells) to produce elevated levels ofiL-17. 
Additionally, B cells potentially lose their ability inhibit T cells (black X) , through both 
induction of Tregs or through IL-10. Overall pathogenic pro-inflammatory cytokines 
produced by immune cells , such as IL-17 which can induce insulin resistance through the 
activation of JNK , affect the adipose tissue . Increasing necrosis in the expanding adipose 
tissue can induce migration ofT cells, B cells and monocytes into adipose tissue (dotted 
line below bracket). Increasing obesity also affects the adipose tissue by inducing 
adipocytes to produce inflammatory mediators (black up arrow below bracket), which 
can affect immune cells. Taken together, all of these factors promote insulin resistance 
and systemic inflammation in T2D. 
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CHAPTER 5- FUTURE DIRECTIONS 
Cytokine specificity in NFKB controlled B cell cytokines in T2D patients. 
The NFKB family of transcription factors is one of the most well-known families 
of proteins involved in the immune response. The NFKB subunit, p65 or RelA is the most 
well understood protein of the NFKB family and is involved in the activation of what is 
considered the canonical NFKB pathway: TLR or cytokine receptor activation (reviewed 
in [48]. The list of NFKB responsive genes seems endless, thus there must be downstream 
specificity to control gene activation. The various NFKB subunits are charged with both 
inducing and resolving inflammation and so there are several negative feed-back loops 
put in place to control NFKB induced inflammation [49] . For example, IKB, the inhibitor 
that sequesters the components of NFKB in the cytoplasm preventing nuclear 
translocation, is an NFKB responsive gene. Another example is that of anti-inflammatory 
IL-l 0 and IL-l 0 related genes such as SOCS-1, which are also NFKB response genes. 
Taken together, these data indicate that there are many levels of regulation for NFKB to 
prevent uncontrolled inflammation. 
IL-10 is an anti-inflammatory cytokine induced by NFKB activation but has 
specific activation requirements. NF-KBl has been shown to be important for the 
production of IL-10 in macrophages [285]. Bcl-3 is a co-activator known to bind to NF-
KBl to induce production of IL-10 [286], however Bcl-3 has only been shown to be 
activated via a non-canonical NFKB pathway, the regulation of which is yet unknown. 
Other transcription factors such as Spl, CCAAT-enhancer-binding proteins (C/EBP), 
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Signal Transducers and Activators of Transcription 3 (ST A T3), c-Maf and nuclear 
transcription factor-Y (NF-Y) have also been shown to bind the human IL-10 promoter 
[285]. IL-10 production (and most likely other cytokines as well) is not a simple event 
and requires many coordinated steps, but is essential in resolution of inflammation. We 
have demonstrated that B cells from T2D patients fail to produce IL-l 0 in response to 
TLR ligands or B cell receptor (BCR) stimulation yet produce other cytokines such as 
GM-CSF, TNF-a and IL-6 at levels comparable to ND donors. B cells from T2D patients 
also produce elevated levels of IL-8 in comparison to ND donors. These data are 
indicative of a potential disturbance in the IL-10 negative feed-back loop, perhaps due to 
changes in transcription factor association to the IL-10 promoter in B cells from T2D 
patients. Furthermore, the elevation in B cell IL-8 seen in T2D patients could be due to 
the loss in the IL-10 negative feed -back loop . Additional studies focused on the specific 
changes in TLR response and NFKB negative feed-back loops in B cells from T2D 
patients would give further insight to the potential disease specific changes that occur in 
the NFKB pathway leading to and sustaining chronic inflammation. 
Our data demonstrates TLR ligand specificity in which TLR ligands alone and in 
combination induce differential cytokine production, indicating TLRs recognize 
differences in ligand structure. We are just beginning to understand the specifics of 
ligand-TLR receptor interactions , in which ligand binding changes the structure of the 
cytoplasmic tail of the TLR receptor , thus recruiting certain adaptor proteins to begin the 
signaling pathway [69] . Ligand-induced changes in receptor structure could be one 
mechanism to promote cytokine specificity in response to particular TLR stimuli. This 
142 
specificity would lend to the ability of the immune cell to respond to microbial stimuli 
appropriately. We demonstrate that co-stimulation of both TLR4 and TLR2leads to 
differential cytokine production in which TLR4 decreases TLR2 stimulated production of 
certain cytokines (GM-CSF, IL-6 and IL-10). TLR4 also decreased TLR2 stimulated 
production of TNFa but only in the T2D cohort, indicating disease-specific changes in 
TLR response. These data demonstrate cytokine specificity in response to specific TLR 
stimulation and NFKB activation. These data begin to show that co-stimulation could 
alter the cytoplasmic tails of the TLR receptors leading to differences in the signaling 
pathway, and thus differences in the cytokines being produced. Further research 
investigating ligand-receptor interactions and adaptor proteins involved in the activation 
of certain cytokines would yield further knowledge into the precise mechanisms of 
cytokine activation, which could be altered in a disease state. 
The effect of temporal changes in IL-10 production on immune cell interactions. 
We have demonstrated that purified B cells from T2D patients make extremely 
low levels of IL-10 constitutively and in response to various TLR ligands and B cell 
receptor stimulation in 24 hour cultures . However, our MBT data indicate no difference 
in IL-10 levels between ND and T2D donors in 40 hour cultures (Fig. 4-5A). There are 
several possibilities that explain these differences , 1) monocyte and/or T cell IL-10 
production mask any changes found in B cell IL-10 in the PBMC cultures and/or 2) there 
are changes in IL-10 production between 24 and 40 hours. B cell IL-10 has been shown 
to be uniquely important for prevention and resolution of inflammatory disease [151]. 
More specifically , the subset of B cells that produce IL-10, called B regulatory cells 
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(Bregs or BlO cells) have been shown to be important in mouse models of inflammatory 
diseases [150, 151, 154]. Recently, a human parallel of mouse BlO cells were identified, 
in which CD24highCD27+ B cells were IL-10+ and could regulate monocyte cytokines 
through IL-10-dependent mechanisms [150]. Focusing on a small proportion of B cells 
akin to studies done to identify roles played by a relatively small percentage of Tregs in 
preventing autoimmune disease/IPEX would yield further insight into whether the 
decrease in B cell IL-10 we observed were due to changes in the Breg population in T2D 
patients (reminiscent of the decrease in the Treg population shown in Fig. 3-7 A,B). 
Another possibility to explain the discrepancies between our PBMC and our 
purified B cell data could be temporal differences in IL-10 production. B cell IL-l 0 
production in T2D patients could lag behind B cell IL-10 production in ND patients and 
so at 24 hours , B cells from T2D patients produce very low levels of IL-10, which by 40 
hours have reached levels equivalent to those in ND patients. Late B cell IL-10 
production in T2D patients could result in an inability to prevent pro-inflammatory 
cytokine production early on in immune cell activation, and perhaps lead to a situation in 
which late B cell IL-10 production no longer has an effect on inflammatory cytokines, 
such as IL-17 . Measuring levels of early vs . late B cell IL-10 production would 
demonstrate whether temporal effects of B cell IL-10 are important in T2D inflammation, 
indicating whether boosting early IL-10 production could facilitate Breg induced 
inhibition of other immune cells. 
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The role ofT cells in the transition to insulin resistance. 
The processes perpetuating the loss of metabolic regulation in only a subset of 
obese individuals are not understood, but focus on human inflammatory T cells have 
yielded some insight into this clinically critical question. Our detailed analysis of IL-17 
showed that although stimulated T cells from both obese/ND and obese/T2D patients 
activate the IL-17 promoter to similar levels, T cells from obese T2D donors have 
significantly elevated IL-17 protein production compared to T cells from obese/ND 
donors (Fig. 3-2A&C). These data indicate that T cells from ND donors have an 
additional layer of regulation that prevents excessive IL-17 protein production. Elevated 
IL-17 production despite structurally similar Th 17 promoter structures, combined with a 
correlation between Th17 cells and body mass index (BMI) in obese/T2D but not in 
obese/insulin sensitive subjects brings up the intriguing possibility that loss of specific 
layers of mRNA regulation in the immune system promotes the transition from insulin 
sensitive to insulin resistant. For example, temporal regulation of activating transcription 
factors as we published for IL-l B [221] could shorten a normally sustained signal, or 
could alter the recruitment ofrepressive factors. It is also possible that the post-
transcriptional mechanisms common to many cytokine mRNAs may yield more moderate 
levels ofT cell IL-17 in insulin sensitive vs. T2D individuals. Although our data only 
address the role of Th17 cells, similar mechanisms may still apply to other cell types, 
leading to a global dysregulation in pro-inflammatory cytokine production. In addition, 
the contribution of coding or non-coding polymorphisms in many immunological active 
genes (287] likely play important roles in human studies. We propose that further studies 
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investigating potential roles of inflammatory T cells (and other immune cells) will assist 
clinicians in preventing the critical transition from obese/insulin sensitive to obese/T2D. 
Mechanism of T2D-induced changes in the Treg compartment. 
In Aim 2 we demonstrated a decreased percentage of circulating Tregs in T2D 
patients. This could be due to: 1) skewing of Tregs towards the Th17 subset, based on the 
Th17/Treg reciprocal relationship or 2) a decrease in the actual percentage ofT cells that 
are differentiating into the Treg subset. Many groups have demonstrated a link between 
Th17 cells and Treg cells (reviewed in [288]. One important connection is their 
requirement for TGF-p, in which TGF-P+IL-2leads to SMAD2/3 activation and Treg 
differentiation , vs. TGF-P+IL-6leads to SMAD7 activation and Th17 differentiation 
[289]. Multiple reports indicate that Tregs may become unstable especially in an 
inflammatory setting and adopt Th17 or Th1-like phenotypes by producing IL-17 or IFNy 
[288]. Notably, the reciprocal conversion ofTh17 cells into Tregs , have not been found 
indicating that the conversion of Tregs into Th17 cells may not be reversible . Using flow 
cytometry , co-staining for CD4+CD25+Foxp3+ and IL-17 would determine whether Tregs 
in T2D patients secrete IL-17 , indicating that perhaps the inflammatory milieu is skewing 
Tregs to produce IL-17. Additional work uncovering the mechanisms through which 
Tregs can adopt Th17 -like characteristics would promote therapies that could block this 
transition. Although we demonstrate a decreased percentage of circulating Tregs , we do 
not touch upon whether there are changes in the actual numbers of circulating Tregs. 
This can be done with a complete blood count (CBC) of the patient at the time of blood 
draw , which counts the total number of white blood cells , allowing for comparison of the 
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number of Tregs (CD4+CD25+Foxp3+) to the total number of circulating white blood 
cells. Unfortunately, this information was not available to us. A decrease in the number 
of Tregs would indicate that perhaps the inflammatory milieu in T2D patients prevents 
Treg differentiation in vivo . Treatments to combat this could include a combination of 
rapamycin and IL-2 which has been shown to promote Treg induction , survival and 
expansion [290] , however the effects of rapamycin in human subjects is unknown and IL-
2 has unpleasant side effects. Perhaps identifying the mechanism of action of rapamycin 
and IL-2 would yield safer therapies. Identifying whether changes in the Treg 
compartment of T2D patients is due to decreases in the number of circulating Tregs or 
skewing of Tregs to a Th17 -like subset would promote targeted therapies that either 
promote Treg differentiation or prevent Treg skewing to a Th17 -like subset to alleviate T 
cell induced inflammation in T2D patients. 
Suppressive capability of Tregs from T2D patients. 
Tregs are charged with containing the immune response by inhibiting T effector 
cells such as the Thl, Th2 and Th17 subsets. Studies in TID patients indicate no change 
in the percentages of Tregs in circulation, but loss of suppression due to a defect in IL-2 
receptor signaling [291]. In contrast , our data indicate a decrease in the percentage of 
circulating Tregs in T2D patients (Fig. 3-7 A&B), however nothing is known about Treg 
function in these patients. There may well be a decrease in the percentage of circulating 
Tregs with no loss in suppressive capability or these Tregs could be diminished in 
number in addition to loss of inhibition. Several studies indicate that Th17 cells are more 
resistant than Thl and Th2 subsets to inhibition by Tregs [292-294], potentially 
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explaining the increase in Th17 cells and IL-17 found in T2D patients . Treg suppressive 
assays in which Tregs from T2D patients are co-cultured with T effector cells from 
healthy donors would indicate whether these Tregs retain their suppressive potential. 
However, such studies are somewhat complicated in their design and interpretation by the 
potential role allogeneic responses may play due to HLA mismatch. Regardless of 
whether Tregs from T2D patients have decreased inhibitory capability, elevated 
percentages of Th 17 cells and elevated IL-17 secretion point toward an inability by the 
Treg compartment to maintain homeostasis. However, it is essential to discover whether 
Tregs from T2D patients are functional to identify whether treatments such as rapamycin 
and IL-2 (as discussed earlier) to boost Treg induction would be appropriate, since 
increased numbers of non-suppressive Tregs would do little to improve T cell induced 
inflammation in T2D patients. 
Discrepancies in T2D-associated changes in IL-lP 
It is generally accepted in the field that T2D patients have elevated levels of IL-l j3 
[123, 213,282, 283]. Most of these studies focus on mRNA levels of IL-1j3, rather than 
the protein levels [123, 282]. One study that does evaluate protein levels measures 
monocyte IL-lj3 in response to a large dose of LPS (5J.Ll/ml) [213], in contrary to our 
studies which use only lOOng/ml of LPS making the studies difficult to compare. Our 
mRNA data also indicate that monocytes from T2D patients have elevated transcription 
of IL-1j3 (Fig. 3-50, top graph). Surprisingly, our protein data in PBMCs indicates no 
difference in IL-113 at 40 hours between ND and T2D patients (Fig. 4-2A). Similarly to B 
cell IL-10, one possible explanation could be temporal changes in IL-113 production, in 
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which monocytes from T2D patients could produce IL-l B faster for an extended period 
of time which we miss at our 40 hour timepoint. One piece of evidence contributing to 
this hypothesis is our preliminary data showing LPS stimulation of monocytes from ND 
donors leads to disassociation of the transcription factor PU .1 from the IL-l B promoter; 
however this does not occur in monocytes from T2D patients (data not shown). Perhaps 
this delay in PU .1 disassociation leads to sustained production of IL-l B after monocyte 
activation. In T2D patients , this sustained release of IL-l B could induce paracrine effects 
on other immune cells which do not occur in ND individuals. IL-lB has been shown to be 
important for Thl7 differentiation [230], and so one potential paracrine effect of IL-l B 
could be to induce differentiation of naive T cells into Th 17 effector cells. Further studies 
exploring temporal differences in IL-lB production by monocytes could explain the 
differences in the Thl7 subset in T2D patients . 
Identifying the specific interactions between monocytes, B cells and T cells that 
lead to changes in the inflammatory state of T2D patients. 
Our data demonstrate a complex interaction between three immune cell types: 
monocytes, B cells and T cells. Although our data depict specific interactions between 
monocytes and T cells, and B cells and T cells, this dissertation is but scratching the 
surface in describing the interactions between each of these immune cells. First, the only 
stimuli used throughout these experiments are T cell specific, a-CD3 and a-CD28, and 
yet we see a requirement for monocyte and B cell interactions with T cells. T cell 
activation seems to yield monocyte and B cell activation factors which are thus far 
unknown. Interestingly, there seems to be a difference between ND and T2D patients in 
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the ability of these T cell factors to activate monocytes and B cells since the monocyte-T 
cell interaction seems to be required for both cohorts for IL-17 production, but elevated 
IL-17 production by T cells from T2D patients only occurs with the B cell-T cell 
interaction. It is quite possible that it is the B cell response toT cell factors in T2D 
patients that results in elevated IL-17 production, in which hyper-activated B cells (in 
response toT cell factors), induce elevated IL-17 production . In an even more complex 
interaction, there seems to be some communication between monocytes and B cells, since 
there are differences between ND and T2D patients in the ability of B cells to induce IL-
17 production without the aid of monocytes, but with LPS stimulation. Many more 
studies are required to unveil the specific interactions between these immune cells, in 
order to gain an appreciation of how to manipulate these relationships . Elucidating the 
disease-specific changes in immune cell interactions could have repercussions well 
beyond T2D into other chronic inflammatory diseases, in addition to yielding new 
promise in the endocrinologist's currently limited array of treatments for a $100 billion-
plus disease. 
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Appendix 1: Insufficient production of the anti-inflammatory cytokine IL-10 
perturbs the balance between pro- and anti-inflammatory factors in type 2 
diabetes (paper submitted). 
Introduction 
Chronic inflammation in T2D stems in part from monocyte IL-l ~ and TNF -a 
secreted in response to stimuli in T2D sera, such as endotoxin [3, 123]. Monocytes 
differentiate into macrophages in obese/T2D adipose tissue, and adopt a classical "Ml" 
phenotype to become a second source of pro-inflammatory cytokines [27, 295]. The 
increase ofMl macrophages is thought to yield to elevation of the generally anti-
inflammatory M2 subset in obese adipose tissue [27, 295]. However, detailed analysis 
found simultaneous presence of both Ml and M2 markers in expanding adipose tissue, 
even at stages thought to be dominated by M2 macrophage cytokines [145] . These 
fmdings indicate that cellular balance determines the inflammatory response to over-
nutrition. The designation of a "healthy" vs. inflammatory cytokine balance defined from 
these cellular changes is unclear. 
Quantifying T2D-associated changes in cytokine balance is necessary to identify 
and target inflammatory mediators naturally altered by metabolic disease. Alterations in 
cytokine responses almost certainly underlie both T2D inflammation and the suboptimal 
immune responses ofT2D patients to some diseases. To define cytokine balance in T2D, 
we tested immediate early cytokine responses of monocytes. Increased pro-inflammatory 
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cytokine production was paralleled by elevation of anti-inflammatory IL-l ra, but 
surprisingly, IL-l 0 was activated only to "non-diabetic" levels. We conclude that lack of 
elevated IL-l 0 expression, in combination with elevated pro-inflammatory cytokines, is a 
dominating characteristic of cytokine imbalance in T2D. 
Methods 
The study protocol was approved by the Boston University Institutional Review 
Board and was conducted in accordance with the Declaration of Helsinki. Human 
samples were obtained following informed consent. T2D patients (n=9) were recruited 
from the Center for Endocrinology, Diabetes and Nutrition at Boston Medical Center 
(Table 4-1 ). This T2D cohort excluded patients with common infections :=:;two weeks 
prior to blood donation or those with non-T2D related inflammatory disease. These 
patients were representative of common T2D and were generally obese. Non-diabetic 
(ND) donor samples were provided by healthy, lean (BMI:=;25) donors (N=9). Smokers 
were always excluded. Cells were isolated from peripheral blood collected by venous 
puncture into heparinized tubes. Peripheral blood mononuclear cells (PBMCs) were 
purified on a Ficoll 1077 cushion. CD14+ monocytes were purified from PBMCs by 
negatively selecting magnetic beads (Miltenyi). Monocytes were rested for 1 hr at 3TC, 
then stimulated with lOOng/ml E. coli LPS (Sigma) for 0.5-6 hrs. prior to harvest. 
mRNA was quantified by real-time PCR as published [296] , using the ~~Ct method. 
eDNA was quantitatively amplified with the following primers: IL-l~: 5' -
ACGAATCTCCGACCACCACT -3 ' and 5 ' -CCATGGCCACAACAACTGAC-3' ; 
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TNFa: 5 '-GGCCTACAGCTTTGATCCCTG-3' and 5 '-
AAAGGCTCCCTGGTCTCCAG- 3 '; IL-lra: 5' -
GAAATAACTAAACTGGGTTTCAATCCT-3 ' and 5'-
TCTATGGAGTGGCCATTCTTTTAT-3 '; IL-10: 5' -
GGGAGAACCTGAAGACCCTCA-3' and 5 '-AAGAAA TCGATGACAGCGCC-3 '; 
GAPDH: 5'-TGGAGATCTGGTTTCCGGAA-3 ' and 5' -
GGAGCCTCAGTCCCATTCC-3 '. Cytokine ratios were calculated by dividing the 
average normalized level of anti-inflammatory cytokines by the average normalized level 
of pro-inflammatory cytokines. Ratios are not meant to take into account biological 
differences among cytokines. Two-way ANOVA compared cytokine production by 
monocytes from T2D or ND donors. The Mann Whitney U test established differences in 
clinical parameters. Analyses were performed on Prism and p _:S0.05 established statistical 
significance. 
Results 
Peak pro-inflammatory cytokine production by T2D monocytes is quantitatively 
elevated and temporally prolonged. 
Previous work demonstrated that monocytes from T2D donors produce elevated 
cytokine levels [213]. Therefore, we anticipated that monocytes from the Boston Medical 
Center T2D cohort would have an elevated immediate early pro-inflammatory response 
to LPS (Figs. 7-1 A,B). More detailed temporal analysis uncovered a previously 
unappreciated difference in pro-inflammatory cytokine gene activation by monocytes 
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from T2D vs. ND donors. IL-1[3 gene activation in ND donor monocytes peaked early 
(0.5 hr. post-stimulation), but IL-1[3 activation in T2D donors monocytes increased 
steadily to a broad peak 1-2 hrs post-stimulation, with maximum production 5 hrs post-
stimulation (Fig. 7-1A). Similarly, peak TNF-a production by monocytes from T2D 
patients was prolonged (1-3 hr. post-stimulation). This pattern contrasted with the 
relatively sharp peak in maximal TNF -a gene expression 2 hrs following stimulation of 
ND donor monocytes (Fig. 7-1 B). These data indicate that immediate early IL-1[3 and 
TNF -a production are elevated and prolonged in monocytes from T2D compared to ND 
donors. Elevated cytokine mRNA corresponds to elevated IL-1[3 and TNF -a protein 
secretion by monocytes from T2D patients [213]. 
Peak anti-inflammatory cytokine production is temporally altered in T2D 
monocytes. 
ND donor monocytes produce pro- and anti-inflammatory cytokines, either of 
which could dominate the net inflammation. To investigate the contribution of 
immediate early anti-inflammatory monocyte responses to T2D inflammation, we 
analyzed monocyte RNA for expression ofiL-10, an anti-inflammatory cytokine 
implicated in T2D protection [167]. Immediate early IL-10 mRNA levels in monocytes 
from T2D and ND donors were overall similar (Fig. 7-1 C), although peak IL-l 0 mRNA 
levels occurred 2 hrs post-stimulation in monocytes from ND donors, compared 4-5 hrs 
following T2D monocyte stimulation. These data suggest a widespread delay in maximal 
cytokine production by T2D donor monocytes, regardless of pro- vs. anti-inflammatory 
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actions of each cytok:ine. More importantly, overall IL-l 0 production was comparable 
between T2D and ND monocytes (p>O.l by 2-way ANOVA). 
To determine whether elevated cytokine production by monocytes from T2D 
patients is more generally limited to pro-inflammatory cytok:ines, we measured 
expression ofiL-ra, the naturally occurring inhibitor ofiL-1 f3 [297]. IL-lRA mRNA 
reached consistent levels 0.5-1 hr post-monocyte stimulation in ND samples (Fig. 7-lD). 
Like IL-lf3, IL-lra production by monocytes from T2D vs. ND donors peaked with 
delayed kinetics, and prolonged IL-lra peak production was temporally similar to 
prolonged IL-lf3 production by the same cells (Figs. 7-lA vs. 7-lD). Taken together, our 
data demonstrate quantitative and temporal changes in cytokine production in monocytes 
from T2D patients. However, elevated anti-inflammatory cytokine production by T2D 
donor monocytes is not universal. 
Altered cytokine ratio during early immediate responses of T2D donor monocytes. 
Our demonstration of altered monocyte production of only some cytok:ines 
suggests that cytokine imbalance determines the final inflammatory profile. To better 
understand the balance between pro- and anti-inflammatory cytokines in T2D, we 
calculated the ratios between average cytokine levels at each time point. This comparison 
demonstrated a relative abundance of IL-l 0 over either pro-inflammatory cytokine in ND 
donor monocytes at most time points (Fig. 7-2 A&B). In contrast, monocytes from T2D 
donors produced IL-l 0 at levels that appeared generally overwhelmed by elevated IL-l f3 
and TNF-a expression (black bars). These data support the conclusion that lack of 
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elevated IL-l 0 production by T2D monocytes combines with elevated inflammatory 
cytokine expression to support chronic inflammation in T2D. 
To estimate the role concomitant IL-l~ and IL-lra elevation (Figs. 7-lA&D) play 
in T2D inflammation, we calculated the ratio between IL-l ra and IL-l~ production by 
monocytes from T2D and ND donors. The IL-lra:TNFa ratio maximally varied by 1.5-
fold in both ND and T2D samples, contrasting with the up to 10-fold differences in IL-
lO:IL-1~ or IL-lO:TNF-a ratios (Fig. 7-2C vs. A-B). Importantly, no consistent 
difference in the IL-lra:TNF-a ratio ofT2D vs. ND samples emerged. To confirm that 
changes in IL-lra production play relatively modest roles in the T2D inflammatory 
balance, we calculated the ratio between IL-lra and IL-l~ production by monocytes from 
T2D and ND donors. No consistent pattern in this ratio emerged (Fig. 7-2D), again 
contrasting with the dominance of IL-l 0 in ratio analysis ofND monocytes (Figs. 7-
2A&B). We conclude that changes in IL-lra production are unlikely to be key 
inflammatory determinants in T2D. Instead, the inability of monocytes to elevate IL-l 0, 
combined with elevated IL-l~ and TNF -a expression, points to a lack of IL-l 0 up 
regulation as an important inflammatory determinant in T2D. 
Discussion 
Our findings indicate that regulation of cytokine balance in ND vs. T2D patients 
is more complex than the simplistic models of"on/off' switches provided by, for 
example, the NF-KB activation known to regulate all four genes analyzed [285, 296, 298, 
299]. Increased basal NF-KB activation in T2D donor monocytes [300] does not hyper-
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activate IL-10 thus pro-inflammatory cytokines increase with anti-inflammatory 
cytokines. These data indicate that unappreciated transcriptional regulatory mechanisms 
allow elevated IL-l~' TNF -a and IL-l ra expression in the absence of altered IL-l 0. The 
inability of monocytes from T2D patients to hyper-activate IL-l 0 mirrors our 
demonstration that T2D patient B cells produce little IL-10 [301]. These findings support 
the likelihood of cell-type independent defects in IL-l 0-activating mechanisms. 
Alternatively, lack of elevated IL-l 0 production by monocytes and B cells from T2D 
donors could result from a cell-extrinsic mechanism triggered by metabolic imbalance or 
by altered T cell cytokine production [179]. 
The acute stimulation of monocytes herein is a model for acute endotoxin release 
that occurs, for example, following a high fat meal [302]. LPS stimulation is also a 
reasonable model for response to pathogenic TLR4-activators such as M tuberculosis 
[303]. Although such acute responses have been widely associated with T2D donor 
monocytes, the relationship between acute hyper-responsiveness and the chronic, low-
level endotoxemia and inflammation in T2D patients remains unknown. Importantly, our 
studies do not uniquely link T2D to endotoxin hyper-responsiveness, because the T2D 
and ND cohorts differ in BMI. Based on our previous analysis, the age difference in 
cohorts is likely inconsequential [168, 301]. However, our results justify comparison of 
cytokine balance in BMI-matched metabolically healthy and unhealthy samples to probe 
the possibility that imbalance is a harbinger of diabetes, and that correcting the IL-l 0 
defect may have efficacy in T2D. 
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Monocytes from patients with T2D produce elevated levels of cytokines in response to 
acute stimuli. Purified monocytes were stimulated for 05.-6 hrs with LPS prior to 
quantification of mRNA encoding (A) IL-l~ (N= 8 each for T2D and ND samples; p= 
0.005); (B) TNF-a (N= 9 or 6 for T2D or ND samples, respectively; p=0.0063); (C) IL-
10 (N= 4 or 5 for T2D or ND samples, respectively; p>O.l ); or (D) IL-lra (N= 7 or 6 for 
T2D or ND samples, respectively; p=0.0029). Bars show average and SEM of relative 
mRNA levels. Differences in cytokine gene expression between monocytes from T2D 
and ND do were identified by 2 way ANOV A with p values indicated above. 
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(filled or open bars, respectively) . Ratios calculated are (A) IL-10 :IL-1~; (B) IL-10:TNF-
a; (C) IL-1ra:TNF-a; (D) IL-1ra:IL-1~. Samples numbers are detailed in the Fig. 1 
legend. 
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Table 4-1: Description of all blood donors 
ND Median (range) T2D Median (range) 
Age (years) 43 (27-46) 53 (43-73) 
Ale(%) N/A 7.8 (6.0-9.6) 
BMI (kg/m2) 22 (19-26) 34 (31-42) 
Glucose N/A 150 (95-177) 
N (9) N (9) 
Females 5 2 
Males 2 7 
Unknown sex 2 0 
Race 
-White 4 4 
-African American 3 4 
Unknown Race 2 1 
ND= Non-Diabetic, T2D= Type 2 Diabetes; Alc=Hemoglobin Ale; BMI=Body 
mass index; NA= Not Available 
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Appendix 2: TLR cross-talk regulates cytokine production in PD patients [168]. 
Introduction 
Chronic inflammation underlies many diseases including periodontal disease and 
T2D [304, 305]. These diseases are generally categorized by pathological changes, but 
many factors mediating morbidity likely stem from the systemic inflammation shared 
amongst these diseases [306, 307]. In general, pathological inflammation results from 
inappropriate immune responses to seemingly innocuous stimuli, such as commensal 
microbes or host-derived ligands. Some chronic inflammatory diseases, such as 
periodontal disease, are thought to initiate as a failure in homeostasis with commensal 
bacteria. The resulting local inflammation is mirrored by increased systemic 
inflammation, which likely explains the link between periodontal disease and 
cardiovascular disease [308]. Similarly, the systemic inflammatory environment in 
diabetes patients probably stems from elevated levels of endogenous ligands, such as free 
fatty acids or advanced glycation end products, that can stimulate innate immune cells to 
produce pro-inflammatory cytokines [125 , 126, 309]. Elevated circulating endotoxin 
levels in diabetes patients [31 0], perhaps originating from compromised mucosal 
surfaces, may further exacerbate the systemic inflammatory response implicated in the 
most serious complications of this disease . 
Toll-like receptors (TLRs) are involved in mounting pathogenic inflammatory 
responses to commensal organisms and host-derived ligands in chronic inflammatory 
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diseases, including periodontal disease and diabetes [5, 311, 312]. The likely role of 
TLRs in human systemic inflammatory disease is supported by multiple reports. First, 
both TLR2 and TLR4 are receptors for products of major periodontal pathogens, 
including Porphyromonas gingiva/is (P. gingiva/is) [313]. Second, TLR4 polymorphisms 
that alter TLR4 function associate with occurrence of periodontal disease and diabetes, at 
least in some cohorts [314, 315]. Third, TLR2 and TLR4 are strongly implicated in 
diabetes by demonstrations that either inhibiting or genetically deleting each receptor in 
mice protects against a key characteristic of type 2 diabetes, insulin resistance [41, 43, 
125]. These observations suggest that altering expression, thus function, of TLRs can 
promote inflammation in chronic diseases. Interestingly, multiple studies , including 
analyses of TLR4+ B cells from periodontal disease patients, show cellular responses to 
TLR41igands can be a mixture of prototypic pro- and anti-inflammatory responses [159, 
316]. 
The concept that cross talk amongst TLR family members defines the innate 
immune response has emerged from studies on immune system sentinel cells , especially 
dendritic cells and macrophages. TLR2 and TLR4 activate these cells through a MyD88-
dependent pathway, but TLR4 also activates the TRIF/TRAM pathway in response to 
select ligands . Pathway overlap explains why in at least some cases , TLR4 engagement 
has the same biological outcome as co-engagement of TLR4 and TLR2 [317 , 318]. 
However, TLR2 and TLR4ligands can also synergize to activate production of pro-
inflammatory cytokines under some conditions [319 , 320]. Engagement of other TLR 
family members , such as TLR9, can alternatively alter cellular responses to either TLR2 
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or TLR4ligands in myeloid cells [320, 321]. Appropriate TLR cross talk therefore plays 
an important role in mounting an effective immune response to the complex 
combinations of TLR ligands presented by pathogens, commensal bacteria, and 
endogenous ligands. 
Studies aimed at understanding the role of innate immune cells and TLR function 
in systemic inflammatory disease, with the exception of studies on TLR9, have largely 
focused on myeloid cells. However, B cells also function as a critical arm of the innate 
immune system, in part due to their ability to respond to TLR ligands and secrete 
cytokines [322]. The role of B cell TLR engagement and subsequent cytokine production 
in chronic inflammatory diseases, including periodontal disease and diabetes, is poorly 
characterized. Our studies suggest activated human B cells can circulate throughout the 
body [160]; therefore, B cells may play an ongoing role in systemic manifestations of 
inflammatory diseases. B cells from periodontal disease patients vs. healthy donors have 
an elevated percentage of TLR2- and TLR4-positive B cells . New data shows these B 
cells constitutively and inducibly secrete elevated levels of cytokines, the latter in 
response to TLR ligands. These studies also uncovered a high degree of specificity in B 
cell cytokine production in response to combinations of TLR ligands. Finally, B cells 
from periodontal disease and diabetes patients responded differently to combinations of 
TLR ligands. Based on this comprehensive analysis of biologically important outcomes 
of TLR pathway cross talk in human inflammatory disease patients, we conclude that 
clinical treatments and vaccines aimed at regulating immune responses through TLRs 
must consider the complex response of B cells to combinations ofTLR ligands. 
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Methods 
Cells: Human samples were obtained following informed consent under a Boston 
University Institutional Review Board-approved protocol. Peripheral blood was collected 
into heparinized tubes by venous puncture . B cells were purified from whole blood using 
histopaque 1077 to isolate the peripheral blood mononuclear layer, then negatively 
selected with magnetic beads to isolate CD19+ B cells according to the manufacturer's 
protocol (Miltenyi). Only B cell preparations that were >95% pure were used in cytokine 
analyses. The majority of contaminating cells in all preparations were CD3+ T cells ; 
monocyte contamination was <1 %. B cells were stimulated for 24 hrs prior to analysis of 
secreted cytokines. The initial B cell concentration for all cultures was 106/ml , and all 
cultures were incubated in U bottom wells . Non-diabetic periodontal disease patients 
(PD) had a diagnosis of localized aggressive periodontitis [217] but no other known 
disease. The PD patients that provided B cells for cytokine analyses are summarized in 
Table S 1. In brief, the PD patients were characterized by periodontal infection with 
multiple organisms including P . gingiva/is and A. actinomycetemcomitans. Clinical and 
radiographic criteria of PD were: age of onset around the circumpubertal period ( <13 
years old), and alveolar bone loss localized around the first permanent molars and 
incisors [217]. In addition , subject's periodontal diagnosis was further confirmed by 
neutrophil functional analysis [218]. Systemically healthy donors who had no sign of 
periodontal disease other than mild gingivitis were matched to PD patients based on age , 
sex and race when possible. Patients and healthy donors were recruited from the Clinical 
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Research Center and the BUSM community and were non-smokers. Gingival tissue was 
collected from patients with PD as part of their routine periodontal surgical treatment. 
Human Mono-Mac-6 monocytes were cultured and stimulated as published [221]. 
Patients with diabetes (DM) were recruited from the Endocrinology , Diabetes and 
Nutrition Clinic at BUMC. Table S2 outlines parameters for the diabetes patients (N=11) 
that provided peripheral blood B cells for cytokine analyses. Periodontal status of these 
patients is unknown. 
Flow cytometry: B cells in whole blood were prepared and analyzed as published [159, 
223]. Intracellular IL-8 was labeled with Fast-Immune (BD PharMingen) . Alternatively, 
purified B cells from healthy donors were incubated for 24 hrs in the presence of the 
TLR9ligand CpG (ODN 2006, 1 ~-tg/ml) or IL-4 (10 ng/ml), alone or in combination for 
72 hrs . before staining for surface TLR4 expression using standard procedures [223]. 
Biochemistry: B cells were isolated by negatively selecting magnetic beads and were 
>95% pure as assayed by flow cytometry with a-CDllb, a-CD3 and a-CD19 (Fig. 2). 
Rested B cells (1 hr 3TC) were stimulated with ligands at 1~-tgl ~-tl (approximately 
equimolar amounts) for 6-24 hrs for chromatin immunoprecipitation (ChiP) or cytokine 
analyses , respectively. ChiPs were completed as published [159]. Alternatively , DNA 
was amplified with IL-8 primers: 5'-TGGGCCATCAGTTGCAAA -3'; 
5 'ACTTATGCACCCTCATCTTTTCATT-3' . Cytokines were quantified on a Luminex 
200 using a 10-plex detection kit that measured IL-1(:3 , IL-2 , IL-4, IL-5, IL-6, IL-8 , IL-10, 
IFN-y , TNF-a and GM-CSF (Invitrogen). TLR4ligands have been described [323, 324]. 
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Statistics: The Mann-Whitney U test was used for non parametric comparisons of group 
means forB cells from peripheral blood. Wilcoxon matched-pairs tests were used for 
cytokine analyses. Linear associations of continuous variables were assessed with 
Spearman's rank correlation coefficient (Prism). ChiPs were analyzed by Student's t test. 
All statistical tests were two-tailed, and p values of less than 0.05 defined statistical 
significance. 
Results: 
B cells from PD patients express functional TLR2 
Our work on B cells from inflamed tonsil and inflammatory bowel disease (IBD) 
patients demonstrated that B cells from inflammatory environments are surface TLR2-
positive and respond to TLR2 ligand by secreting IL-8 [160, 223]. To test whether B cells 
from another chronic inflammatory disease , aggressive periodontitis (PD) , are similarly 
altered, we measured the percentage of TLR2-positive B cells in whole blood and 
inflamed gingiva from PD patients (Figs. 6-1A-C). PD patients had a modest but 
statistically significant increased percentage of TLR2-positive B cells compared to 
healthy donors (Fig. 6-IB). A high percentage of B cells in inflamed gingiva also 
express TLR2 (Fig. 6-1C), but the absence of healthy B cells from non-inflamed gingiva 
prevented a comparison to gingival B cells from PD patients [159]. TLR2-positive B cells 
were equivalently represented in the CD19+/CD38+, CD19+/CD38- and CD19+/CD27+ 
populations (not shown). This finding is consistent with data showing similar expression 
levels ofTLRs 1,2,7 ,9 , and 10 amongst na"ive, germinal center and memory B cells [325]. 
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To determine whether the modest elevation of circulating TLR2-positive B cells in PD 
patients correlated with increased TLR2 responsiveness, we stimulated highly purified 
CD19+ B cells from PD patients (Fig. 6-lD) with the prototypic TLR2ligand 
Pam3CSK4 (Pam3). B cells from PD patients secrete IL-8 in response to TLR2 
engagement (Figs. lE&F; *=p<0.05). This contrasts with the lack of IL-8 production by 
B cells from healthy donors (Fig lF). Differences in IL-8 secretion between B cells from 
healthy vs. PD donors were statistically significant (Fig. 6-lF; compare white and black 
bars; p<0.05 under all conditions), including media incubation. These data suggest that B 
cells from PO patients are constitutively activated, perhaps by in vivo ligands from 
common periodontal pathogens, such asP. gingiva/is [326]. We conclude that modest 
TLR2 elevation on B cells from PD patients confers significant increases in TLR2 ligand 
response. 
A theoretical source of IL-8 in our cultures are the small number of contaminating 
cells, especially monocytes, that secrete high levels of cytokines in response to TLR2 
(and TLR4) ligand. The lack of IL-8 in samples from healthy donors (Fig. 6-lF) 
discounts this possibility. However, to further test the role of contaminating non-B cells 
in constitutive and inducible IL-8 production, we determined the relationship between B 
cell purity (%CD19+) and cytokine production (ng/ml) by Spearmans rank correlation. 
No correlation emerged (p>O.l; not shown), confirming that contaminating cells are 
unlikely sources of IL-8 or other cytokines in these cultures. Furthermore, preliminary 
examination of monocyte-contaminated B cell preparations indicated that <1% 
contaminating monocytes would insignificantly contribute to overall cytokine levels 
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measured in our highly purified B cell populations ( <10% of total cytokine production, 
data not shown). We conclude that contaminating monocytes are unlikely sources of 
TLR2 (and TLR4)-induced IL-8 in our purified B cell cultures. These findings support 
our conclusion that the relatively modest increase in TLR2-positive B cells in PD patients 
confers robust responsiveness to TLR2 ligand as measured by IL-8 secretion . 
To identify mechanisms driving IL-8 production by B cells from PD patients , we 
examined IL-8 promoter association with a transcription factor that activates IL-8 in 
myeloid cells, dun [327]. dun constitutively associated with the IL-8 promoter in 
freshly isolated B cells from PD patients (Fig. 6-1H) , and association is maintained after 
24 hrs. in culture (Fig. 6-11, leftmost white bars). dun/IL-8 association is further 
increased in B cells activated through TLR2 (Pam3; Fig. 6-11) . These data suggest that 
TLR2 activates dun resulting in constitutive and inducible IL-8 production in B cells 
from PD patients. 
To confirm B cells from PD patients produce IL-8 in vivo, and to further test 
similarities between circulating and gingival B cells (Fig. 6-1A and 1C), we measured 
intracellular IL-8 expression in fresh ex vivo peripheral blood and gingival B cells from 
PD patients . Blood B cells from PD patients , but not healthy donors , were intracellular 
IL-8-positive (Fig. 6-11). Likewise, B cells isolated from inflamed gingiva produced IL-
8 (Fig. 6-1K) . These data confirm that B cells , rather than contaminating cells, are the 
source of IL-8 in our ex vivo experiments, and support the likelihood that B cells produce 
IL-8 in vivo. We conclude that activation of the IL-8 promoter by TLR2 engagement and 
dun/IL-8 association drives IL-8 production by B cells in PD patients . 
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B cells from PD patients constitutively secrete IL-l~ 
In addition to IL-8 , multiple pro-inflammatory cytokines , such as IL-l~, IL-6 and 
TNF-a have been implicated in PD and in a second inflammatory disease that is a strong 
risk factor for PD, diabetes [208, 328-330]. To more comprehensively identify the role B 
cells play in chronic inflammatory disease, we first measured secretion of additional 
cytokines by fresh ex vivo B cells from healthy or PD patients. On average, B cells from 
PD patients vs. healthy donors constitutively secreted elevated levels ofiL-1~ (Fig. 6-2). 
All B cells constitutively secreted low levels of GM-CSF, IFN-y, IL-10 and TNF-a (Fig. 
6-2) , and undetectable levels of IL-2, IL-4 and IL-5 (not shown). IL-6 production was 
highly variable in all assays hence uninterpretable (not shown). We conclude that B cells 
from PD patients may contribute to chronic systemic inflammation through constitutive 
IL-8 and IL-l~ secretion. 
B cell TLR2 engagement activates select cytokines and other signatures of 
inflammatory cells 
To more broadly evaluate the role of increased B cell TLR expression (Fig. 6-1 
and Ref. [159] in chronic inflammatory disease, we measured secretion of additional 
cytokines by B cells responding to TLR ligands. The first series of analyses focused on 
cytokine secretion by B cells responding to single TLR ligands. B cells from PD patients 
responded to the TLR2 ligand Pam3 by significantly increasing production of all 
cytokines (Fig. 6-8) although some cytokine levels were indistinguishable, on average, 
from levels produced by TLR2-stimulated B cells from healthy donors (Fig. 6-3A; GM-
CSF and IFN-y). A weak TLR2 response in B cells from healthy donors is consistent 
169 
with published data [223, 325]. However, a subset of cytokines , specifically IL-113 and 
TNF-a, are secreted at significantly elevated levels (p<0.05) by TLR2-stimulated B cells 
from PD vs. healthy donors (Fig . 6-3A). IL-10 secretion was also preferentially induced 
in B cells from PD patients, but this increase was statistically insignificant (p>0.05), due 
to greater variability in inducible IL-10 secretion. IL-2, -4, and -5 were undetectably 
secreted by all B cells responding to all stimuli tested (not shown). These data further 
support the conclusion that elevated surface TLR2 expression on B cells from PD 
patients may have pro-inflammatory outcomes, and suggest that constitutively elevated 
IL-113 production by B cells from PD patients (Fig. 6-2) could result from TLR2 
engagement by in vivo ligands . 
TLR2 and TLR4 regulate each other in mouse B cells [331]; therefore, we asked 
how elevated TLR2 activity might affect TLR4 in B cells from PD patients. To test 
whether TLR2 engagement affected TLR4 gene activation in B cells from PD patients , 
we treated B cells from PD patients with TLR2ligand (Pam3) and measured inducible 
association of the TLR4-activating transcription factor PU .1 [332] with the TLR4 
promoter (Fig. 6-3B). PU.l association with the TLR4 promoter increased about 5-fold 
in TLR2-stimulated B cells, and increased somewhat less (3-fold) in cells stimulated with 
TLR2ligand (Pam3) plus TLR41igand (rLPS) . As expected, TLR2ligand also up 
regulated surface TLR4 expression as assayed by flow cytometry (Fig. 6-3C). We 
conclude that TLR2ligand activates TLR4 expression in B cells from PD patients. 
Interestingly, these findings identify a mechanism by which in vivo TLR2ligands may 
regulate TLR4-mediated B cell activation in PD [159]. 
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B cell TLR4 engagement activates a subset of cytokines activated by TLR2 
To further explore potential physiological outcomes of TLR2-mediated TLR4 
activation in B cells from PD patients , we measured B cell responses to TLR4 ligands. 
We measured cytokine responses to rLPS, the TLR4 ligand that alters gene expression in 
B cells from PD patients [159]. Although , on average , rLPS increased production of most 
cytokines in PD B cells (GM-CSF, IFN-y, IL-lf3 and IL-10; Fig. 6-9), only IL-8 and 
TNF-a production was significantly higher in B cells from PD vs. healthy donors (Figs. 
6-lF and 6-30). Interestingly, increased IL-8 secretion in response to rLPS did not 
correlate with inducible cJun/IL-8 promoter association (Fig. 6-11) indicating that , at least 
in some cases, IL-8 can be activated in the absence of cJun binding. We conclude that 
TLR4 significantly activates only a subset of TLR2-activatable cytokines in B cells from 
PD vs. healthy donors. 
TLR9 engagement activates cytokine and TLR4 expression by B cells from 
healthy and PD donors. 
To more comprehensively identify outcomes of TLR activation in B cells from 
inflammatory disease patients compared to healthy donors, we stimulated B cells with the 
TLR9 ligand CpG and measured cytokine production. CpG-mediated TLR9 activation up 
regulated multiple cytokines in B cells from both PD and healthy donors, on average, to 
an equivalent level (Figs. 6-3E and 6-10). Differences in cytokine production between PD 
and healthy donors were not significant (p>O.l). These data suggest that the MyD88-
dependent TLR pathway, presumably activated by all three TLR ligands tested , is not 
fundamentally hyperactive in B cells from PD patients. Furthermore , like TLR2 ligand, 
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TLR9ligand activated TLR4 expression, as measured by an increased mean fluorescence 
intensity (MFI) of TLR4 staining on CpG-treated B cells (Fig. 6-3F). We conclude that 
activation ofTLRs up regulated on B cells from PD patients (TLR2, TLR4) selectively 
increases cytokine production, but that activation of TLRs expressed on B cells from 
healthy donors (i.e. TLR9) generally increases cytokine production in all B cells. 
Furthermore, our demonstration that TLR2 and TLR9 activate TLR4 expression predicts 
that the outcome of B cell TLR engagement may be influenced by cross-talk between 
members of the TLR family. 
Cytokine-specific outcomes of TLR co-stimulation identify B cell cytokines 
regulated predominantly by TLR2 vs. TLR4 
TLR family cross talk results in alteration of cytokine production, compared to 
cytokine production in the presence of single TLR ligands [333]. The paucity of TLR2 
and TLR4 expression on B cells from healthy donors [156] had previously made 
TLR2/4/9 cross talk studies irrelevant in B cells. However, the demonstrations that 1. 
TLR2 and TLR4 are up regulated on B cells from inflammatory disease patients (18, 26; 
Fig. 6-1 herein); and 2. TLR2ligand activates the TLR4 gene (Fig. 6-3B) make 
investigation of TLR2/4 cross talk critical for identifying roles forB cells in disease 
pathogenesis. Understanding up regulated TLR cross talk is also essential for safe 
vaccine design for the large number of individuals affected by inflammatory diseases. To 
begin testing how TLR cross talk affects B cell cytokine production, we stimulated these 
cells in vitro with TLR21igand (Pam3) in combination with the TLR4ligand rLPS. 
Levels of some cytokines, specifically IFN-y, TNF-a, and IL-8 were indistinguishable in 
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B cells stimulated with Pam3 +1- rLPS (Figs. 6-4A, 6-4B, and 6-lF). The lack of an 
effect of rLPS on Pam3-induced IL-8 production (Fig. 6-lF) is consistent with the 
indistinguishable change in cJun/IL-8 promoter association in Pam3 +/- rLPS-stimulated 
B cells (Fig. 6-11). In contrast, Fig. 6-4C shows that B cells from PD patients stimulated 
with Pam3 plus rLPS secreted significantly lower levels of IL-10 , on average, compared 
to B cells stimulated with TLR2ligand (Pam 3) alone (*p=0.037). IL-l~ was modestly, 
but statistically significantly lower in B cells stimulated with TLR2+ TLR4 ligand 
(Pam3+rLPS) vs. TLR2ligand (Pam 3) alone (Fig. 6-4D; p=0.027 ; 10 of 12 samples had 
lower IL-l~ levels in Pam3+rLPS vs. Pam3-stimulated cultures) . The biological 
significance of this modest IL-l~ decrease remains to be determined. However, 
decreased IL-l~ protein secretion corresponds to significantly decreased association 
between the IL-1~ promoter and an IL-l~ activating transcription factor, cJun [334] in 
cells treated with Pam3+rLPS vs. Pam3 alone (Fig . 6-4E). The ability of rLPS to decrease 
Pam3-mediated IL-10 and IL-l~ production in B cells contrasts with the inability of rLPS 
to affect Pam3-induced IL-l~ mRNA production by monocytes (Fig. 6-4F). This finding 
further supports the conclusion that TLR4 has different functional consequences in B 
cells vs. monocytes. As expected, B cells from healthy donors produced low amounts of 
cytokines in response to all stimuli (Figs. 6-4A-D, white bars) . We conclude that rLPS 
predominantly regulates both IL-l~ and IL-10 genes in the presence of TLR2 ligand 
(Pam3). This result contrasts with similar levels of TNF-a production by B cell 
stimulated with TLR2+/-TLR4ligand , or each ligand alone , and suggest TLR2 and TLR4 
activated pathways are redundant for only a subset of cytokines. 
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To determine how TLR41igand from a periodontal pathogen (P. gingivalis LPS 
1690) influences B cell activation, we stimulated purified B cells from PD or healthy 
donors with LPS 1690 in the presence or absence ofTLR21igand (Pam3) . LPS 1690 
alone had little effect on cytokine production (Fig. 6-4G-I , and 6-11). Furthermore , LPS 
1690 insignificantly changed Pam3-induced cytokine production (Figs. 6-4G-I). Overall , 
data in Fig. 6-4 indicate that co-engagement of TLR2 and TLR4 on B cells from PD 
patients has cytokine-specific (IL-10 and IL-l~ vs. TNF-a) and ligand-specific (LPS 
1690 vs . rLPS) outcomes. 
TLR2 and TLR4 insignificantly affect TLR9-mediated cytokine production by B 
cells from healthy and PD donors 
To further test the possibility that TLR cross talk regulates cytokine production by 
B cells, we stimulated cells with CpG alone or in combination with Pam3 or rLPS to 
activate TLR9 , TLR2 or TLR4, respectively , and measured cytokine production . B cells 
from PD and healthy donors produced similar levels of cytokines in response to all 
stimulation conditions (Fig. 6-5). Note that cytokine values in Fig. 6-5 cannot be 
quantitatively compared to values from Fig. 6-3 (single TLR ligand stimulations) because 
not all samples in Fig. 6-3 yielded a sufficient number of cells for additional analysis. 
Furthermore, insufficient numbers and variability of measurements for IL-8 (n=3-4) 
made any conclusions on IL-8 production in response to TLR9 ligand unreliable. 
Regardless of these caveats, multiple conclusions are implied by these data. First, the 
TLR-triggered MyD88-dependent pathway that lies downstream ofTLR2, TLR4 and 
TLR9 [335, 336] is probably fundamentally similar in B cells from PD and healthy 
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donors. This finding strengthens our conclusion that cytokine production is regulated 
through ligand-specific (unknown) mechanisms. Second, these data show that TLR2 or 
TLR4 up-regulation does not alter response to a TLR normally expressed in human B 
cells, TLR9 [155, 156, 337]. The precise response ofB cells is therefore determined by 
the availability of specific TLR ligands. Finally , the similar response of B cells from 
healthy and PD donors indicates that B cell TLR9-mediated cytokine production plays no 
critical role in these patients. 
IL-l~ production uncovers differences in the TLR responses ofB cells from PD 
vs. DM patients 
IL-l~ is a key pro-inflammatory cytokine in multiple chronic inflammatory 
diseases with systemic manifestations, including PD and DM [79, 338]. Because IL-1~ 
secretion is constitutive by B cells from PD patients (Fig. 6-2), but is further regulated by 
TLR2 and TLR4ligands (Figs. 6-3A and 6-4D), we asked whether IL-l~ is similarly 
regulated in B cells from DM patients, who often have confounding oral inflammation. 
In contrast to B cells from PD patients, B cells from DM patients do not constitutively 
secrete IL-l~ at levels that are significantly greater, on average, than levels secreted by B 
cells from healthy donors (Fig. 6-6A) . We next considered the possibility that TLR 
ligands regulate inducible IL-l~ production by B cells from DM patients. Ligands to 
TLR2, TLR4 and TLR9 modestly (albeit statistically significantly) increased IL-l~ 
secretion (Fig. 6-6B). This result contrasts with the significant increase in IL-1(3 
production by B cells from PD patients responding to TLR2 ligand (Pam3; Fig. 6-3A). 
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We conclude that TLR-mediated IL-l~ regulation differs in B cells from DM vs. PD 
patients. 
To test whether B cells from DM patients, like other innate immune cell types 
(but in contrast to B cells from PD patients), synergistically activate cytokine production 
in response to combinations of TLR ligands, we measured responses of cells stimulated 
with multiple TLR ligands. Fig. 6-6C shows that the oral pathogen TLR41igand LPS 
1690 insignificantly altered IL-l~ production by B cells from either DM or PD patients 
(p>O.l in Pam3 vs. Pam3+LPS 1690 samples, "NS"). Although the TLR41igand rLPS 
modestly decreased IL-l~ TLR2 (Pam3)-activated IL-l~ production in B cells from PD 
patients (Fig. 6D, "*"), TLR41igand did not affect IL-l~ production by TLR2-stimulated 
B cells from DM patients (Fig. 6-6D, "NS"). Similarly, Pam3 further activated TLR4-
mediated IL-l~ production by B cells from DM patients, but not PD patients (Fig. 6-6E). 
Under all stimulation conditions, IL-l~ production by B cells from DM patients was low. 
However, the data support the idea of fundamental differences in TLR pathway "wiring" 
in B cells from DM vs. PD patients. Preliminary analysis of addition cytokines produced 
by B cells from DM patients is consistent with this interpretation (not shown). Taken 
together, these new findings on B cell cytokine production in PD and DM raise the 
possibility that alteration of TLR pathways, and therefore outcomes of TLR activation, 
significantly influence systemic inflammatory responses by altering B cell cytokine 
production, most potently in PD patients. 
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An elevated percentage of CD 19+ B cells from PD patients express functional TLR2 and 
secrete IL-8. (A) Representative flow cytometric plot ofB cells in peripheral blood from 
a PD patient stained for surface TLR2 expression relative to isotype control. A low 
percentage of CD 19+ TLR2+ B cells in blood of healthy donors has been published [223] . 
(B) Analysis of percentage and median percentage (horizontal line) ofTLR2+ B cells in 
32 healthy and 27 PD donors. Each point represents one donor. The percentage of 
TLR2+ B cells are significantly different (p=0.048 by Mann Whitney U test) between the 
two cohorts. Medians were: healthy=8.97%; PD=12.5% TLR2-positive B cells. (C) Flow 
cytometric plot showing percentage ofCD19+TLR2+ B cells in surgically excised 
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gingival tissue from PD patients. One of three similar results. (D) Representative re-
analysis of isolated B cells from peripheral blood to demonstrate purity in samples 
subjected to biochemical analyses. The CD 19-CD 14- population (lower left) was 
predominantly CD3+ T cells (not shown). (E) IL-8 secretion by peripheral blood B cells 
from 10 PD patients incubated in the absence vs. presence of the TLR2 ligand 
Pam3CSK4. A paired t test established significance (p=0.0098, shown in upper left). 
Each set of paired points shows results from a single donor under unstimulated (left) or 
stimulated (right) conditions. (F) IL-8 secretion in B cells from PD (white bars) and 
healthy (black bars) donors in the absence or presence of TLR2 (Pam3) and/or TLR4 
(rLPS) ligand. Shown is average and SEM of 11 PD donors. "*" highlights a significant 
difference (p<0.05). "NS" indicates p>0.1. (G) IL-8 secretion by human monocytes 
stimulated for 24 hrs as indicated. Shown is average and SD of determinations from 
three donor samples. (H) Chromatin immunoprecipitation (ChiP) measuring constitutive 
association between the IL-8 activating transcription factor cJun and the IL-8 promoter in 
fresh ex vivo B cells from healthy (black bar) or PD (white bar) donors. (I) ChiP 
measuring cJun association with the IL-8 promoter in B cells from healthy (gray bars) or 
PD (white bars) donors incubated for 6 hrs. with stimulus indicated on the X-axis. Panels 
H and I show fold increase in DNA amplification in samples precipitated with the 
indicated antibody compared to an irrelevant antibody (anti-GST). Error bars show range 
from 2-3 donors for each treatment. (J) Flow cytometry measuring intracellular IL-8 in B 
cells from PD or healthy donors as indicated. Isotype control was performed on the PD 
sample shown in the middle panel. Note that permeabilization decreases the CD 19 signal 
178 
non-specifically. Percentage of CD 19+ cells in the IL-8-positive gate is indicated. (K) 
Flow cytometry measuring intracellular IL-8 in B cells from surgically excised gingiva 
from PD patients. Cells were gated on CD 19. 44% of the 31,000 cells analyzed were IL-
8+ in this sample. Panels J and K represent independent determinations from three 
donors. 
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B cells from PD patients constitutively secrete IL-l~- Cytokine production by purified B 
cells from PD patients was quantified after 24 hrs. in media. Differences in cytokine 
production between B cells from healthy (white bars) and PD (gray bars) donors were 
analyzed by Wilcoxon matched pairs tests. P values were >0.05 except as indicated for 
IL-l~ (p=0.042). N=13 for GM-CSF and IL-l~ . N=l2 for IFN-y, IL-10 and TNF-a. 
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B cells from PD patients activate multiple inflammatory modulators in response to single 
TLR ligands. (A) TLR2ligation with Pam3CSK4 (Pam3) induces a subset of cytokines in 
B cells from PD patients. Secretion of the indicated cytokines by B cells from PD 
patients. Shown in all bars graphs are average +/-SEM. N values are listed in Fig. 2. Non-
parametric two-tailed t test established significance of the Pam3-mediated increase in IL-
113 and TNF-a production by B cells from PD vs. healthy donors (gray or white bars, 
respectively). P values for tests that showed statistical significance are listed above the 
results for all bar graphs. Although IL-l 0 was, on average, more highly expressed by B 
cells from PD patients (Fig. Sl), variability prevented statistical significance. (B) ChiP 
showing association of the TLR4-activating transcription factors cJun (black bars) or 
PU .1 (white bars) in B cells from PD patients treated for 6 hrs as indicated. Shown is 
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average fold increase in DNA amplification in samples precipitated with the indicated 
antibody compared to a control antibody (anti-GST). Error shows range from 2-3 healthy 
or 3 PD donors. (C) Cytokine production by B cells from healthy or PD patients treated 
with the TLR4ligand rLPS (Rhodobacter sphaeroids LPS). Details are as in panel A. N= 
11 for GM-CSF and IL-l~. N=lO for IFN-y, IL-10 and TNF-a. Data for individual 
donors is in Fig. S2. (D) Cytokine production by B cells from PD or healthy donors 
treated with the TLR91igand CpG. Details are as in panel A. N= 6 for GM-CSF and IL-
l~. N=S for IFN-y, IL-10 and TNF-a. (E) CpG treatment up regulates surface TLR4 
expression on B cells from healthy donors. Flow cytometric analysis of B cells from a 
healthy donor treated as indicated for 72 hrs. then stained for surface TLR4. IL-4 was 
added as indicated to enhance survival. Panel E represents similar results from three 
different donors. 
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A select TLR4 ligand decreases TLR2-mediated activation of a restricted set of 
cytokines. (A-D) B cells from PD patients were stimulated with the TLR2ligand Pam3 in 
the presence or absence of the TLR4ligand rLPS. Shown is average and SEM of (A) 
IFN-y, (B) TNF-a, (C) IL-10, and (D) IL-1(3 production. Analysis was described in Fig. 
3. P values for all comparisons >0.1 are emphasized by "NS" (not significant);"*" 
emphasizes a p value of <0.05 . The number ofPam3-stimulated samples is as in Fig. 3. 
For rLPS N=11 for IL-1(3, and N=10 for IFN-y, TNF-a and IL-10. For Pam3+rLPS N=12 
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for IL-1[3, and N=11 for IFN-y, TNF-a and IL-10. (E) ChiP analysis of transcription 
factors associating with the IL-1[3 promoter in B cells from healthy (left) or PD (right) 
donors stimulated as indicated. "*"highlights a significant difference (p=0.04 by paired 
Student's t test) in cJun/IL-1[3 promoter association in B cells from PD patients 
stimulated with Pam3 alone or in combination with rLPS. Shown is average and SEM 
from 2-3 healthy and 3 PD donors. (F) IL-1[3 mRNA production by monocytes stimulated 
with the indicated ligand(s) for 20 hrs. mRNA was normalized to GAPDH and quantified 
by the ~~Ct method. Y axis shows mRNA in stimulated vs. unstimulated monocytes. The 
latter value was set to equal 1. Shown are average and SD of 3 independent experiments. 
(G-I) B cells from healthy or PD donors were stimulated with TLR2 (Pam3) or TLR4 
(LPS 1690) alone and in combination as indicated. "NS" emphasizes no significant 
difference between Pam3 and Pam3+ 1690-stimulated B cells from PD patients. Results 
shown for (G) TNF-a, (H) IL-10, or (I) IL-1[3. Bars show average ofN=4 for 1690-
stimulated cells, and N=6 for Pam3+ 1690 stimulated cells. 
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TLR9 equivalently activates cytokine production by B cells from PD and healthy donors. 
(A-D) B cells from PD patients were stimulated with the TLR9 ligand CpG ODN 2006 in 
the presence or absence of the TLR2ligand Pam3, or the TLR4 ligand rLPS as indicated. 
P values for comparison of results from B cells from PD vs. healthy donors (gray or 
white bars, respectively) were all >0.1. No significant difference was detected between 
TLR9 and TLR9+2 or TLR9+4 stimulated cells (p>O.l). Cytokines measured were (A) 
IFN-y, (B) TNF-a, (C) IL-10, and (D) IL-l~. Bar shows average ofN=6 (for IL-l~) or 
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N=S (for IFN-y, TNF-a and IL-10) for CpG or CpG+rLPS-treated samples. N=5 (for IL-
113) or N=4 (for IFN-y, TNF-a and IL-10) for CpG+Pam3-treated samples. 
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TLR cross talk differentially activates IL-l~ production by B cells from diabetes patients 
compared to PD patients. (A) Constitutive IL-l~ production by B cells from DM or 
healthy donors as indicated. Difference was not significant (p=0.2; N=l2). (B) IL-l~ 
production by B cells from DM patients stimulated as indicated. Average IL-l~ 
production over media controls is shown. All conditions significantly elevated IL-l~ 
levels compared to media (p<0.05). N=l2 for Pam3 and CpG; N=8 for rLPS. (C-E) B 
cells from DM or PD patients stimulated with ligands as shown. Production over media 
controls is shown. Statistical differences between cytokine production in B cells 
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stimulated with one vs. two TLR ligands (as labeled) are highlighted with a"*". NS 
indicates statistically insignificant differences. Number of samples analyzed from DM 
patients was: panel C: 5; panel D:8; panel E: 8. Number ofPD samples analyzed are as 
listed in other figures. 
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Table 4-1. Descriptive statistics of PD and healthy subjects. 
Age (years) 
N 
Males(%) 
Race n(%) 
-Caucasian 
-African American 
-Asian 
-Hispanic 
-Unknown 
PD Median 
(Range) 
32 (20-38) 
14 
7 (50%) 
2(14.3) 
11(78.6) 
1(7.1) 
1 (7 .1) 
0(0) 
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Healthy Median 
(Range) 
31 (27-52) 
16 
8 (50%) 
6(37.5) 
8 (50) 
0(0) 
1(6.3) 
1(6.3) 
Table 4-2. Descriptive statistics of 11 subjects with DM. 
Median Range 
Age (years) 55 38 to 72 
Ale(%) 8.2 6.0 to 14.9 
Duration DM (years) 10 5 to 32 
BMI (kg/m2) 32.4 17.0 to 43 .1 
CRP* (mg/dL) 0.9 0.1 to 16.4 
n 0/o 
T2DM 9 81.8 
Males 6 54.5 
Race 
-Caucasian 6 54.5 
-African American 5 45.5 
DM=Diabetes mellitus; Alc=Hemoglobin Ale; BMI=Body mass index; CRP=C-reactive 
protein T2DM=Type 2 diabetes mellitus 
* CRP values available for 9 of 11 subjects 
190 
PD Healthy 
..... ,.o-..c::sF lhii!P OM .est: 
.. 
·O C(ICO' ... I) «oo'b 
- ~ - ~ -, .. ... , l • / ~ 1 ./ 
·" 
.. "'" .. -. 11! ............ 
: .. UWill 1M •0 !f) 
* 
Itt . 
... .... 
. .. 
.. .. 
/ ~~ .,. .~ 
II"'P~·1b lllvtPil,-11> 
'* 0~  :j C!QOS 1Uil 
- z ,... t4!0 ' 
.l - ,~· 
• 
./ 1~ / 1~ 
ll \'aPII.-10 Mvtl>ll,-10 
- ocoa 
- 1 - F ;~ • 
/ .~ / .~ 
...... , ... II.,.Pt'Hf .. 
~I ~~  § uo~ 1- . 
~~ ~ ~ • 71f!i I 
.. ,. ( 
,... / .r 
191 
Figure 7-7 
Two point graphs showing cytokine production (designated at top of each graph) by B 
cells from PD (left column) and healthy (right column) donors. "MvsP" indicates a 
comparison between cells incubated in media (left dot of graph) and cells from the same 
donor incubated in Pam3 (right dot of graph). P values from paired nonparametric 
analysis are shown in upper left of each graph. N' s for each analysis are as in main text. 
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Figure 7-8 
Two point graphs showing cytokine production (designated at top of each graph) by B 
cells from PD (left column) and healthy (right column) donors. "MvsR" indicates a 
comparison between cells incubated in media (left dot of graph) and cells from the same 
donor incubated in rLPS (right dot of graph). P values from paired nonparametric 
analysis are shown in upper left of each graph. N' s for each analysis are as in main text. 
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Figure 7-9 
Two point graphs showing cytokine production (designated at top of each graph) by B 
cells from PD (left column) and healthy (right column) donors. "MvsCpG" indicates a 
comparison between cells incubated in media (left dot of graph) and cells from the same 
donor incubated in CpG (right dot of graph). P values from paired nonparametric analysis 
are shown in upper left of each graph. N' s for each analysis are as in main text. 
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Figure 7-10 
Two point graphs showing cytokine production (designated at top of each graph) by B 
cells from PD (left column) and healthy (right column) donors. "Mvs1690" indicates a 
comparison between cells incubated in media (left dot of graph) and cells from the same 
donor incubated in P. gingiva/is LPS 1690 (right dot of graph). P values from paired 
nonparametric analysis are shown in upper left of each graph. N' s for each analysis are as 
in main text. 
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Cytokine production by B cells from individual donors 
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Cytokine production by B cells from 9 individual PD patients emphasizes similarities 
among individual results. Concentration of each cytokine shown on the X-axis secreted 
by B cells from donors 1-9. Results from each treatment are shown as a single dot for 
each cytokine to indicate the overall pattern of cytokine production by B cells from that 
donor. Log scale on Y axis minimizes differences apparent in other figures. Media 
controls have lowest levels of cytokine production shown in each cluster of dots (not 
shown). 
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Discussion 
Our data identify disease- , stimulus- and cytok:ine-specific B cell responses to 
combinations of TLR ligands . Findings herein also suggest mechanistic differences to 
explain the elegant specificity of human B cell responses to disease-associated 
combinations of TLR ligands . This response occurs despite modest elevation of surface 
TLRs , indicating surface expression may underestimate ligand responsiveness. Many 
pathogens, including the periodontal pathogen P. gingiva/is, produce ligands that activate 
TLR2 and TLR4 [226, 313, 339, 340], two TLRs elevated on the surface of B cells from 
PD patients. Similarly , multiple TLRs would be engaged in B cells responding to TLR-
activating vaccine adjuvant or confounding PD in the multitude of diabetic individual s 
with naturally elevated levels of TLR4ligands including free fatty acids and/or systemic 
endotoxin [3, 126, 341]. Understanding the response ofB cells to combinations ofTLR 
ligands will aid in rational vaccine strategies that use TLR ligands as adjuvants and are 
targeted to a broad cross-section of individuals inevitably including PD and DM patients. 
Both TLR expression and TLR function differ between B cells from inflammatory 
disease patients and human myeloid cells. One interpretation of these findings is that B 
cell TLRs are "hard wired" differently from myeloid cell TLRs . A second possibility is 
that mechanisms driving cytokine activation are fundamentally different in B cells vs . 
myeloid cells. The results from ChiP assays and the relatively "normal" activation of the 
MyD88-dependent pathway in B cells preliminarily discount this explanation . A third 
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possibility is that TLR function differs, regardless of cell type, in patients with 
inflammatory disease compared to healthy individuals. This scenario emphasizes the 
importance of testing responses to TLR ligands in primary cells from patients prior to 
clinical trials to identify disease-specific outcomes that cannot be predicted by analysis of 
cells from healthy donors. In addition, the demonstration that B cells from individual 
donors with PD tend to exhibit similar cytokine responses (Fig. 6-12) suggests that efforts 
to further understand, then harness TLR cross talk to regulate cytokine production by B 
cells are likely to have widespread efficacy. 
The change in cytokine production by B cells was low for some cytokines, 
regardless of statistically significance. A modest change in average cytokine production 
may hold higher significance in the subset of patients with more responsive B cells, and 
therefore may identify subsets of patients within our cross-sectional cohort. Regardless, 
cytokines often function through feed-back loops that can amplify the short-term signals 
measured in our 24 hr. cultures. Low levels of IL-l~ are particularly effective in 
activating a positive feed-back loop to achieve robust IL-l~ production in an 
autocrine/paracrine mechanism [342]. Changes in the absolute value of cytokine 
production may therefore inaccurately estimate the physiological relevance of such 
changes in the complex in vivo environment. Future studies would benefit from a model 
organism that, unlike mice, generally houses a low percentage ofTLR2+/TLR4+ B cells. 
This model remains to be identified. 
Periodontal disease is a common confounder of diabetes, therefore the response of 
B cells in diabetic patients could result solely from oral inflammation. However, the 
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distinct differences in IL- l~ response in B cells from PD vs. DM patients demonstrates 
that the B cells are functionally different, regardless of the co-occurrence of PD in 
diabetics . One possible explanation is that PD can be divided into multiple classes, based 
on a series of over 100 measurements of the oral cavity. B cells from the localized 
aggressive periodontitis patients comprising the PD cohort herein may be different from 
the chronic periodontitis more common in DM patients. A direct comparison of the role 
of PD vs. diabetes in B cell function will require analysis of additional DM patients with 
healthy gingiva, which represent only about 30% of our clinical population. 
Alternatively, analysis of chronic periodontitis patients without confounding DM would 
determine the role this type of PD might play in B cells responses in DM patients with 
confounding oral inflammation. These comparisons will be important to determine if B 
cells in PD patients are likely to respond uniquely to treatments developed to counter 
TLR activation in diabetes. 
The paradigm for TLR cross talk summarized from various studies on myeloid 
lineage cells is shown in Fig. 6-7A. Based on our data, we propose a revised model to 
describe the effect of TLR cross talk through surface molecules up regulated in B cells 
from inflammatory disease patients (Figs. 6-7B&C). Our data support the conclusion that 
select cytokines (in gray) are predominantly regulated by TLR2 (panel B), or TLR4 
(panel C). TLR responses are influenced by idiosyncrasies of the inflammatory disease 
(PD vs. DM, not shown in model). TLR2 and TLR4 insignificantly influence TLR9-
mediated cytokine production (thick black arrow), in contrast to the generally additive 
effects of multiple TLR ligands on cytokine production in dendritic cells [321, 343, 344]. 
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This model makes testable predictions for understanding mechanisms responsible for the 
high specificity of TLR-triggered cellular responses likely to play important roles in 
disease pathogenesis. 
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Figure 8-1 
Models explaining biological outcomes ofTLR cross talk in hematopoietic cells. (A) 
Toll-like receptor cross talk in myeloid cells is complex. Numerous studies show myeloid 
cells, predominantly dendritic cells and macrophages, respond to TLR2/4 co-engagement 
by synergistically increasing IL-6 and TNF -a production [319, 320] although some 
studies indicated cytokine production decreases [317] or does not change in human 
monocytes responding to a combination ofTLR2 and TLR4 vs. a single TLR ligand 
alone [318]. TLR2/4 cross talk is represented by a gray double-headed arrow. TLR2 and 
TLR9 (leftmost double-headed black arrow) also cooperate to increase cytokine 
responses, although synergy in TNF-a production (in gray) is minimal [320]. Co-
engagement ofTLR4 and TLR9 (rightmost black double-headed arrow) resulted in 
additive/synergistic activation ofiL-12 and IL-6 (in black) but not other cytokines [321]. 
At least some of the apparent inconsistencies in these results are likely due to different 
outcomes triggered by different ligands that bind the same TLR. (B-C) Model for TLR 
cross talk in B cells from inflammatory disease patients. Our studies show B cells from 
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these patients express TLR2 and TLR4 and regulate select cytokines using mechanisms 
than likely vary from those used by myeloid cells. TLR2/4 cross talk did not result in 
additive cytokine activation in B cells. We instead identified cytokines that are 
predominantly regulated by (B) TLR2 (IL-8, TNF-a, gray) or (C) TLR4 (IL-l~ and IL-
l 0, gray) even in the presence of ligands for both. ".l" sign indicates that dominant 
regulation of cytokine production by TLR2 or TLR4 may involve direct interference of 
TLR-activated pathways, although this possibility remains to be tested. Decreased 
cytokine production was demonstrated for only one oftwo TLR4ligands tested. Our data 
also show that TLR2 and TLR4ligand do not detectably change TLR9-mediated B cell 
cytokine production (thick black arrow). The response of inflammatory disease patient B 
cells to other TLR2, TLR4 or TLR9 ligands remains to be determined. Interestingly, 
studies in wild-derived mouse strains support our conclusion that TLR responses differ 
between B cells and myeloid cells in outbred populations [345]. 
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